(1)

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 6, 2005, 15:52:13 ; Search time 1 Seconds
(without alignments)
4.145 Million cell updates/sec

Title: US-10-630-399-3
Perfect score: 922
Sequence: 1 gacagtggttattaaagcat.....ctggacttctaatatataga 922

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 134 seqs, 2248 residues

Total number of hits satisfying chosen parameters: 268

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 134 summaries

Database : rge3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20	2.2	20	1	AR475597	ACCESSION:AR475597
c	2	20	2.2	20	1	AR475598	ACCESSION:AR475598
c	3	20	2.2	20	1	AR475599	ACCESSION:AR475599
c	4	20	2.2	20	1	AR475600	ACCESSION:AR475600
c	5	20	2.2	20	1	AR475601	ACCESSION:AR475601
c	6	20	2.2	20	1	AR475602	ACCESSION:AR475602
c	7	20	2.2	20	1	AR475603	ACCESSION:AR475603
c	8	20	2.2	20	1	AR475604	ACCESSION:AR475604
c	9	20	2.2	20	1	AR475605	ACCESSION:AR475605
c	10	20	2.2	20	1	AR475606	ACCESSION:AR475606
c	11	20	2.2	20	1	AR475607	ACCESSION:AR475607
c	12	20	2.2	20	1	AR475608	ACCESSION:AR475608
c	13	20	2.2	20	1	AR475609	ACCESSION:AR475609
c	14	20	2.2	20	1	AR475610	ACCESSION:AR475610
c	15	20	2.2	20	1	AR475611	ACCESSION:AR475611
c	16	20	2.2	20	1	AR475612	ACCESSION:AR475612
c	17	20	2.2	20	1	AR475613	ACCESSION:AR475613
c	18	20	2.2	20	1	AR475614	ACCESSION:AR475614
c	19	20	2.2	20	1	AR475615	ACCESSION:AR475615
c	20	20	2.2	20	1	AR475616	ACCESSION:AR475616
c	21	20	2.2	20	1	AR475617	ACCESSION:AR475617
c	22	20	2.2	20	1	AR475618	ACCESSION:AR475618
c	23	20	2.2	20	1	AR475619	ACCESSION:AR475619
c	24	20	2.2	20	1	AR475620	ACCESSION:AR475620
c	25	20	2.2	20	1	AR475621	ACCESSION:AR475621
c	26	20	2.2	20	1	AR475622	ACCESSION:AR475622
c	27	20	2.2	20	1	AR475623	ACCESSION:AR475623
c	28	20	2.2	20	1	AR475624	ACCESSION:AR475624
	29	18	2.0	20	1	AR117683	ACCESSION:AR117683
	30	17	1.8	17	1	AX760453	ACCESSION:AX760453
c	31	16	1.7	17	1	AX649705	ACCESSION:AX649705
c	32	16	1.7	17	1	AX649706	ACCESSION:AX649706
	33	15.8	1.7	19	1	AR299993	ACCESSION:AR299993
c	34	15.4	1.7	17	1	AX649703	ACCESSION:AX649703
c	35	15.4	1.7	17	1	AX649704	ACCESSION:AX649704
c	36	15	1.6	16	1	AR328634	ACCESSION:AR328634
c	37	15	1.6	17	1	AX649707	ACCESSION:AX649707
	38	15	1.6	18	1	BD176280	ACCESSION:BD176280
	39	15	1.6	18	1	BD090202	ACCESSION:BD090202
c	40	14.4	1.6	17	1	AX649702	ACCESSION:AX649702
c	41	14.4	1.6	17	1	AX734430	ACCESSION:AX734430
c	42	14.4	1.6	17	1	AX734488	ACCESSION:AX734488
	43	14.4	1.6	17	1	AX760843	ACCESSION:AX760843
	44	14.4	1.6	17	1	AX761964	ACCESSION:AX761964
c	45	14	1.5	17	1	AR188899	ACCESSION:AR188899
c	46	14	1.5	17	1	AR190454	ACCESSION:AR190454
c	47	14	1.5	17	1	AR324752	ACCESSION:AR324752
c	48	14	1.5	17	1	AR325377	ACCESSION:AR325377
c	49	14	1.5	17	1	AX649708	ACCESSION:AX649708
c	50	14	1.5	17	1	AX727495	ACCESSION:AX727495
	51	14	1.5	17	1	AX734753	ACCESSION:AX734753
c	52	13.8	1.5	17	1	A88600	ACCESSION:A88600
c	53	13.8	1.5	17	1	A90567	ACCESSION:A90567
	54	13.8	1.5	17	1	AR034270	ACCESSION:AR034270
c	55	13.8	1.5	17	1	AR046375	ACCESSION:AR046375
c	56	13.8	1.5	17	1	AR046377	ACCESSION:AR046377
c	57	13.8	1.5	17	1	AR083059	ACCESSION:AR083059
c	58	13.8	1.5	17	1	AR167916	ACCESSION:AR167916
	59	13.8	1.5	17	1	CQ618041	ACCESSION:CQ618041
c	60	13.8	1.5	17	1	I53427	ACCESSION:I53427
c	61	13.8	1.5	17	1	I53429	ACCESSION:I53429
c	62	13.8	1.5	17	1	AR188898	ACCESSION:AR188898
c	63	13.8	1.5	17	1	AR190453	ACCESSION:AR190453
c	64	13.8	1.5	17	1	AR324751	ACCESSION:AR324751
c	65	13.8	1.5	17	1	AR325376	ACCESSION:AR325376
c	66	13.8	1.5	17	1	AR328081	ACCESSION:AR328081
	67	13.8	1.5	17	1	AR459104	ACCESSION:AR459104
c	68	13.8	1.5	17	1	AX531188	ACCESSION:AX531188
c	69	13.8	1.5	17	1	AX531189	ACCESSION:AX531189
c	70	13.8	1.5	17	1	AX649193	ACCESSION:AX649193
	71	13.8	1.5	17	1	AX745290	ACCESSION:AX745290
	72	13.8	1.5	17	1	AX759395	ACCESSION:AX759395
c	73	13.8	1.5	17	1	BD066113	ACCESSION:BD066113
c	74	13.4	1.5	16	1	CQ828930	ACCESSION:CQ828930
c	75	13.4	1.5	16	1	I38662	ACCESSION:I38662
c	76	13.4	1.5	16	1	I38663	ACCESSION:I38663
c	77	13.4	1.5	16	1	I38692	ACCESSION:I38692
c	78	13.4	1.5	16	1	I38698	ACCESSION:I38698
c	79	13.4	1.5	16	1	AX572137	ACCESSION:AX572137
c	80	13.4	1.5	16	1	ATH523894	ACCESSION:AJ523894
c	81	13	1.4	15	1	AR041231	ACCESSION:AR041231
c	82	13	1.4	15	1	AX636694	ACCESSION:AX636694
c	83	13	1.4	16	1	AR435811	ACCESSION:AR435811
c	84	12.8	1.4	16	1	A88599	ACCESSION:A88599
c	85	12.8	1.4	16	1	A90566	ACCESSION:A90566
c	86	12.8	1.4	16	1	AR033128	ACCESSION:AR033128
	87	12.8	1.4	16	1	BD226644	ACCESSION:BD226644
	88	12.8	1.4	16	1	BD226649	ACCESSION:BD226649
c	89	12.8	1.4	16	1	I41208	ACCESSION:I41208
c	90	12.8	1.4	16	1	I92440	ACCESSION:I92440
c	91	12.8	1.4	16	1	AR328635	ACCESSION:AR328635
	92	12.8	1.4	16	1	AR329711	ACCESSION:AR329711
c	93	12.8	1.4	16	1	AR435950	ACCESSION:AR435950
c	94	12.8	1.4	16	1	AX255763	ACCESSION:AX255763
c	95	12.8	1.4	16	1	BD066112	ACCESSION:BD066112
	96	12.4	1.3	15	1	A33037	ACCESSION:A33037
c	97	12.4	1.3	15	1	AR033322	ACCESSION:AR033322
	98	12.4	1.3	15	1	AR056010	ACCESSION:AR056010
c	99	12.4	1.3	15	1	AR113144	ACCESSION:AR113144
	100	12.4	1.3	15	1	AR113768	ACCESSION:AR113768
c	101	12.4	1.3	15	1	BD184130	ACCESSION:BD184130
c	102	12.4	1.3	15	1	BD207055	ACCESSION:BD207055
c	103	12.4	1.3	15	1	BD208985	ACCESSION:BD208985
c	104	12.4	1.3	15	1	I57551	ACCESSION:I57551
	105	12.4	1.3	15	1	AX572592	ACCESSION:AX572592
	106	12.4	1.3	15	1	AX633098	ACCESSION:AX633098

c 107	12.4	1.3	15	1	AX742306	ACCESSION:AX742306
108	12.4	1.3	15	1	ATH529196	ACCESSION:AJ529196
109	12	1.3	12	1	CQ766241	ACCESSION:CQ766241
110	12	1.3	13	1	AX394466	ACCESSION:AX394466
c 111	12	1.3	13	1	AX394494	ACCESSION:AX394494
c 112	12	1.3	14	1	A40583	ACCESSION:A40583
c 113	12	1.3	14	1	A89107	ACCESSION:A89107
c 114	12	1.3	14	1	AR232863	ACCESSION:AR232863
c 115	12	1.3	14	1	AX030158	ACCESSION:AX030158
c 116	12	1.3	14	1	AX316479	ACCESSION:AX316479
117	12	1.3	14	1	AX525338	ACCESSION:AX525338
118	12	1.3	14	1	AX525386	ACCESSION:AX525386
119	12	1.3	14	1	AX572590	ACCESSION:AX572590
120	12	1.3	14	1	AX572591	ACCESSION:AX572591
121	12	1.3	14	1	AX572642	ACCESSION:AX572642
c 122	12	1.3	14	1	BD066620	ACCESSION:BD066620
c 123	12	1.3	15	1	AR132205	ACCESSION:AR132205
c 124	12	1.3	15	1	AR132206	ACCESSION:AR132206
c 125	12	1.3	15	1	AR132207	ACCESSION:AR132207
c 126	12	1.3	15	1	AR132208	ACCESSION:AR132208
c 127	12	1.3	15	1	AR132209	ACCESSION:AR132209
c 128	12	1.3	15	1	AR133631	ACCESSION:AR133631
c 129	12	1.3	15	1	AR133905	ACCESSION:AR133905
130	12	1.3	15	1	AX572585	ACCESSION:AX572585
131	12	1.3	15	1	AX572593	ACCESSION:AX572593
132	12	1.3	15	1	AX572638	ACCESSION:AX572638
133	12	1.3	15	1	AX572640	ACCESSION:AX572640
134	12	1.3	15	1	AX587034	ACCESSION:AX587034

ALIGNMENTS

RESULT 1
AR475597/c
LOCUS AR475597 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 52 from patent US 6692959.
ACCESSION AR475597
VERSION AR475597.1 GI:42715080
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4 expression
JOURNAL Patent: US 6692959-A 52 17-FEB-2004;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1548 GACAGTGGTTATTAAAGCAT 1567
||||||||||||||||||||
Db 20 GACAGTGGTTATTAAAGCAT 1

RESULT 2
AR475598/c
LOCUS AR475598 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 53 from patent US 6692959.
ACCESSION AR475598
VERSION AR475598.1 GI:42715081
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4 expression
JOURNAL Patent: US 6692959-A 53 17-FEB-2004;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1560 TAAAGCATGGGTTGAACTTC 1579
||||||||||||||||||||
Db 20 TAAAGCATGGGTTGAACTTC 1

RESULT 3
AR475599/c
LOCUS AR475599 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 54 from patent US 6692959.
ACCESSION AR475599
VERSION AR475599.1 GI:42715082
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4 expression
JOURNAL Patent: US 6692959-A 54 17-FEB-2004;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1646 TACAGTAATCCCTGAGAAAT 1665
||||||||||||||||||||
Db 20 TACAGTAATCCCTGAGAAAT 1

RESULT 4
AR475600/c
LOCUS AR475600 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 55 from patent US 6692959.
ACCESSION AR475600
VERSION AR475600.1 GI:42715083
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4 expression
JOURNAL Patent: US 6692959-A 55 17-FEB-2004;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1674 AGCATCACCAAACACAGTTT 1693
||||||||||||||||||||

```
Db         20 AGCATCACCAAACACAGTTT 1


RESULT 5
AR475601/c
LOCUS       AR475601                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 56 from patent US 6692959.
ACCESSION   AR475601
VERSION     AR475601.1  GI:42715084
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 56 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1711 CAAAAAGAGCCTGGGCTGTA 1730
             ||||||||||||||||||||
Db         20 CAAAAAGAGCCTGGGCTGTA 1


RESULT 6
AR475602/c
LOCUS       AR475602                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 57 from patent US 6692959.
ACCESSION   AR475602
VERSION     AR475602.1  GI:42715085
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 57 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 CCTGGGCTGTATGTAGGGTG 1739
             ||||||||||||||||||||
Db         20 CCTGGGCTGTATGTAGGGTG 1


RESULT 7
AR475603/c
LOCUS       AR475603                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 58 from patent US 6692959.
ACCESSION   AR475603
VERSION     AR475603.1  GI:42715086
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 58 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1737 GTGGAAACACTCTGATCTGA 1756
             ||||||||||||||||||||
Db         20 GTGGAAACACTCTGATCTGA 1


RESULT 8
AR475604/c
LOCUS       AR475604                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 59 from patent US 6692959.
ACCESSION   AR475604
VERSION     AR475604.1  GI:42715087
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 59 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1756 AAGCCCAGCTGACTCCACTA 1775
             ||||||||||||||||||||
Db         20 AAGCCCAGCTGACTCCACTA 1


RESULT 9
AR475605/c
LOCUS       AR475605                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 60 from patent US 6692959.
ACCESSION   AR475605
VERSION     AR475605.1  GI:42715088
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 60 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1810 CTGCTGTGAGCCACTAATAA 1829
             ||||||||||||||||||||
Db         20 CTGCTGTGAGCCACTAATAA 1
```

```
RESULT 10
AR475606/c
LOCUS       AR475606                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 61 from patent US 6692959.
ACCESSION   AR475606
VERSION     AR475606.1  GI:42715089
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 61 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1829 ACATTGGGCTAATATCTGCT 1848
              ||||||||||||||||||||
Db         20 ACATTGGGCTAATATCTGCT 1


RESULT 11
AR475607/c
LOCUS       AR475607                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 62 from patent US 6692959.
ACCESSION   AR475607
VERSION     AR475607.1  GI:42715090
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 62 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1846 GCTGTGCTTCTCTGACAGGT 1865
              ||||||||||||||||||||
Db         20 GCTGTGCTTCTCTGACAGGT 1


RESULT 12
AR475608/c
LOCUS       AR475608                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 63 from patent US 6692959.
ACCESSION   AR475608
VERSION     AR475608.1  GI:42715091
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 63 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1854 TCTCTGACAGGTAGTCATGA 1873
              ||||||||||||||||||||
Db         20 TCTCTGACAGGTAGTCATGA 1


RESULT 13
AR475609/c
LOCUS       AR475609                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 64 from patent US 6692959.
ACCESSION   AR475609
VERSION     AR475609.1  GI:42715092
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 64 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1894 TATACAAGCACTTTGTAAAT 1913
              ||||||||||||||||||||
Db         20 TATACAAGCACTTTGTAAAT 1


RESULT 14
AR475610/c
LOCUS       AR475610                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 65 from patent US 6692959.
ACCESSION   AR475610
VERSION     AR475610.1  GI:42715093
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 65 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1951 TTACAAAATCCTATTAGTCA 1970
              ||||||||||||||||||||
Db         20 TTACAAAATCCTATTAGTCA 1
```

```
RESULT 15
AR475611/c
LOCUS       AR475611                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 66 from patent US 6692959.
ACCESSION   AR475611
VERSION     AR475611.1  GI:42715094
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 66 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1985 GTGTTCACAGCAATCATTTA 2004
             ||||||||||||||||||||
Db         20 GTGTTCACAGCAATCATTTA 1


RESULT 16
AR475612/c
LOCUS       AR475612                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 67 from patent US 6692959.
ACCESSION   AR475612
VERSION     AR475612.1  GI:42715095
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 67 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2066 TTACATGACAAAGTTGAAGG 2085
             ||||||||||||||||||||
Db         20 TTACATGACAAAGTTGAAGG 1


RESULT 17
AR475613/c
LOCUS       AR475613                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 68 from patent US 6692959.
ACCESSION   AR475613
VERSION     AR475613.1  GI:42715096
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 68 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2089 TTGGCAGATGCAGTTAAGGT 2108
             ||||||||||||||||||||
Db         20 TTGGCAGATGCAGTTAAGGT 1


RESULT 18
AR475614/c
LOCUS       AR475614                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 69 from patent US 6692959.
ACCESSION   AR475614
VERSION     AR475614.1  GI:42715097
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 69 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2137 AAAGGGCCTGACCTAATCCA 2156
             ||||||||||||||||||||
Db         20 AAAGGGCCTGACCTAATCCA 1


RESULT 19
AR475615/c
LOCUS       AR475615                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 70 from patent US 6692959.
ACCESSION   AR475615
VERSION     AR475615.1  GI:42715098
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 70 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2191 GCCTTGAAGAAGTATGTGAG 2210
             ||||||||||||||||||||
Db         20 GCCTTGAAGAAGTATGTGAG 1
```

```
RESULT 20
AR475616/c
LOCUS       AR475616                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 71 from patent US 6692959.
ACCESSION   AR475616
VERSION     AR475616.1  GI:42715099
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 71 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2211 AGGGCCACATTGGCTAAAAC 2230
             ||||||||||||||||||||
Db         20 AGGGCCACATTGGCTAAAAC 1


RESULT 21
AR475617/c
LOCUS       AR475617                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 72 from patent US 6692959.
ACCESSION   AR475617
VERSION     AR475617.1  GI:42715100
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 72 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 CATTGGCTAAAACCTAAAGG 2237
             ||||||||||||||||||||
Db         20 CATTGGCTAAAACCTAAAGG 1


RESULT 22
AR475618/c
LOCUS       AR475618                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 73 from patent US 6692959.
ACCESSION   AR475618
VERSION     AR475618.1  GI:42715101
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 73 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2223 GCTAAAACCTAAAGGTGGCC 2242
             ||||||||||||||||||||
Db         20 GCTAAAACCTAAAGGTGGCC 1


RESULT 23
AR475619/c
LOCUS       AR475619                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 74 from patent US 6692959.
ACCESSION   AR475619
VERSION     AR475619.1  GI:42715102
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 74 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2236 GGTGGCCTCTAGGAGATGAG 2255
             ||||||||||||||||||||
Db         20 GGTGGCCTCTAGGAGATGAG 1


RESULT 24
AR475620/c
LOCUS       AR475620                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 75 from patent US 6692959.
ACCESSION   AR475620
VERSION     AR475620.1  GI:42715103
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 75 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2256 ACCTACCTTCCAGTTGTCAG 2275
             ||||||||||||||||||||
Db         20 ACCTACCTTCCAGTTGTCAG 1


RESULT 25
```

```
AR475621/c
LOCUS       AR475621                20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 76 from patent US 6692959.
ACCESSION   AR475621
VERSION     AR475621.1  GI:42715104
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 76 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2267 AGTTGTCAGCAAGCAGGAAA 2286
              ||||||||||||||||||||
Db         20 AGTTGTCAGCAAGCAGGAAA 1


RESULT 26
AR475622/c
LOCUS       AR475622                20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 77 from patent US 6692959.
ACCESSION   AR475622
VERSION     AR475622.1  GI:42715105
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 77 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2364 AAGCTTCAGATGATAACCAC 2383
              ||||||||||||||||||||
Db         20 AAGCTTCAGATGATAACCAC 1


RESULT 27
AR475623/c
LOCUS       AR475623                20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 78 from patent US 6692959.
ACCESSION   AR475623
VERSION     AR475623.1  GI:42715106
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 78 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2377 TAACCACAGCCTGGGCTGAC 2396
              ||||||||||||||||||||
Db         20 TAACCACAGCCTGGGCTGAC 1


RESULT 28
AR475624/c
LOCUS       AR475624                20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 79 from patent US 6692959.
ACCESSION   AR475624
VERSION     AR475624.1  GI:42715107
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of IL-1 receptor-associated kinase-4
            expression
  JOURNAL   Patent: US 6692959-A 79 17-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2419 ATCCTCAGTATGAGAATCTA 2438
              ||||||||||||||||||||
Db         20 ATCCTCAGTATGAGAATCTA 1


RESULT 29
AR117683
LOCUS       AR117683                20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 80 from patent US 6140125.
ACCESSION   AR117683
VERSION     AR117683.1  GI:14098589
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Taylor,J.K. and Cowsert,L.M.
  TITLE     Antisense inhibition of bcl-6 expression
  JOURNAL   Patent: US 6140125-A 80 31-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 18;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 8;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1902 CACTTTGTAAATTGTAAA 1919
              ||||||||||||||||||
Db          3 CACTTTGTAAATTGTAAA 20


RESULT 30
AX760453
LOCUS       AX760453                17 bp    DNA     linear   PAT 25-JUN-2003
```

```
DEFINITION  Sequence 3774 from Patent WO03040369.
ACCESSION   AX760453
VERSION     AX760453.1  GI:32255069
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 3774 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.8%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 8;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1750 GATCTGAAGCCCAGCTG 1766
              |||||||||||||||||
Db          1 GATCTGAAGCCCAGCTG 17


RESULT 31
AX649705/c
LOCUS       AX649705                  17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 1545 from Patent EP1273660.
ACCESSION   AX649705
VERSION     AX649705.1  GI:29152523
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 1545 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.7%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAGCC 1760
              ||||||||||||||||
Db         17 ACTCTGATCTGAAGCC 2


RESULT 32
AX649706/c
LOCUS       AX649706                  17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 1546 from Patent EP1273660.
ACCESSION   AX649706
VERSION     AX649706.1  GI:29152524
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 1546 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.7%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAGCC 1760
              ||||||||||||||||
Db         16 ACTCTGATCTGAAGCC 1


RESULT 33
AR299993
LOCUS       AR299993                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 11728 from patent US 6537751.
ACCESSION   AR299993
VERSION     AR299993.1  GI:31687277
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 11728 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 19;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2146 GACCTAATCCAAGTGAACC 2164
              || | ||||||||||||||
Db          1 GAACAAATCCAAGTGAACC 19


RESULT 34
AX649703/c
LOCUS       AX649703                  17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 1543 from Patent EP1273660.
ACCESSION   AX649703
VERSION     AX649703.1  GI:29152521
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 1543 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.7%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 17;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1747 TCTGATCTGAAGCCCAG 1763
              ||||||||||||||| ||
Db         17 TCTGATCTGAAGCCAAG 1


RESULT 35
AX649704/c
LOCUS       AX649704                  17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 1544 from Patent EP1273660.
ACCESSION   AX649704
VERSION     AX649704.1  GI:29152522
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 1544 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.7%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 17;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1746 CTCTGATCTGAAGCCCA 1762
              ||||||||||||||| |
Db         17 CTCTGATCTGAAGCCAA 1


RESULT 36
AR328634/c
LOCUS       AR328634                  16 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6036 from patent US 6566127.
ACCESSION   AR328634
VERSION     AR328634.1  GI:33714442
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6036 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.6%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 17;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1897 ACAAGCACTTTGTAA 1911
              |||||||||||||||
Db         16 ACAAGCACTTTGTAA 2


RESULT 37
AX649707/c
LOCUS       AX649707                  17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 1547 from Patent EP1273660.
ACCESSION   AX649707
VERSION     AX649707.1  GI:29152525
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 1547 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.6%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAGC 1759
              |||||||||||||||
Db         15 ACTCTGATCTGAAGC 1


RESULT 38
BD176280
LOCUS       BD176280                  18 bp    DNA     linear   PAT 18-MAR-2003
DEFINITION  A method of arraying genome clone.
ACCESSION   BD176280
VERSION     BD176280.1  GI:29121986
KEYWORDS    WO 02072815-A/80.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: WO 02072815-A 80 19-SEP-2002;
            EIICHI SOEDA,TAKESHI KUKITA
COMMENT     OS   Artificial Sequence
            PN   WO 02072815-A/80
            PD   19-SEP-2002
            PF   17-MAY-2001 WO 2001JP004139
            PR   12-MAR-2001 JP 01P    68285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12Q1/68
            CC   Description of Artificial Sequence: Synthetic DNA FH   Key
                    Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.6%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAAATCCTATTAGTC 1969
              |||||||||||||||
Db          4 AAAATCCTATTAGTC 18


RESULT 39
BD090202
LOCUS       BD090202                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD090202
VERSION     BD090202.1  GI:22635812
KEYWORDS    JP 2001321190-A/2446.
SOURCE      synthetic construct
```

```
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 2446 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/2446
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             1.6%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAAATCCTATTAGTC 1969
              |||||||||||||||
Db          4 AAAATCCTATTAGTC 18


RESULT 40
AX649702/c
LOCUS       AX649702                  17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 1542 from Patent EP1273660.
ACCESSION   AX649702
VERSION     AX649702.1  GI:29152520
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 1542 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 27;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CTGATCTGAAGCCCAG 1763
              |||||||||||||| ||
Db         17 CTGATCTGAAGCCAAG 2


RESULT 41
AX734430/c
LOCUS       AX734430                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 20 from Patent WO03025177.
ACCESSION   AX734430
VERSION     AX734430.1  GI:30513707
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 20 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 27;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1583 AATATAAAAATAGAGC 1598
              |||||||||||||| |
Db         16 AATATAAAAATAGATC 1


RESULT 42
AX734488/c
LOCUS       AX734488                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 78 from Patent WO03025177.
ACCESSION   AX734488
VERSION     AX734488.1  GI:30513765
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 78 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 27;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2016 AATATCCCTTGATGAT 2031
              ||||||| ||||||||
Db         17 AATATCCATTGATGAT 2


RESULT 43
AX760843
LOCUS       AX760843                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4164 from Patent WO03040369.
ACCESSION   AX760843
VERSION     AX760843.1  GI:32255459
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
```

```
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4164 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 27;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1750 GATCTGAAGCCCAGCT 1765
              ||||||||||||||| |
Db          1 GATCTGAAGCCCAGGT 16


RESULT 44
AX761964
LOCUS       AX761964                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 5285 from Patent WO03040369.
ACCESSION   AX761964
VERSION     AX761964.1  GI:32256580
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 5285 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 27;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1750 GATCTGAAGCCCAGCT 1765
              ||||| ||||||||||
Db          1 GATCTTAAGCCCAGCT 16


RESULT 45
AR188899/c
LOCUS       AR188899                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 4387 from patent US 6346398.
ACCESSION   AR188899
VERSION     AR188899.1  GI:20234864
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 4387 12-FEB-2002;
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 46
AR190454/c
LOCUS       AR190454                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 5942 from patent US 6346398.
ACCESSION   AR190454
VERSION     AR190454.1  GI:20236419
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 5942 12-FEB-2002;
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 47
AR324752/c
LOCUS       AR324752                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2154 from patent US 6566127.
ACCESSION   AR324752
VERSION     AR324752.1  GI:33710560
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2154 20-MAY-2003;
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unknown"
                      /mol_type="unassigned RNA"

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 48
AR325377/c
LOCUS       AR325377                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2779 from patent US 6566127.
ACCESSION   AR325377
VERSION     AR325377.1  GI:33711185
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2779 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 49
AX649708/c
LOCUS       AX649708                  17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 1548 from Patent EP1273660.
ACCESSION   AX649708
VERSION     AX649708.1  GI:29152526
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 1548 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAG 1758
              ||||||||||||||
Db         14 ACTCTGATCTGAAG 1


RESULT 50
AX727495/c
LOCUS       AX727495                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5182 from Patent WO03025176.
ACCESSION   AX727495
VERSION     AX727495.1  GI:30506838
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5182 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2282 GGAAAAAAAAATTG 2295
              ||||||||||||||
Db         17 GGAAAAAAAAATTG 4


RESULT 51
AX734753
LOCUS       AX734753                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 343 from Patent WO03025177.
ACCESSION   AX734753
VERSION     AX734753.1  GI:30514030
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 343 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1954 CAAAATCCTATTAG 1967
              ||||||||||||||
Db          4 CAAAATCCTATTAG 17


RESULT 52
A88600/c
LOCUS       A88600                    17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 748 from Patent WO9833904.
ACCESSION   A88600
VERSION     A88600.1  GI:6737170
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 748 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1918 AAATGATACAAAATTTA 1934
              ||||||||  ||  |||||
```

```
Db         17 AAATGATAAAACATTTA 1


RESULT 53
A90567/c
LOCUS       A90567                  17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 748 from Patent EP0856579.
ACCESSION   A90567
VERSION     A90567.1  GI:6739081
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 748 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1918 AAATGATACAAAATTTA 1934
              ||||||||  || |||||
Db         17 AAATGATAAAACATTTA 1


RESULT 54
AR034270
LOCUS       AR034270                17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 2 from patent US 5869336.
ACCESSION   AR034270
VERSION     AR034270.1  GI:5949875
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Meyer,S.L., Scott,R.W. and Siman,R.
  TITLE     Recombinant enzymatically active calpain expressed in a baculovirus
            system
  JOURNAL   Patent: US 5869336-A 2 09-FEB-1999;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 CACTCTGATCTGAAGCC 1760
              ||| ||||||||||| |
Db          1 CACCCTGATCTGAAGAC 17


RESULT 55
AR046375/c
LOCUS       AR046375                17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1168 from patent US 5817796.
ACCESSION   AR046375
VERSION     AR046375.1  GI:5967840
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 1168 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1574 AACTTCCAAAATATAAA 1590
              |||| ||||| ||||||
Db         17 AACTCCCAAATTATAAA 1


RESULT 56
AR046377/c
LOCUS       AR046377                17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1170 from patent US 5817796.
ACCESSION   AR046377
VERSION     AR046377.1  GI:5967842
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 1170 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1573 GAACTTCCAAAATATAA 1589
              ||||| ||||| |||||
Db         17 GAACTCCCAAATTATAA 1


RESULT 57
AR083059/c
LOCUS       AR083059                17 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 3 from patent US 5976799.
ACCESSION   AR083059
VERSION     AR083059.1  GI:10009849
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   O'Brien,T.J. and Shiqemasa,K.
  TITLE     Early detection of ovarian carcinoma using P16 gene products
  JOURNAL   Patent: US 5976799-A 3 02-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2315 AAGGAACTGAATTCTGC 2331
              |||||||||| ||| ||
Db         17 AAGGAACTGACTTCGGC 1
```

```
RESULT 58
AR167916/c
LOCUS       AR167916                  17 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 3 from patent US 6287775.
ACCESSION   AR167916
VERSION     AR167916.1  GI:17903728
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   O'Brien,T.J. and Shigemasa,K.
  TITLE     Early detection of ovarian carcinoma using p16 gene products
  JOURNAL   Patent: US 6287775-A 3 11-SEP-2001;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2315 AAGGAACTGAATTCTGC 2331
              ||||||||||| ||| ||
Db         17 AAGGAACTGACTTCGGC 1


RESULT 59
CQ618041
LOCUS       CQ618041                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 2781 from Patent WO0192524.
ACCESSION   CQ618041
VERSION     CQ618041.1  GI:41668259
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2781 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1666 CTCCTTCAAGCATCACC 1682
              | ||||||||||| ||||
Db          1 CACCTTCAAGCACCACC 17


RESULT 60
I53427/c
LOCUS       I53427                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 1168 from patent US 5646042.
ACCESSION   I53427
VERSION     I53427.1  GI:2474630
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 1168 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1574 AACTTCCAAAATATAAA 1590
              |||| ||||| ||||||
Db         17 AACTCCCAAATTATAAA 1


RESULT 61
I53429/c
LOCUS       I53429                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 1170 from patent US 5646042.
ACCESSION   I53429
VERSION     I53429.1  GI:2474632
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 1170 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1573 GAACTTCCAAAATATAA 1589
              ||||| ||||| |||||
Db         17 GAACTCCCAAATTATAA 1


RESULT 62
AR188898/c
LOCUS       AR188898                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 4386 from patent US 6346398.
ACCESSION   AR188898
VERSION     AR188898.1  GI:20234863
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 4386 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              |||||||||||||  ||
Db         17 TGAAAATCAAATGCGGC 1


RESULT 63
```

```
AR190453/c
LOCUS       AR190453                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 5941 from patent US 6346398.
ACCESSION   AR190453
VERSION     AR190453.1  GI:20236418
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 5941 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              ||||||||||||  ||
Db         17 TGAAAATCAAATGTGGC 1


RESULT 64
AR324751/c
LOCUS       AR324751                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2153 from patent US 6566127.
ACCESSION   AR324751
VERSION     AR324751.1  GI:33710559
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2153 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              ||||||||||||  ||
Db         17 TGAAAATCAAATGCGGC 1


RESULT 65
AR325376/c
LOCUS       AR325376                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2778 from patent US 6566127.
ACCESSION   AR325376
VERSION     AR325376.1  GI:33711184
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2778 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              ||||||||||||  ||
Db         17 TGAAAATCAAATGTGGC 1


RESULT 66
AR328081/c
LOCUS       AR328081                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 5483 from patent US 6566127.
ACCESSION   AR328081
VERSION     AR328081.1  GI:33713889
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 5483 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1899 AAGCACTTTGTAAATTG 1915
              |||||||||||||| | |
Db         17 AAGCACTTTGTAACTAG 1


RESULT 67
AR459104
LOCUS       AR459104                 17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2781 from patent US 6686188.
ACCESSION   AR459104
VERSION     AR459104.1  GI:42694161
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2781 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1666 CTCCTTCAAGCATCACC 1682
              | |||||||||| ||||
Db          1 CACCTTCAAGCACCACC 17


RESULT 68
```

```
AX531188/c
LOCUS       AX531188                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 697 from Patent EP1239051.
ACCESSION   AX531188
VERSION     AX531188.1  GI:25254169
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 697 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2042 TGATATGTCCATTATTA 2058
              |||||| ||| ||||||
Db         17 TGATATCTCCCTTATTA 1


RESULT 69
AX531189/c
LOCUS       AX531189                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 698 from Patent EP1239051.
ACCESSION   AX531189
VERSION     AX531189.1  GI:25254171
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 698 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2041 ATGATATGTCCATTATT 2057
              ||||||| ||| |||||
Db         17 ATGATATCTCCCTTATT 1


RESULT 70
AX649193/c
LOCUS       AX649193                  17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 1033 from Patent EP1273660.
ACCESSION   AX649193
VERSION     AX649193.1  GI:29152011
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 1033 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2274 AGCAAGCAGGAAAAAAA 2290
              || |||||||||||| |
Db         17 AGAAAGCAGGAAAAACA 1


RESULT 71
AX745290
LOCUS       AX745290                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1255 from Patent WO03031621.
ACCESSION   AX745290
VERSION     AX745290.1  GI:30723957
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1255 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CCCTGAGAAATCTCCTT 1671
              ||||||||| | |||||
Db         1 CCCTGAGAAGTTTCCTT 17


RESULT 72
AX759395
LOCUS       AX759395                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 2716 from Patent WO03040369.
ACCESSION   AX759395
VERSION     AX759395.1  GI:32254011
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 2716 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2095 GATGCAGTTAAGGTTCC 2111
              ||| ||||| |||||||
Db          1 GATCCAGTTCAGGTTCC 17


RESULT 73
BD066113/c
LOCUS       BD066113                  17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066113
VERSION     BD066113.1  GI:22611716
KEYWORDS    JP 2001511000-A/748.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 748 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/748
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 36;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1918 AAATGATACAAAATTTA 1934
              |||||||| || |||||
Db         17 AAATGATAAAACATTTA 1


RESULT 74
CQ828930/c
LOCUS       CQ828930                  16 bp    DNA     linear   PAT 05-JUL-2004
DEFINITION  Sequence 648 from Patent WO2004053120.
ACCESSION   CQ828930
VERSION     CQ828930.1  GI:49732413
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Weihe,E., Bieller,A. and Schaefer,M.K.
  TITLE     Regulatory elements in the 5' region of the vr1 gene
  JOURNAL   Patent: WO 2004053120-A 648 24-JUN-2004;
            Gruenenthal GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="V$FREAC7 01"

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 36;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1970 ATATATTTATAGATT 1984
              |||||||||||.|||
Db         15 ATATATTTATATATT 1


RESULT 75
I38662/c
LOCUS       I38662                    16 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 22 from patent US 5614617.
ACCESSION   I38662
VERSION     I38662.1  GI:2084716
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Cook,P.D. and Sanghvi,Y.S.
  TITLE     Nuclease resistant, pyrimidine modified oligonucleotides that
            detect and modulate gene expression
  JOURNAL   Patent: US 5614617-A 22 25-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 36;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2389 GGGCTGACACCTGGA 2403
              |||| ||||||||||
Db         15 GGGCGGACACCTGGA 1


RESULT 76
I38663/c
LOCUS       I38663                    16 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 23 from patent US 5614617.
ACCESSION   I38663
VERSION     I38663.1  GI:2084717
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Cook,P.D. and Sanghvi,Y.S.
  TITLE     Nuclease resistant, pyrimidine modified oligonucleotides that
            detect and modulate gene expression
  JOURNAL   Patent: US 5614617-A 23 25-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 36;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2389 GGGCTGACACCTGGA 2403
              |||| ||||||||||
Db         15 GGGCGGACACCTGGA 1


RESULT 77
I38692/c
LOCUS       I38692                    16 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 52 from patent US 5614617.
ACCESSION   I38692
```

```
VERSION     I38692.1  GI:2084746
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Cook,P.D. and Sanghvi,Y.S.
  TITLE     Nuclease resistant, pyrimidine modified oligonucleotides that
            detect and modulate gene expression
  JOURNAL   Patent: US 5614617-A 52 25-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 36;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2389 GGGCTGACACCTGGA 2403
              |||| ||||||||||
Db         15 GGGCGGACACCTGGA 1


RESULT 78
I38698/c
LOCUS       I38698                   16 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 58 from patent US 5614617.
ACCESSION   I38698
VERSION     I38698.1  GI:2084752
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Cook,P.D. and Sanghvi,Y.S.
  TITLE     Nuclease resistant, pyrimidine modified oligonucleotides that
            detect and modulate gene expression
  JOURNAL   Patent: US 5614617-A 58 25-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 36;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2389 GGGCTGACACCTGGA 2403
              |||| ||||||||||
Db         15 GGGCGGACACCTGGA 1


RESULT 79
AX572137/c
LOCUS       AX572137                 16 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 177 from Patent WO02055741.
ACCESSION   AX572137
VERSION     AX572137.1  GI:26004227
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 177 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 36;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1969 CATATATTTATAGAT 1983
              |||||||| ||||||
Db         16 CATATATTGATAGAT 2


RESULT 80
ATH523894/c
LOCUS       ATH523894                16 bp    DNA     linear   PLN 29-MAR-2003
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            064A08.
ACCESSION   AJ523894
VERSION     AJ523894.1  GI:26792130
KEYWORDS    left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 16)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="064A08"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .16
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 36;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1927 AAAATTTAAAGTTTA 1941
              ||||| |||||||||
Db         16 AAAATGTAAAGTTTA 2


RESULT 81
AR041231/c
```

```
LOCUS       AR041231                15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 21 from patent US 5811300.
ACCESSION   AR041231
VERSION     AR041231.1  GI:5961727
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
  TITLE     TNF-.alpha. ribozymes
  JOURNAL   Patent: US 5811300-A 21 22-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 36;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2201 AGTATGTGAGAGG 2213
              |||||||||||||
Db         15 AGTATGTGAGAGG 3


RESULT 82
AX636694/c
LOCUS       AX636694                15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3833 from Patent EP1260586.
ACCESSION   AX636694
VERSION     AX636694.1  GI:28472308
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 3833 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             1.4%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 36;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2201 AGTATGTGAGAGG 2213
              |||||||||||||
Db         15 AGTATGTGAGAGG 3


RESULT 83
AR435811/c
LOCUS       AR435811                16 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 70 from patent US 6656731.
ACCESSION   AR435811
VERSION     AR435811.1  GI:40198895
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Eckstein,F., Ludwig,J. and Beigelman,L.
  TITLE     Nucleic acid catalysts with endonuclease activity
  JOURNAL   Patent: US 6656731-A 70 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 13;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 43;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2278 AGCAGGAAAAAAA 2290
              |||||||||||||
Db         13 AGCAGGAAAAAAA 1


RESULT 84
A88599/c
LOCUS       A88599                  16 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 747 from Patent WO9833904.
ACCESSION   A88599
VERSION     A88599.1  GI:6737169
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 747 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1918 AAATGATACAAAATTT 1933
              |||||||| || ||||
Db         16 AAATGATAAAACATTT 1


RESULT 85
A90566/c
LOCUS       A90566                  16 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 747 from Patent EP0856579.
ACCESSION   A90566
VERSION     A90566.1  GI:6739080
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 747 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1918 AAATGATACAAAATTT 1933
              |||||||| || ||||
```

```
Db         16 AAATGATAAAACATTT 1


RESULT 86
AR033128/c
LOCUS       AR033128                  16 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 15 from patent US 5869248.
ACCESSION   AR033128
VERSION     AR033128.1  GI:5948733
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Yuan,Y., Guerrier-Takada,C., Altman,S. and Liu,F.
  TITLE     Targeted cleavage of RNA using ribonuclease P targeting and
            cleavage sequences
  JOURNAL   Patent: US 5869248-A 15 09-FEB-1999;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CCTTCAAGCATCACCA 1683
              |||||| || ||||||
Db         16 CCTTCATGCCTCACCA 1


RESULT 87
BD226644
LOCUS       BD226644                  16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Use of antiprolactin agent for remedy of hypercytosis.
ACCESSION   BD226644
VERSION     BD226644.1  GI:33036414
KEYWORDS    JP 2002515404-A/2.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Chen,W.Y. and Wagner,T.E.
  TITLE     Use of antiprolactin agent for remedy of hypercytosis
  JOURNAL   Patent: JP 2002515404-A 2 28-MAY-2002;
            WEN Y CHEN,THOMAS E WAGNER
COMMENT     OS   Artificial Sequence
            PN   JP 2002515404-A/2
            PD   28-MAY-2002
            PF   11-MAY-1999 JP 2000547993
            PR   12-MAY-1998 US    60/085128,05-FEB-1999 US    09/246041 PI
            WEN Y CHEN,THOMAS E WAGNER
            PC   A61K38/22,A61K31/138,A61P35/00,C07K14/575,C07K14/72// PC
            (A61K38/22,A61K31:133),A61K37/24,(A61K37/24,A61K31:133) CC
            Artificially synthesized primer sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATGAT 1885
              ||||| |||||| |||
Db          1 ATGAACATCAAAGGAT 16


RESULT 88
BD226649
LOCUS       BD226649                  16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Use of antiprolactin agent for remedy of hypercytosis.
ACCESSION   BD226649
VERSION     BD226649.1  GI:33036419
KEYWORDS    JP 2002515404-A/7.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Chen,W.Y. and Wagner,T.E.
  TITLE     Use of antiprolactin agent for remedy of hypercytosis
  JOURNAL   Patent: JP 2002515404-A 7 28-MAY-2002;
            WEN Y CHEN,THOMAS E WAGNER
COMMENT     OS   Artificial Sequence
            PN   JP 2002515404-A/7
            PD   28-MAY-2002
            PF   11-MAY-1999 JP 2000547993
            PR   12-MAY-1998 US    60/085128,05-FEB-1999 US    09/246041 PI
            WEN Y CHEN,THOMAS E WAGNER
            PC   A61K38/22,A61K31/138,A61P35/00,C07K14/575,C07K14/72// PC
            (A61K38/22,A61K31:133),A61K37/24,(A61K37/24,A61K31:133) CC
            Artificially synthesized primer sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATGAT 1885
              ||||| |||||| |||
Db          1 ATGAACATCAAAGGAT 16


RESULT 89
I41208/c
LOCUS       I41208                    16 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 15 from patent US 5624824.
ACCESSION   I41208
VERSION     I41208.1  GI:2081798
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Yuan,Y., Guerrier-Takada,C., Altman,S. and Liu,F.
  TITLE     Targeted cleavage of RNA using eukaryotic ribonuclease P and
            external guide sequence
  JOURNAL   Patent: US 5624824-A 15 29-APR-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CCTTCAAGCATCACCA 1683
              |||||| || ||||||
Db         16 CCTTCATGCCTCACCA 1


RESULT 90
```

```
I92440/c
LOCUS       I92440                  16 bp    DNA     linear   PAT 01-DEC-1998
DEFINITION  Sequence 15 from patent US 5728521.
ACCESSION   I92440
VERSION     I92440.1  GI:3936910
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Yuan,Y., Guerrier-Takada,C., Altman,S. and Liu,F.
  TITLE     Targeted cleavage of RNA using eukaryotic ribonuclease P and
            external guide sequence
  JOURNAL   Patent: US 5728521-A 15 17-MAR-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CCTTCAAGCATCACCA 1683
              |||||| || ||||||
Db         16 CCTTCATGCCTCACCA 1


RESULT 91
AR328635/c
LOCUS       AR328635                16 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6037 from patent US 6566127.
ACCESSION   AR328635
VERSION     AR328635.1  GI:33714443
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6037 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1893 ATATACAAGCACTTTG 1908
              ||  ||||||||||||
Db         16 ATGAACAAGCACTTTG 1


RESULT 92
AR329711
LOCUS       AR329711                16 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 7113 from patent US 6566127.
ACCESSION   AR329711
VERSION     AR329711.1  GI:33715519
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 7113 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 GAAATCTCCTTCAAGC 1676
              |||||||| | |||||
Db          1 GAAATCTCTTGCAAGC 16


RESULT 93
AR435950/c
LOCUS       AR435950                16 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 209 from patent US 6656731.
ACCESSION   AR435950
VERSION     AR435950.1  GI:40199034
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Eckstein,F., Ludwig,J. and Beigelman,L.
  TITLE     Nucleic acid catalysts with endonuclease activity
  JOURNAL   Patent: US 6656731-A 209 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1974 ATTTATAGATTGTGTT 1989
              ||||| |||||||| |
Db         16 ATTTACAGATTGTGCT 1


RESULT 94
AX255763/c
LOCUS       AX255763                16 bp    DNA     linear   PAT 10-OCT-2001
DEFINITION  Sequence 184 from Patent WO0170982.
ACCESSION   AX255763
VERSION     AX255763.1  GI:16074818
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Beger,C., Barber,J. and Wong-Staal,F.
  TITLE     Brca-1 regulators and methods of use
  JOURNAL   Patent: WO 0170982-A 184 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2289 AAAATTGGGACCTCAG 2304
              ||||| |||||| |||
Db         16 AAAATAGGGACCACAG 1


RESULT 95
```

```
BD066112/c
LOCUS       BD066112                 16 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066112
VERSION     BD066112.1  GI:22611715
KEYWORDS    JP 2001511000-A/747.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 747 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/747
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 47;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1918 AAATGATACAAAATTT 1933
              |||||||| || ||||
Db         16 AAATGATAAAACATTT 1


RESULT 96
A33037
LOCUS       A33037                   15 bp    DNA     linear   PAT 11-DEC-1996
DEFINITION  Synthetic gene III fdTdeltaBst construct.
ACCESSION   A33037
VERSION     A33037.1  GI:1926674
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   .
  TITLE     METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS
  JOURNAL   Patent: WO 9201047-A 160 23-JAN-1992;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2127 GAGACTGTTGAAAG 2140
              || ||||||||||||
Db          1 GAAACTGTTGAAAG 14


RESULT 97
AR033322/c
LOCUS       AR033322                 15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 88 from patent US 5869253.
ACCESSION   AR033322
VERSION     AR033322.1  GI:5948927
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Method and reagent for inhibiting hepatitis C virus replication
  JOURNAL   Patent: US 5869253-A 88 09-FEB-1999;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1597 GCCACCATATCAAC 1610
              |||||||||||| ||
Db         15 GCCACCATATCCAC 2


RESULT 98
AR056010
LOCUS       AR056010                 15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 214 from patent US 5837542.
ACCESSION   AR056010
VERSION     AR056010.1  GI:5981587
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 214 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2019 ATCCCTTGATGATA 2032
              | ||||||||||||
Db          2 AACCCTTGATGATA 15


RESULT 99
AR113144/c
LOCUS       AR113144                 15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 88 from patent US 6132966.
ACCESSION   AR113144
VERSION     AR113144.1  GI:14093466
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Method and reagent for inhibiting hepatitis C virus replication
  JOURNAL   Patent: US 6132966-A 88 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
```

```
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1597 GCCACCATATCAAC 1610
              ||||||||||| ||
Db         15 GCCACCATATCCAC 2


RESULT 100
AR113768
LOCUS       AR113768                 15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 214 from patent US 6132967.
ACCESSION   AR113768
VERSION     AR113768.1  GI:14094090
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 214 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2019 ATCCCTTGATGATA 2032
              | ||||||||||||
Db          2 AACCCTTGATGATA 15


RESULT 101
BD184130/c
LOCUS       BD184130                 15 bp    DNA     linear   PAT 17-JUN-2003
DEFINITION  Method and detector for identifying subtypes of human papiloma
            viruses.
ACCESSION   BD184130
VERSION     BD184130.1  GI:31876330
KEYWORDS    JP 2002360271-A/109.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Ling,C., Lin,R., Yoo,Z., Huang,X., Lee,B., Lee,S., Lin,Y.,
            Huang,C., Hsu,H., Shi,C., Yeh,C., Cao,Y. and Pan,C.
  TITLE     Method and detector for identifying subtypes of human papiloma
  JOURNAL   Patent: JP 2002360271-A 109 17-DEC-2002;
            KING CAR FOOD INDUSTRIAL CO LTD
COMMENT     OS   Artificial Sequence
            PN   JP 2002360271-A/109
            PD   17-DEC-2002
            PF   28-NOV-2001 JP 2001362595
            PR   04-MAY-2001 TW     90110785
            PI   CHING-YEE LING,RUEY-WEN LIN,ZHOU-MENG YOO,XIN-HSUAN HUANG,BOW-
            PI   HAENG LEE,
            PI   SHENG-HSIUNG LEE,YI-JU LIN,CI-CHUNG HUANG,HAN-CHANG HSU,CHA-
            PI   WEN SHI,
            PI   CHIH-XIN YEH,YI-FENG CAO,CHIH-LONG PAN
            PC   C12N15/09,C12N15/09,C12M1/34,C12Q1/04,C12Q1/42,C12Q1/68 PC
            ,C12Q1/70,G01N21/64,
            PC   G01N33/53,G01N33/574,G01N33/58,G01N37/00//(C12M1/34,C12R1:93),
            PC   (C12Q1/70,C12R1:93),C12N15/00,C12N15/00
            CC   Oligonucleotide M3203 for identifying HPV 32. FH   Key
                Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1639 CAGTTCTTACAGTA 1652
              ||||| ||||||||
Db         14 CAGTTGTTACAGTA 1


RESULT 102
BD207055/c
LOCUS       BD207055                 15 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD207055
VERSION     BD207055.1  GI:33016825
KEYWORDS    JP 2002512791-A/645.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 645 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/645
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                    related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                    virus)'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1597 GCCACCATATCAAC 1610
              ||||||||||| ||
Db         15 GCCACCATATCCAC 2


RESULT 103
BD208985/c
LOCUS       BD208985                 15 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION   BD208985
VERSION     BD208985.1  GI:33018755
```

```
KEYWORDS    JP 2002512791-A/2575.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Blatt,L., Mcswiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
  JOURNAL   Patent: JP 2002512791-A 2575 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Hepatitis virus (hepatitis C virus)
            PN   JP 2002512791-A/2575
            PD   08-MAY-2002
            PF   26-APR-1999 JP 2000545991
            PR   27-APR-1998 US    60/083217,18-SEP-1998 US    60/100842 PR
            25-FEB-1999 US    09/257608,23-MAR-1999 US    09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A  PI
            PAVCO,
            PI   DENNIS MACEJAK
            PC   C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC   A61K37/66,
            PC   C12N15/00
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
            CC   hepatitis C virus infection.
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Hepatitis virus (hepatitis C  FT
                              virus)'.
FEATURES            Location/Qualifiers
     source         1. .15
                    /organism="unidentified"
                    /mol_type="genomic RNA"
                    /db_xref="taxon:32644"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1866 AGTCATGAAAATCA 1879
              |||||| |||||||
Db         15 AGTCATCAAAATCA 2


RESULT 104
I57551/c
LOCUS       I57551                    15 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 88 from patent US 5610054.
ACCESSION   I57551
VERSION     I57551.1  GI:2482615
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Draper,K.G.
  TITLE     Enzymatic RNA molecule targeted against Hepatitis C virus
  JOURNAL   Patent: US 5610054-A 88 11-MAR-1997;
FEATURES            Location/Qualifiers
     source         1. .15
                    /organism="unknown"
                    /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1597 GCCACCATATCAAC 1610
              |||||||||| ||
Db         15 GCCACCATATCCAC 2


RESULT 105
AX572592
LOCUS       AX572592                  15 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 632 from Patent WO02055741.
ACCESSION   AX572592
VERSION     AX572592.1  GI:26004682
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 632 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES            Location/Qualifiers
     source         1. .15
                    /organism="Human immunodeficiency virus"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:12721"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1727 TGTATGTAGGGTGG 1740
              |||||||||||| |
Db         2 TGTATGTAGGGTCG 15


RESULT 106
AX633098
LOCUS       AX633098                  15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 237 from Patent EP1260586.
ACCESSION   AX633098
VERSION     AX633098.1  GI:28468712
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 237 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES            Location/Qualifiers
     source         1. .15
                    /organism="unidentified"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:32644"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2019 ATCCCTTGATGATA 2032
              | ||||||||||||
Db         2 AACCCTTGATGATA 15


RESULT 107
AX742306/c
LOCUS       AX742306                  15 bp    DNA     linear   PAT 12-MAY-2003
DEFINITION  Sequence 109 from Patent EP1302550.
ACCESSION   AX742306
VERSION     AX742306.1  GI:30576274
KEYWORDS    .
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Lin,C.Y., Lin,R.W., You,C.M., Huang,H.H., Lee,B.H., Lee,H.H.,
            Lin,Y.J., Fan,C.C., Hsu,H.C., Shih,C.W., Yeh,C.H., Kao,Y.F.,
            Pan,C.L. and Chan,P.
  TITLE     Method and detector for identifying subtypes of human papilloma
            viruses
  JOURNAL   Patent: EP 1302550-A 109 16-APR-2003;
            King Car Food Industrial Co., Ltd. (TW)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide for Identifying HPV 32"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1639 CAGTTCTTACAGTA 1652
              ||||| ||||||||
Db         14 CAGTTGTTACAGTA 1

RESULT 108
ATH529196
LOCUS       ATH529196                 15 bp    DNA     linear   PLN 29-MAR-2003
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            180D01.
ACCESSION   AJ529196
VERSION     AJ529196.1  GI:26797456
KEYWORDS    left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 15)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="180D01"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .15
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 48;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2045 TATGTCCATTATTA 2058
              |||||||||| |||
Db          2 TATGTCCATTGTTA 15

RESULT 109
CQ766241
LOCUS       CQ766241                  12 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 202 from Patent WO2004005547.
ACCESSION   CQ766241
VERSION     CQ766241.1  GI:44908501
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Weinzierl,R.
  TITLE     Method
  JOURNAL   Patent: WO 2004005547-A 202 15-JAN-2004;
            IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="HS motif"

  Query Match             1.3%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1583 AATATAAAAATA 1594
              ||||||||||||
Db          1 AATATAAAAATA 12

RESULT 110
AX394466
LOCUS       AX394466                  13 bp    DNA     linear   PAT 18-MAY-2002
DEFINITION  Sequence 11 from Patent WO0218638.
ACCESSION   AX394466
VERSION     AX394466.1  GI:21065604
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Risinger,C., Andersson,M.K., Lewander,T. and Oliasson,E.
  TITLE     Detection of cyp2d6 polymorphisms
  JOURNAL   Patent: WO 0218638-A 11 07-MAR-2002;
            Gemini Genomics PLC (GB)
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide"

  Query Match             1.3%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAA 1592
              ||||||||||||
Db          1 AAAATATAAAAA 12
```

```
RESULT 111
AX394494/c
LOCUS       AX394494                  13 bp    DNA     linear   PAT 18-MAY-2002
DEFINITION  Sequence 39 from Patent WO0218638.
ACCESSION   AX394494
VERSION     AX394494.1  GI:21065632
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Risinger,C., Andersson,M.K., Lewander,T. and Oliasson,E.
  TITLE     Detection of cyp2d6 polymorphisms
  JOURNAL   Patent: WO 0218638-A 39 07-MAR-2002;
            Gemini Genomics PLC (GB)
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide"

  Query Match             1.3%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAA 1592
              ||||||||||||
Db         13 AAAATATAAAAA 2


RESULT 112
A40583/c
LOCUS       A40583                    14 bp    DNA     linear   PAT 05-MAR-1997
DEFINITION  Sequence 120 from Patent WO9425578.
ACCESSION   A40583
VERSION     A40583.1  GI:2296618
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   .
  TITLE     ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE
            EFFECTS OF TRANSFORMING GROWTH FACTOR--g(b) (TGF--g(b))
  JOURNAL   Patent: WO 9425578-A 120 10-NOV-1994;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2443 TTCTGTGCTGGA 2454
              ||||||||||||
Db         12 TTCTGTGCTGGA 1


RESULT 113
A89107/c
LOCUS       A89107                    14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 1255 from Patent WO9833904.
ACCESSION   A89107
VERSION     A89107.1  GI:6737677
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 1255 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2443 TTCTGTGCTGGA 2454
              ||||||||||||
Db         12 TTCTGTGCTGGA 1


RESULT 114
AR232863/c
LOCUS       AR232863                  14 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 120 from patent US 6455689.
ACCESSION   AR232863
VERSION     AR232863.1  GI:27275201
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,G.-F., Brysch,W., Schlingensiepen,K.-H.,
            Schlingensiepen,R. and Bogdahn,U.
  TITLE     Antisense-oligonucleotides for transforming growth factor-.beta.
            (TGF-.beta.)
  JOURNAL   Patent: US 6455689-A 120 24-SEP-2002;
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2443 TTCTGTGCTGGA 2454
              ||||||||||||
Db         12 TTCTGTGCTGGA 1


RESULT 115
AX030158/c
LOCUS       AX030158                  14 bp    DNA     linear   PAT 16-SEP-2000
DEFINITION  Sequence 120 from Patent EP1008649.
ACCESSION   AX030158
VERSION     AX030158.1  GI:10190375
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Bogdahn,U., Brysch,W., Schlingensiepen,G.F., Schlingensiepen,K.H.
            and Schlingensiepen,R.
  TITLE     Antisense-oligonucleotides for the treatment of immuno-suppressive
            effects of transforming growth factor-b2(tgf-b2)
  JOURNAL   Patent: EP 1008649-A 120 14-JUN-2000;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
```

```
                    /db_xref="taxon:9606"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2443 TTCTGTGCTGGA 2454
              ||||||||||||
Db         12 TTCTGTGCTGGA 1


RESULT 116
AX316479/c
LOCUS       AX316479                  14 bp    DNA     linear   PAT 14-DEC-2001
DEFINITION  Sequence 120 from Patent EP1160319.
ACCESSION   AX316479
VERSION     AX316479.1  GI:17899652
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Schlingensiepen,G.F., Brysch,W., Schlingensiepen,K.H.,
            Schlingensiepen,R. and Bogdahn,U.
  TITLE     Antisense-oligonucleotides for the treatment of immunosuppressive
            effects of transforming growth factor-beta (tgf-beta)
  JOURNAL   Patent: EP 1160319-A 120 05-DEC-2001;
            BIOGNOSTIK GESELLSCHAFT FUER BIOMOLEKULARE DIAGNOSTIK mbH (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="Description of unknown: unknown"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2443 TTCTGTGCTGGA 2454
              ||||||||||||
Db         12 TTCTGTGCTGGA 1


RESULT 117
AX525338
LOCUS       AX525338                  14 bp    DNA     linear   PAT 21-NOV-2002
DEFINITION  Sequence 25 from Patent WO02066676.
ACCESSION   AX525338
VERSION     AX525338.1  GI:25170227
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Pugnere,D., Marti,J., Manchon,L. and Piquemal,D.
  TITLE     Method for qualitative and quantitative analysis of a population of
            nucleic acids contained in a sample
  JOURNAL   Patent: WO 02066676-A 25 29-AUG-2002;
            CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="TAG"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2272 TCAGCAAGCAGG 2283
              ||||||||||||
Db          3 TCAGCAAGCAGG 14


RESULT 118
AX525386
LOCUS       AX525386                  14 bp    DNA     linear   PAT 21-NOV-2002
DEFINITION  Sequence 73 from Patent WO02066676.
ACCESSION   AX525386
VERSION     AX525386.1  GI:25170275
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
  AUTHORS   Pugnere,D., Marti,J., Manchon,L. and Piquemal,D.
  TITLE     Method for qualitative and quantitative analysis of a population of
            nucleic acids contained in a sample
  JOURNAL   Patent: WO 02066676-A 73 29-AUG-2002;
            CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="TAG"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2272 TCAGCAAGCAGG 2283
              ||||||||||||
Db          3 TCAGCAAGCAGG 14


RESULT 119
AX572590
LOCUS       AX572590                  14 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 630 from Patent WO02055741.
ACCESSION   AX572590
VERSION     AX572590.1  GI:26004680
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 630 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 TGTATGTAGGGT 1738
              ||||||||||||
Db          1 TGTATGTAGGGT 12


RESULT 120
AX572591
LOCUS       AX572591                  14 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 631 from Patent WO02055741.
ACCESSION   AX572591
VERSION     AX572591.1  GI:26004681
```

```
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 631 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 TGTATGTAGGGT 1738
              ||||||||||||
Db          1 TGTATGTAGGGT 12


RESULT 121
AX572642
LOCUS       AX572642                  14 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 682 from Patent WC02055741.
ACCESSION   AX572642
VERSION     AX572642.1  GI:26004732
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 682 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 TGTATGTAGGGT 1738
              ||||||||||||
Db          1 TGTATGTAGGGT 12


RESULT 122
BD066620/c
LOCUS       BD066620                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066620
VERSION     BD066620.1  GI:22612223
KEYWORDS    JP 2001511000-A/1255.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 1255 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/1255
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 47;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2443 TTCTGTGCTGGA 2454
              ||||||||||||
Db         12 TTCTGTGCTGGA 1


RESULT 123
AR132205/c
LOCUS       AR132205                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 630 from patent US 6194150.
ACCESSION   AR132205
VERSION     AR132205.1  GI:14121110
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 630 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
              ||||||||||||
Db         15 ATCCTATTAGTC 4


RESULT 124
AR132206/c
LOCUS       AR132206                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 631 from patent US 6194150.
ACCESSION   AR132206
VERSION     AR132206.1  GI:14121111
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 631 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

```
  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
              ||||||||||||
Db         15 ATCCTATTAGTC 4


RESULT 125
AR132207/c
LOCUS       AR132207                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 632 from patent US 6194150.
ACCESSION   AR132207
VERSION     AR132207.1  GI:14121112
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 632 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
              ||||||||||||
Db         15 ATCCTATTAGTC 4


RESULT 126
AR132208/c
LOCUS       AR132208                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 633 from patent US 6194150.
ACCESSION   AR132208
VERSION     AR132208.1  GI:14121113
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 633 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
              ||||||||||||
Db         12 ATCCTATTAGTC 1


RESULT 127
AR132209/c
LOCUS       AR132209                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 634 from patent US 6194150.
ACCESSION   AR132209
VERSION     AR132209.1  GI:14121114
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 634 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
              ||||||||||||
Db         12 ATCCTATTAGTC 1


RESULT 128
AR133631/c
LOCUS       AR133631                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 2056 from patent US 6194150.
ACCESSION   AR133631
VERSION     AR133631.1  GI:14122536
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 2056 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2271 GTCAGCAAGCAG 2282
              ||||||||||||
Db         14 GTCAGCAAGCAG 3


RESULT 129
AR133905/c
LOCUS       AR133905                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 2330 from patent US 6194150.
ACCESSION   AR133905
VERSION     AR133905.1  GI:14122810
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 2330 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2271 GTCAGCAAGCAG 2282
              ||||||||||||
```

```
Db         14 GTCAGCAAGCAG 3


RESULT 130
AX572585
LOCUS       AX572585                  15 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 625 from Patent WO02055741.
ACCESSION   AX572585
VERSION     AX572585.1  GI:26004675
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 625 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 TGTATGTAGGGT 1738
              ||||||||||||
Db          2 TGTATGTAGGGT 13


RESULT 131
AX572593
LOCUS       AX572593                  15 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 633 from Patent WO02055741.
ACCESSION   AX572593
VERSION     AX572593.1  GI:26004683
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 633 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 TGTATGTAGGGT 1738
              ||||||||||||
Db          4 TGTATGTAGGGT 15


RESULT 132
AX572638
LOCUS       AX572638                  15 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 678 from Patent WO02055741.
ACCESSION   AX572638
VERSION     AX572638.1  GI:26004728
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 678 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 TGTATGTAGGGT 1738
              ||||||||||||
Db          2 TGTATGTAGGGT 13


RESULT 133
AX572640
LOCUS       AX572640                  15 bp    DNA     linear   PAT 29-NOV-2002
DEFINITION  Sequence 680 from Patent WO02055741.
ACCESSION   AX572640
VERSION     AX572640.1  GI:26004730
KEYWORDS    .
SOURCE      Human immunodeficiency virus
  ORGANISM  Human immunodeficiency virus
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   de Smet,K. and Stuyver,L.
  TITLE     Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
  JOURNAL   Patent: WO 02055741-A 680 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Human immunodeficiency virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:12721"

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1727 TGTATGTAGGGT 1738
              ||||||||||||
Db          1 TGTATGTAGGGT 12


RESULT 134
AX587034
LOCUS       AX587034                  15 bp    DNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 56 from Patent WO02072883.
ACCESSION   AX587034
VERSION     AX587034.1  GI:27655909
KEYWORDS    .
SOURCE      Pantoea agglomerans
  ORGANISM  Pantoea agglomerans
            Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
            Enterobacteriaceae; Pantoea.
REFERENCE   1
  AUTHORS   Roetger,A.
  TITLE     Nucleotide carrier for diagnosing and treating oral diseases
  JOURNAL   Patent: WO 02072883-A 56 19-SEP-2002;
```

ROETGER, Antje (DE)

```
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Pantoea agglomerans"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:549"

  Query Match              1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2085 GAATTTGGCAGA 2096
              ||||||||||||
Db          1 GAATTTGGCAGA 12


Search completed: April  6, 2005, 15:52:15
Job time : 2 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 6, 2005, 15:54:25 ; Search time 1 Seconds
(without alignments)
4.568 Million cell updates/sec

Title: US-10-630-399-3
Perfect score: 922
Sequence: 1 gacagtggttattaaagcat.....ctggacttctaatatataga 922

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 148 seqs, 2477 residues

Total number of hits satisfying chosen parameters: 296

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 149 summaries

Database : rng3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	50	5.4	50	1	ABZ03275	Human leukocyte ge
c	2	20	2.2	20	1	ACC58943	Human IL-1 recepto
c	3	20	2.2	20	1	ACC58950	Human IL-1 recepto
c	4	20	2.2	20	1	ACC58957	Human IL-1 recepto
c	5	20	2.2	20	1	ACC58942	Human IL-1 recepto
c	6	20	2.2	20	1	ACC58949	Human IL-1 recepto
c	7	20	2.2	20	1	ACC58968	Human IL-1 recepto
c	8	20	2.2	20	1	ACC58948	Human IL-1 recepto
c	9	20	2.2	20	1	ACC58951	Human IL-1 recepto
c	10	20	2.2	20	1	ACC58954	Human IL-1 recepto
c	11	20	2.2	20	1	ACC58963	Human IL-1 recepto
c	12	20	2.2	20	1	ACC58961	Human IL-1 recepto
c	13	20	2.2	20	1	ACC58967	Human IL-1 recepto
c	14	20	2.2	20	1	ACC58969	Human IL-1 recepto
c	15	20	2.2	20	1	ACC58959	Human IL-1 recepto
c	16	20	2.2	20	1	ACC58964	Human IL-1 recepto
c	17	20	2.2	20	1	ACC58947	Human IL-1 recepto
c	18	20	2.2	20	1	ACC58944	Human IL-1 recepto
c	19	20	2.2	20	1	ACC58962	Human IL-1 recepto
c	20	20	2.2	20	1	ACC58946	Human IL-1 recepto
c	21	20	2.2	20	1	ACC58955	Human IL-1 recepto
c	22	20	2.2	20	1	ACC58953	Human IL-1 recepto
c	23	20	2.2	20	1	ACC58965	Human IL-1 recepto
c	24	20	2.2	20	1	ACC58945	Human IL-1 recepto
c	25	20	2.2	20	1	ACC58956	Human IL-1 recepto
c	26	20	2.2	20	1	ACC58960	Human IL-1 recepto
c	27	20	2.2	20	1	ACC58966	Human IL-1 recepto
c	28	20	2.2	20	1	ACC58952	Human IL-1 recepto
c	29	20	2.2	20	1	ACC58958	Human IL-1 recepto
	30	18	2.0	20	1	AAC81214	Human bcl-6 phosph
	31	17.8	1.9	22	1	ADF13662	Vascular endotheli
	32	17	1.8	17	1	ADB43451	Tumour suppression
c	33	16.8	1.8	21	1	ABS98265	Human lactoferrin
c	34	16	1.7	17	1	ADC05059	Human Na/H exchang
c	35	16	1.7	17	1	ADC05058	Human Na/H exchang
	36	15.8	1.7	19	1	AAZ77372	Human biallelic ma
	37	15.8	1.7	19	1	ADF36507	Human VEGFR1 short
c	38	15.8	1.7	19	1	ADF36080	Human VEGFR1 short
	39	15.8	1.7	19	1	ADR77901	Human apolipoprote
	40	15.8	1.7	19	1	ADR77863	Human apolipoprote
	41	15.8	1.7	19	1	ADR80521	Human apolipoprote
	42	15.8	1.7	19	1	ADR80559	Human apolipoprote
c	43	15.4	1.7	17	1	ADC05056	Human Na/H exchang
c	44	15.4	1.7	17	1	ADC05057	Human Na/H exchang
c	45	15.4	1.7	19	1	ADO15165	Human PDGFr-target
	46	15.4	1.7	19	1	ADO14854	Human PDGFr-target
c	47	15	1.6	17	1	ADC05060	Human Na/H exchang
	48	15	1.6	18	1	ABL45402	Human chromosome 2
c	49	14.8	1.6	18	1	ADH36295	Human purinergic r
	50	14.4	1.6	17	1	ADB43841	Tumour suppression
c	51	14.4	1.6	17	1	ADC05055	Human Na/H exchang
	52	14.4	1.6	17	1	ADB44962	Tumour suppression
c	53	14.4	1.6	17	1	ADI47575	Human tumour suppr
c	54	14.4	1.6	17	1	ADI47517	Human tumour suppr
c	55	14	1.5	17	1	AAX73192	Mouse flk-1 VEGF r
c	56	14	1.5	17	1	AAX71637	Human KDR VEGF rec
c	57	14	1.5	17	1	ACC67935	Murine oligonucleo
c	58	14	1.5	17	1	ADC05061	Human Na/H exchang
	59	14	1.5	17	1	ADI47840	Human tumour suppr
	60	14	1.5	17	1	ADL50250	Human PKR substrat
	61	14	1.5	17	1	ADL48957	Human PKR substrat
c	62	13.8	1.5	15	1	AAQ05540	Probe to sequence
	63	13.8	1.5	17	1	AAT12725	Human Calpain I ge
c	64	13.8	1.5	17	1	AAT81498	Human c-myb hammer
c	65	13.8	1.5	17	1	AAT81623	Human c-myb hammer
c	66	13.8	1.5	17	1	AAT81624	Human c-myb hammer
c	67	13.8	1.5	17	1	AAX71636	Human KDR VEGF rec
c	68	13.8	1.5	17	1	AAX73191	Mouse flk-1 VEGF r
c	69	13.8	1.5	17	1	AAV49159	rb gene antisense
c	70	13.8	1.5	17	1	AAV91108	Human C-raf target
c	71	13.8	1.5	17	1	AAV91107	Human C-raf target
	72	13.8	1.5	17	1	AAA25079	Oestrogen receptor
	73	13.8	1.5	17	1	ABN02789	Human GDMLP-1 17-m
c	74	13.8	1.5	17	1	AAS17003	Human p21 sense PC
c	75	13.8	1.5	17	1	ABV89984	Human POSHL1 scann
c	76	13.8	1.5	17	1	ABV89985	Human POSHL1 scann
	77	13.8	1.5	17	1	ACD00758	G-protein coupled
c	78	13.8	1.5	17	1	ABZ60839	Human K-Ras DNAzym
c	79	13.8	1.5	17	1	ACD54840	HBV DNAzyme substr
	80	13.8	1.5	17	1	ACD51179	HBV hammerhead rib
	81	13.8	1.5	17	1	ADB42393	Tumour suppression
c	82	13.8	1.5	17	1	ADC04546	Human Na/H exchang
	83	13.8	1.5	17	1	ADL46517	Human NOGO recepto
c	84	13.8	1.5	17	1	ADL50306	Human PKR substrat
c	85	13.8	1.5	17	1	ADM59993	Hepatitis B virus
	86	13.8	1.5	17	1	ADM58340	Hepatitis B virus
	87	13.8	1.5	17	1	ACN65879	Human GDMLP-1 prob
c	88	13.6	1.5	15	1	ACF57579	Human ALDOB gene a
	89	13.4	1.5	15	1	AAF47767	IGFBP3 oligonucleo
	90	13.4	1.5	15	1	AAF47768	IGFBP3 oligonucleo
c	91	13.4	1.5	16	1	ABZ33935	HIV-1 reverse tran
c	92	13.4	1.5	16	1	ADQ30355	Human VR1 exon 1d
c	93	13.2	1.4	50	1	ABZ03275	Human leukocyte ge
c	94	13	1.4	13	1	ABC12913	Oligonucleotide SE
c	95	13	1.4	13	1	ABH02414	Oligonucleotide SE
	96	13	1.4	13	1	ABC12912	Oligonucleotide SE
	97	13	1.4	13	1	ABH53074	Oligonucleotide SE
c	98	13	1.4	13	1	ABC23754	Oligonucleotide SE
	99	13	1.4	13	1	ABH02415	Oligonucleotide SE
c	100	13	1.4	13	1	ABF62300	Oligonucleotide SE
c	101	13	1.4	13	1	ABH47035	Oligonucleotide SE
	102	13	1.4	13	1	ABC50481	Oligonucleotide SE
	103	13	1.4	13	1	ABH15319	Oligonucleotide SE
	104	13	1.4	13	1	ABF79796	Oligonucleotide SE
c	105	13	1.4	13	1	ABF79797	Oligonucleotide SE
c	106	13	1.4	13	1	ABF00805	Oligonucleotide SE

c 107	13	1.4	13	1	ABF32140	Oligonucleotide SE
c 108	13	1.4	13	1	ABC50480	Oligonucleotide SE
c 109	13	1.4	13	1	ABC52298	Oligonucleotide SE
110	13	1.4	13	1	ABC52299	Oligonucleotide SE
111	13	1.4	13	1	ABH47034	Oligonucleotide SE
112	13	1.4	13	1	ABC23755	Oligonucleotide SE
113	13	1.4	13	1	ABF32141	Oligonucleotide SE
c 114	13	1.4	13	1	ABF93762	Oligonucleotide SE
c 115	13	1.4	13	1	ABH53075	Oligonucleotide SE
116	13	1.4	13	1	ABF93763	Oligonucleotide SE
117	13	1.4	13	1	ABF62301	Oligonucleotide SE
118	13	1.4	13	1	ABF00804	Oligonucleotide SE
c 119	13	1.4	13	1	ABH15318	Oligonucleotide SE
120	13	1.4	14	1	ADF61903	Ribosome binding s
c 121	13	1.4	15	1	AAT55633	Human TNF-alpha ha
c 122	13	1.4	15	1	ABS51921	Human FMO2 gene po
123	13	1.4	15	1	ABI99114	Human PCDH2 ASO PC
c 124	13	1.4	16	1	ADR74580	Allele specific pr
c 125	13	1.4	16	1	ADR74581	Allele specific pr
c 126	12.8	1.4	15	1	AAQ05541	Probe to sequence
c 127	12.8	1.4	16	1	AAQ50518	tRNAtyr/CAT chimer
c 128	12.8	1.4	16	1	AAQ98791	CAT mRNA/E.coli tR
c 129	12.8	1.4	16	1	AAV49158	rb gene antisense
c 130	12.8	1.4	16	1	AAZ23160	p21 gene amplifyin
131	12.8	1.4	16	1	AAZ48622	PCR primer for hum
132	12.8	1.4	16	1	AAZ48617	PCR primer for hum
133	12.8	1.4	16	1	AAL46073	Human prolactin co
c 134	12.8	1.4	16	1	AAS56909	Validation ribozym
135	12.8	1.4	16	1	ACA60933	Human prolactin se
c 136	12.6	1.4	13	1	ABF11493	Oligonucleotide SE
c 137	12.6	1.4	13	1	ABC14272	Oligonucleotide SE
138	12.6	1.4	13	1	ABC31897	Oligonucleotide SE
139	12.6	1.4	13	1	ABC04860	Oligonucleotide SE
140	12.6	1.4	13	1	ABF11492	Oligonucleotide SE
141	12.6	1.4	13	1	ABC14273	Oligonucleotide SE
142	12.6	1.4	13	1	ABC59749	Oligonucleotide SE
c 143	12.6	1.4	13	1	ABC31896	Oligonucleotide SE
c 144	12.6	1.4	13	1	ABC59748	Oligonucleotide SE
c 145	12.6	1.4	13	1	ABC38162	Oligonucleotide SE
146	12.6	1.4	13	1	ABC38163	Oligonucleotide SE
c 147	12.6	1.4	13	1	ABC04861	Oligonucleotide SE
c 148	12.6	1.4	15	1	AAQ05538	Probe to sequence
149	12.6	1.4	15	1	ABL01281	Human MMP3 gene po

ALIGNMENTS

RESULT 1
ABZ03275
ID ABZ03275 standard; DNA; 50 BP.
XX
AC ABZ03275;
XX
DT 09-JAN-2003 (first entry)
XX
DE Human leukocyte gene expression profiling probe SEQ ID NO 3266.
XX
KW T7; leukocyte; gene expression profiling; allograft rejection;
KW atherosclerosis; congestive heart failure; systemic lupus erythematosus;
KW rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
KW ss.
XX
OS Homo sapiens.
XX
PN WO200257414-A2.
XX
PD 25-JUL-2002.
XX
PF 22-OCT-2001; 2001WO-US047856.
XX
PR 20-OCT-2000; 2000US-0241994P.
PR 08-JUN-2001; 2001US-0296764P.
XX
PA (BIOC-) BIOCARDIA INC.
XX
PI Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;
PI Ly N, Woodward R, Quertermous T, Johnson F;
XX
DR WPI; 2002-636525/68.
XX
PT New system for leukocyte expression profiling, diagnosing a disease, or
PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
PT or congestive heart failure, comprises diagnostic oligonucleotides.
XX
PS Claim 1; Page 431; 0pp; English.
XX
CC The invention relates to a system for detecting gene expression, which
CC comprises one or two isolated DNA molecules that detect expression of a
CC gene, where the gene corresponds to any of 8143 oligonucleotides
CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
CC for leukocyte expression profiling. It is particularly useful for
CC diagnosing a disease, monitoring (rate of) progression of a disease,
CC predicting therapeutic outcome, determining prognosis for a patient,
CC predicting disease complications in an individual or monitoring response
CC to treatment in an individual. The diseases include cardiac allograft
CC rejection, kidney allograft rejection, liver allograft rejection,
CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
XX
SQ Sequence 50 BP; 12 A; 11 C; 11 G; 16 T; 0 U; 0 Other;

Query Match 5.4%; Score 50; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 0.0022;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1819 GCCACTAATAACATTGGGCTAATATCTGCTGTGCTTCTCTGACAGGTAGT 1868
||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 GCCACTAATAACATTGGGCTAATATCTGCTGTGCTTCTCTGACAGGTAGT 50

RESULT 2
ACC58943/c
ID ACC58943 standard; DNA; 20 BP.
XX
AC ACC58943;
XX
DT 11-JUL-2003 (first entry)
XX
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156496.
XX
KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1. .5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16. .20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003028636-A2.
XX
PD 10-APR-2003.

```
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1560 TAAAGCATGGGTTGAACTTC 1579
              ||||||||||||||||||||
Db         20 TAAAGCATGGGTTGAACTTC 1

RESULT 3
ACC58950/c
ID   ACC58950 standard; DNA; 20 BP.
XX
AC   ACC58950;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156510.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1810 CTGCTGTGAGCCACTAATAA 1829
              ||||||||||||||||||||
Db         20 CTGCTGTGAGCCACTAATAA 1

RESULT 4
ACC58957/c
ID   ACC58957 standard; DNA; 20 BP.
XX
AC   ACC58957;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156524.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
```

```
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC, Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 5 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2066 TTACATGACAAAGTTGAAGG 2085
              ||||||||||||||||||||
Db         20 TTACATGACAAAGTTGAAGG 1


RESULT 5
ACC58942/c
ID   ACC58942 standard; DNA; 20 BP.
XX
AC   ACC58942;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156494.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC, Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 6 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1548 GACAGTGGTTATTAAAGCAT 1567
              ||||||||||||||||||||
Db         20 GACAGTGGTTATTAAAGCAT 1


RESULT 6
ACC58949/c
ID   ACC58949 standard; DNA; 20 BP.
XX
AC   ACC58949;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156508.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
```

```
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 3 A; 3 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1756 AAGCCCAGCTGACTCCACTA 1775
              ||||||||||||||||||||
Db         20 AAGCCCAGCTGACTCCACTA 1


RESULT 7
ACC58968/c
ID   ACC58968 standard; DNA; 20 BP.
XX
AC   ACC58968;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156546.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 76; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2377 TAACCACAGCCTGGGCTGAC 2396
              ||||||||||||||||||||
Db         20 TAACCACAGCCTGGGCTGAC 1


RESULT 8
ACC58948/c
ID   ACC58948 standard; DNA; 20 BP.
XX
AC   ACC58948;
```

```
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156506.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1737 GTGGAAACACTCTGATCTGA 1756
              ||||||||||||||||||||
Db         20 GTGGAAACACTCTGATCTGA 1

RESULT 9
ACC58951/c
ID   ACC58951 standard; DNA; 20 BP.
XX
AC   ACC58951;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156512.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1829 ACATTGGGCTAATATCTGCT 1848
              ||||||||||||||||||||
Db         20 ACATTGGGCTAATATCTGCT 1
```

RESULT 10
ACC58954/c
ID ACC58954 standard; DNA; 20 BP.
XX
AC ACC58954;
XX
DT 11-JUL-2003 (first entry)
XX
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156518.
XX
KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX
OS Homo sapiens.
XX

FH	Key	Location/Qualifiers
FT	modified_base	1. .20
FT		/*tag= a
FT		/mod_base= OTHER
FT		/note= "Phosphorothioate linkages. All cytosines are 5-methylcytosine"
FT	modified_base	1. .5
FT		/*tag= b
FT		/mod_base= OTHER
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	modified_base	16. .20
FT		/*tag= c
FT		/mod_base= OTHER
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX
PN WO2003028636-A2.
XX
PD 10-APR-2003.
XX
PF 26-SEP-2002; 2002WO-US030574.
XX
PR 28-SEP-2001; 2001US-00966451.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Freier SM;
XX
DR WPI; 2003-363256/34.
XX
PT New antisense oligonucleotides for modulating IL-1 receptor-associated
PT kinase-4 gene expression, particularly useful for preventing, delaying or
PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT infection.
XX
PS Claim 3; Page 75; 119pp; English.
XX
CC The invention relates to a compound of 8-50 nucleobases which is targeted
CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC the expression of the encoded product. Also disclosed is the compound
CC hybridising with an 8-nucleobase portion of an active site on a nucleic
CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC oligonucleotide is useful for treating an animal having a disease or
CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC (particularly renal cancer), inflammatory disease or an infection. The
CC antisense compounds are useful for diagnostics, therapeutics,
CC prophylaxis, or as research reagents or kits. The current sequence
CC represents a human IL-1 receptor-associated kinase-4 expression antisense
CC inhibitor oligonucleotide
XX
SQ Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;

```
  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1894 TATACAAGCACTTTGTAAAT 1913
              ||||||||||||||||||||
Db         20 TATACAAGCACTTTGTAAAT 1
```

RESULT 11
ACC58963/c
ID ACC58963 standard; DNA; 20 BP.
XX
AC ACC58963;
XX
DT 11-JUL-2003 (first entry)
XX
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156536.
XX
KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX
OS Homo sapiens.
XX

FH	Key	Location/Qualifiers
FT	modified_base	1. .20
FT		/*tag= a
FT		/mod_base= OTHER
FT		/note= "Phosphorothioate linkages. All cytosines are 5-methylcytosine"
FT	modified_base	1. .5
FT		/*tag= b
FT		/mod_base= OTHER
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	modified_base	16. .20
FT		/*tag= c
FT		/mod_base= OTHER
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX
PN WO2003028636-A2.
XX
PD 10-APR-2003.
XX
PF 26-SEP-2002; 2002WO-US030574.
XX
PR 28-SEP-2001; 2001US-00966451.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Freier SM;
XX
DR WPI; 2003-363256/34.
XX
PT New antisense oligonucleotides for modulating IL-1 receptor-associated
PT kinase-4 gene expression, particularly useful for preventing, delaying or
PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT infection.
XX
PS Claim 3; Page 75; 119pp; English.
XX
CC The invention relates to a compound of 8-50 nucleobases which is targeted
CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC the expression of the encoded product. Also disclosed is the compound
CC hybridising with an 8-nucleobase portion of an active site on a nucleic
CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC oligonucleotide is useful for treating an animal having a disease or
CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC (particularly renal cancer), inflammatory disease or an infection. The
CC antisense compounds are useful for diagnostics, therapeutics,

```
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2223 GCTAAAACCTAAAGGTGGCC 2242
              ||||||||||||||||||||
Db         20 GCTAAAACCTAAAGGTGGCC 1


RESULT 12
ACC58961/c
ID   ACC58961 standard; DNA; 20 BP.
XX
AC   ACC58961;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156532.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2211 AGGGCCACATTGGCTAAAAC 2230
              ||||||||||||||||||||
Db         20 AGGGCCACATTGGCTAAAAC 1


RESULT 13
ACC58967/c
ID   ACC58967 standard; DNA; 20 BP.
XX
AC   ACC58967;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156544.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Example 15; Page 75; 119pp; English.
XX
```

```
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 4 A; 3 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2364 AAGCTTCAGATGATAACCAC 2383
              ||||||||||||||||||||
Db         20 AAGCTTCAGATGATAACCAC 1


RESULT 14
ACC58969/c
ID   ACC58969 standard; DNA; 20 BP.
XX
AC   ACC58969;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156548.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 76; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 6 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2419 ATCCTCAGTATGAGAATCTA 2438
              ||||||||||||||||||||
Db         20 ATCCTCAGTATGAGAATCTA 1


RESULT 15
ACC58959/c
ID   ACC58959 standard; DNA; 20 BP.
XX
AC   ACC58959;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156528.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
```

```
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2137 AAAGGGCCTGACCTAATCCA 2156
              ||||||||||||||||||||
Db         20 AAAGGGCCTGACCTAATCCA 1


RESULT 16
ACC58964/c
ID   ACC58964 standard; DNA; 20 BP.
XX
AC   ACC58964;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156538.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2236 GGTGGCCTCTAGGAGATGAG 2255
              ||||||||||||||||||||
Db         20 GGTGGCCTCTAGGAGATGAG 1


RESULT 17
ACC58947/c
ID   ACC58947 standard; DNA; 20 BP.
XX
AC   ACC58947;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156504.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
```

```
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 6 A; 9 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 CCTGGGCTGTATGTAGGGTG 1739
              ||||||||||||||||||||
Db         20 CCTGGGCTGTATGTAGGGTG 1


RESULT 18
ACC58944/c
ID   ACC58944 standard; DNA; 20 BP.
XX
AC   ACC58944;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156498.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1646 TACAGTAATCCCTGAGAAAT 1665
              ||||||||||||||||||||
Db         20 TACAGTAATCCCTGAGAAAT 1


RESULT 19
ACC58962/c
ID   ACC58962 standard; DNA; 20 BP.
XX
AC   ACC58962;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156534.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
```

```
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC, Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 4 A; 4 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 CATTGGCTAAAACCTAAAGG 2237
              ||||||||||||||||||||
Db         20 CATTGGCTAAAACCTAAAGG 1


RESULT 20
ACC58946/c
ID   ACC58946 standard; DNA; 20 BP.
XX
AC   ACC58946;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156502.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers

FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC, Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Example 15; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1711 CAAAAAGAGCCTGGGCTGTA 1730
              ||||||||||||||||||||
Db         20 CAAAAAGAGCCTGGGCTGTA 1


RESULT 21
ACC58955/c
ID   ACC58955 standard; DNA; 20 BP.
XX
AC   ACC58955;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156520.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
```

```
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 7 A; 1 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1951 TTACAAAATCCTATTAGTCA 1970
              ||||||||||||||||||||
Db         20 TTACAAAATCCTATTAGTCA 1


RESULT 22
ACC58953/c
ID   ACC58953 standard; DNA; 20 BP.
XX
AC   ACC58953;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156516.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1854 TCTCTGACAGGTAGTCATGA 1873
              ||||||||||||||||||||
Db         20 TCTCTGACAGGTAGTCATGA 1


RESULT 23
ACC58965/c
ID   ACC58965 standard; DNA; 20 BP.
```

```
XX
AC   ACC58965;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156540.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2256 ACCTACCTTCCAGTTGTCAG 2275
              ||||||||||||||||||||
Db         20 ACCTACCTTCCAGTTGTCAG 1
```

```
RESULT 24
ACC58945/c
ID   ACC58945 standard; DNA; 20 BP.
XX
AC   ACC58945;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156500.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 4 A; 2 C; 6 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
```

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1674 AGCATCACCAAACACAGTTT 1693
              ||||||||||||||||||||
Db         20 AGCATCACCAAACACAGTTT 1


RESULT 25
ACC58956/c
ID   ACC58956 standard; DNA; 20 BP.
XX
AC   ACC58956;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156522.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1985 GTGTTCACAGCAATCATTTA 2004
              ||||||||||||||||||||
Db         20 GTGTTCACAGCAATCATTTA 1


RESULT 26
ACC58960/c
ID   ACC58960 standard; DNA; 20 BP.
XX
AC   ACC58960;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156530.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Example 15; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
```

```
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2191 GCCTTGAAGAAGTATGTGAG 2210
              ||||||||||||||||||||
Db         20 GCCTTGAAGAAGTATGTGAG 1


RESULT 27
ACC58966/c
ID   ACC58966 standard; DNA; 20 BP.
XX
AC   ACC58966;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156542.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2267 AGTTGTCAGCAAGCAGGAAA 2286
              ||||||||||||||||||||
Db         20 AGTTGTCAGCAAGCAGGAAA 1


RESULT 28
ACC58952/c
ID   ACC58952 standard; DNA; 20 BP.
XX
AC   ACC58952;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156514.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
```

```
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1846 GCTGTGCTTCTCTGACAGGT 1865
              ||||||||||||||||||||
Db         20 GCTGTGCTTCTCTGACAGGT 1

RESULT 29
ACC58958/c
ID   ACC58958 standard; DNA; 20 BP.
XX
AC   ACC58958;
XX
DT   11-JUL-2003  (first entry)
XX
DE   Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156526.
XX
KW   Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW   interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW   inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages. All cytosines are 5-
FT                   methylcytosine"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2003028636-A2.
XX
PD   10-APR-2003.
XX
PF   26-SEP-2002; 2002WO-US030574.
XX
PR   28-SEP-2001; 2001US-00966451.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett FC,  Freier SM;
XX
DR   WPI; 2003-363256/34.
XX
PT   New antisense oligonucleotides for modulating IL-1 receptor-associated
PT   kinase-4 gene expression, particularly useful for preventing, delaying or
PT   treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT   infection.
XX
PS   Claim 3; Page 75; 119pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases which is targeted
CC   to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC   kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC   the expression of the encoded product. Also disclosed is the compound
CC   hybridising with an 8-nucleobase portion of an active site on a nucleic
CC   acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC   oligonucleotide is useful for treating an animal having a disease or
CC   conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC   (particularly renal cancer), inflammatory disease or an infection. The
CC   antisense compounds are useful for diagnostics, therapeutics,
CC   prophylaxis, or as research reagents or kits. The current sequence
CC   represents a human IL-1 receptor-associated kinase-4 expression antisense
CC   inhibitor oligonucleotide
XX
SQ   Sequence 20 BP; 6 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2089 TTGGCAGATGCAGTTAAGGT 2108
              ||||||||||||||||||||
Db         20 TTGGCAGATGCAGTTAAGGT 1

RESULT 30
AAC81214
ID   AAC81214 standard; DNA; 20 BP.
XX
AC   AAC81214;
XX
DT   23-FEB-2001  (first entry)
XX
DE   Human bcl-6 phosphorothioate antisense oligonucleotide, SEQ ID NO:80.
XX
KW   Human; bcl-6; transcriptional repressor; germinal centre formation;
KW   Th-2 mediated antibody affinity maturation; apoptosis regulator;
KW   chromosome 3q27; lymphoma; acute lymphoblastic leukaemia;
KW   post-transplant lymphoproliferative disorder; expression inhibition;
KW   phosphorothioate; antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   US6140125-A.
XX
PD   31-OCT-2000.
XX
PF   15-OCT-1999;   99US-00418640.
XX
PR   15-OCT-1999;   99US-00418640.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Taylor JK,  Cowsert LM;
XX
DR   WPI; 2001-048959/06.
XX
PT   Antisense compounds which specifically hybridize with and inhibit human
PT   bcl-6 expression, useful for treating bcl-6 related disorders, and
PT   preventing or delaying inflammation or tumor formation.
XX
PS   Example 15; Col 45-46; 42pp; English.
XX
CC   Sequences AAC81144-C81223 represent antisense oligonucleotides targetted
CC   to the human bcl-6 gene, which inhibit its expression. The antisense
CC   oligonucleotides were designed to target different regions of the human
```

CC bcl-6 mRNA, and were analysed for their effect on bcl-6 mRNA levels by
CC quantitative real-time PCR. Bcl-6 (also known as B-cell CLL/ lymphoma 6,
CC zinc finger protein 51 and LAZ3) is a sequence-specific DNA-binding
CC transcriptional repressor. The bcl-6 gene is expressed in germinal centre
CC B- and T- cells and is required for germinal centre formation and Th-2
CC mediated antibody affinity maturation. Bcl-6 may also play a role in the
CC regulation of apoptosis. The bcl-6 gene is located on chromosome 3q27, a
CC region which undergoes a high frequency of translocation events. Such
CC chromosomal translocations can result in aberrant forms of bcl-6, which
CC are strongly implicated in the pathogenesis of several types of lymphoma,
CC and have also been reported in acute lymphoblastic leukaemia and post-
CC transplant lymphoproliferative disorders. The oligonucleotides of the
CC invention are useful for diagnosis, prevention and treatment of
CC conditions associated with aberrant forms of bcl-6, such as lymphomas,
CC acute lymphoblastic leukaemia and post-transplant lymphoproliferative
CC disorders
XX
SQ Sequence 20 BP; 8 A; 3 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1902 CACTTTGTAAATTGTAAA 1919
||||||||||||||||||
Db 3 CACTTTGTAAATTGTAAA 20

RESULT 31
ADF13662
ID ADF13662 standard; DNA; 22 BP.
XX
AC ADF13662;
XX
DT 12-FEB-2004 (first entry)
XX
DE Vascular endothelial growth factor (VEGF), BaySNP 900097, PCR primer #3.
XX
KW Cardiant; antiarteriosclerotic; vasotropic; cerebroprotective;
KW hypotensive; gene therapy; human; Vascular endothelial growth factor;
KW VEGF; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003072813-A2.
XX
PD 04-SEP-2003.
XX
PF 14-FEB-2003; 2003WO-EP001514.
XX
PR 27-FEB-2002; 2002EP-00004258.
XX
PA (FARB) BAYER AG.
XX
PI Stropp U, Schwers S, Kallabis H;
XX
DR WPI; 2003-712738/67.
XX
PT New isolated polynucleotide encoded by a phenotype-associated gene,
PT useful for prognosticating statin therapy response, and diagnosing or
PT treating cardiovascular diseases, such as hypertension, myocardial
PT infarction and stroke.
XX
PS Example 1; Page 75; 182pp; English.
XX
CC The present invention relates to human phenotype-associated (PA) genes (I
CC ; ADF13307-ADF13386) which contain a Single Nucleotide Polymorphism
CC (SNP). The SNP is given in the sequence as a variant nucleotide. Also
CC claimed are methods for screening for agents which regulate the activity
CC of a PA gene and reagents that modulate the activity of a PA polypeptide
CC or a polynucleotide where the reagent is identified by the screening
CC methods. The methods and compositions of the present invention are useful
CC for prognosticating, diagnosing and treating cardiovascular diseases,
CC such as atherosclerosis, hypertension, restenosis, arterial inflammation,
CC myocardial infarction and stroke. The present sequence is a PCR primer,
CC used in the examples from the invention.
XX
SQ Sequence 22 BP; 5 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.9%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 29;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2295 GGGACCTCAGTTGCAACCACA 2315
||||||| |||||| ||||||
Db 1 GGGACCTTAGTTGCCACCACA 21

RESULT 32
ADB43451
ID ADB43451 standard; DNA; 17 BP.
XX
AC ADB43451;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #3774.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 473; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.

```
XX
SQ   Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 17;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 23;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1750 GATCTGAAGCCCAGCTG 1766
              |||||||||||||||||
Db          1 GATCTGAAGCCCAGCTG 17


RESULT 33
ABS98265/c
ID   ABS98265 standard; DNA; 21 BP.
XX
AC   ABS98265;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human lactoferrin (LTF) gene polymorphic sequence #28.
XX
KW   Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
KW   cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW   adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW   aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW   cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW   epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW   glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW   HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW   NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
KW   UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW   UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW   multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW   multidrug resistance associated protein 3; cancer; prostate;
KW   acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW   altered drug metabolism; cardiovascular function; colorectal tumour;
KW   central nervous system; pulmonary; immunological; SNP;
KW   single nucleotide polymorphism.
XX
OS   Homo sapiens.
XX
PN   WO200257410-A2.
XX
PD   25-JUL-2002.
XX
PF   28-NOV-2001; 2001WO-US044838.
XX
PR   28-NOV-2000; 2000US-00724389.
XX
PA   (DNAS-) DNA SCI LAB INC.
XX
PI   Guida M,  Hall J;
XX
DR   WPI; 2002-698522/75.
XX
PT   Isolated nucleic acid molecules having polymorphisms in known human genes
PT   e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
PT   for locating, identifying and characterizing the genes responsible for
PT   disorder-related traits.
XX
PS   Example 23; Page 148; 714pp; English.
XX
CC   This invention relates to the sequence of an isolated nucleic acid
CC   molecule comprising at least one base variation from that of a known
CC   human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC   cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
CC   aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC   (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
CC   inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
CC   protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
CC   transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl
CC   transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC   sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC   (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC   transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
CC   (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC   (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
CC   receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC   The polymorphisms in the human genes cited in the invention are useful as
CC   genetic linkage markers for locating and characterising the genes that
CC   are responsible for specific traits within the genome and eventually
CC   identifying the genes responsible for a variety of disorder-related
CC   traits as a result of their e.g., overexpression, constitutive
CC   expression, mutation or underexpression, which may be used in diagnosing
CC   and/or treating the disorders. The nucleic acid molecules comprising the
CC   polymorphic sequences contained in CYP4501A1, CYPP4501A2, CYP4502E1,
CC   ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
CC   MDR1 and/or MDR3 are useful for screening individuals for altered drug
CC   metabolism. The polymorphic sequences contained in CYP4501A1, CYPP4501A2,
CC   AHR, MDR1 and/or MDR3 may also be used to screen individuals for
CC   susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
CC   used to screen for altered cardiovascular function, in COX2 for altered
CC   susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
CC   nervous system function, in FLAP and HNMT for altered pulmonary,
CC   immunological or haematological function, in KLK2 for altered serine
CC   protease activity in the prostate, in LTF for altered immunological or
CC   haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC   peripheral nervous system function. The present sequence represents a
CC   polymorphic DNA sequence of the invention
XX
SQ   Sequence 21 BP; 5 A; 11 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             1.8%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 37;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1718 AGCCTGGGCTGTATGTAGGG 1737
              || |||||||||||||| |||
Db         21 AGGCTGGGCTGTATGTGGGG 2


RESULT 34
ADC05059/c
ID   ADC05059 standard; DNA; 17 BP.
XX
AC   ADC05059;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #1506.
XX
KW   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW   NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS   Homo sapiens.
XX
PN   EP1273660-A2.
XX
PD   08-JAN-2003.
XX
PF   25-JAN-2002; 2002EP-00001160.
XX
PR   30-JAN-2001; 2001WO-US000666.
PR   23-MAY-2001; 2001US-00864761.
PR   21-DEC-2001; 2001US-0343331P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y;
XX
DR   WPI; 2003-302724/30.
XX
PT   New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT   passive replacement therapy or as a vaccine for treating or preventing
PT   disorders associated with aberrant expression or activity of human
```

PT NHELP1.
XX
PS Example 2; SEQ ID NO 1546; 468pp; English.
XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHELP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1745 ACTCTGATCTGAAGCC 1760
||||||||||||||||
Db 16 ACTCTGATCTGAAGCC 1

RESULT 35
ADC05058/c
ID ADC05058 standard; DNA; 17 BP.
XX
AC ADC05058;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1505.
XX
KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS Homo sapiens.
XX
PN EP1273660-A2.
XX
PD 08-JAN-2003.
XX
PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y;
XX
DR WPI; 2003-302724/30.
XX
PT New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHELP1.
XX
PS Example 2; SEQ ID NO 1545; 468pp; English.
XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHELP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1745 ACTCTGATCTGAAGCC 1760
||||||||||||||||
Db 17 ACTCTGATCTGAAGCC 2

RESULT 36
AAZ77372
ID AAZ77372 standard; DNA; 19 BP.
XX
AC AAZ77372;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:11728.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 9; Page 2731; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX

```
SQ   Sequence 19 BP; 9 A; 5 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 43;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2146 GACCTAATCCAAGTGAACC 2164
              || | ||||||||||||||
Db          1 GAACAAATCCAAGTGAACC 19


RESULT 37
ADF36507
ID   ADF36507 standard; RNA; 19 BP.
XX
AC   ADF36507;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:796.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 796; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 8 A; 3 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 43;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1893 ATATACAAGCACTTTGTAA 1911
              |:  ||||||||:::|:||
Db          1 AUGAACAAGCACUUUGUAA 19


RESULT 38
ADF36080/c
ID   ADF36080 standard; RNA; 19 BP.
XX
AC   ADF36080;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:369.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 369; 207pp; English.
```

```
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 5 A; 3 C; 3 G; 0 T; 8 U; 0 Other;

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 43;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1893 ATATACAAGCACTTTGTAA 1911
              ||  ||||||||||||||||
Db         19 ATGAACAAGCACTTTGTAA 1


RESULT 39
ADR77901
ID   ADR77901 standard; DNA; 19 BP.
XX
AC   ADR77901;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human apolipoprotein B (ApoB) oligonucleotide seqid 2386.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW   RNA interference; iRNA; antisense technology; lipid metabolism;
KW   cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW   coronary artery disease; CAD; coronary heart disease; CHD;
KW   atherosclerosis; hepatic glucose production;
KW   glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW   colon cancer; lung cancer; neurological disease; Huntington disease;
KW   spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080406-A2.
XX
PD   23-SEP-2004.
XX
PF   08-MAR-2004; 2004WO-US007070.
XX
PR   07-MAR-2003; 2003US-0452682P.
PR   12-MAR-2003; 2003US-0454265P.
PR   13-MAR-2003; 2003US-0454962P.
PR   13-MAR-2003; 2003US-0455050P.
PR   14-APR-2003; 2003US-0462894P.
PR   17-APR-2003; 2003US-0463772P.
PR   25-APR-2003; 2003US-0465665P.
PR   25-APR-2003; 2003US-0465802P.
PR   09-MAY-2003; 2003US-0469612P.
PR   08-AUG-2003; 2003US-0493986P.
PR   11-AUG-2003; 2003US-0494597P.
PR   26-SEP-2003; 2003US-0506341P.
PR   09-OCT-2003; 2003US-0510246P.
PR   10-OCT-2003; 2003US-0510318P.
PR   07-NOV-2003; 2003US-0518453P.
XX
PA   (ALNY-) ALNYLAM PHARM.
XX
PI   Manoharan M, Bumcrot D;
XX
DR   WPI; 2004-677362/66.
XX
PT   Interference RNA agent useful for treating dyslipidemias, coronary artery
PT   disease, diabetes, cancer or neurological disease, comprises sense
PT   sequence and antisense sequence which has specific modifications.
XX
PS   Example 5; SEQ ID NO 2386; 378pp; English.
XX
CC   The invention describes a RNA interference (iRNA) agent (I) comprising a
CC   sense sequence and an antisense sequence, where the sense sequences have
CC   one or more asymmetrical 2'-O alkyl modifications, the antisense
CC   sequences have one or more asymmetrical phosphorothioate modifications
CC   and the antisense sequence targets a human gene sequence. Also described
CC   are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC   levels or glucose-6-phosphatase levels in a subject; producing (I);
CC   stabilising (I), involves selecting a sequence with activity and
CC   introducing one or more asymmetrical modification in the sequence, where
CC   the modification decreases nuclease sensitivity while not decreasing its
CC   activity; a kit comprising (I) and instruction for its use; and a device
CC   that can be dispense or administer a composition comprising (I). (I) is
CC   useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC   is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC   The subject is suffering from a disorder characterised by elevated or
CC   otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC   levels of cholesterol, and/or disregulation of lipid metabolism. The
CC   disorder is chosen from the HDL/LDL cholesterol imbalance,
CC   dyslipidaemias, hypercholestorolaemia, statin-resistant
CC   hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC   disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC   inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC   treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC   lung cancer), neurological disease (e.g., Huntington disease or
CC   spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC   represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC   can be used to control ApoB gene expression.
XX
SQ   Sequence 19 BP; 13 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 43;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1575 ACTTCCAAAATATAAAAAT 1593
              ||||  |||||||||||||
Db          1 ACTTAAAAAATATAAAAAT 19


RESULT 40
ADR77863
ID   ADR77863 standard; DNA; 19 BP.
XX
AC   ADR77863;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human apolipoprotein B (ApoB) oligonucleotide seqid 2348.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW   RNA interference; iRNA; antisense technology; lipid metabolism;
KW   cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW   coronary artery disease; CAD; coronary heart disease; CHD;
KW   atherosclerosis; hepatic glucose production;
KW   glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW   colon cancer; lung cancer; neurological disease; Huntington disease;
KW   spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
```

XX
OS Homo sapiens.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
DR WPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 2348; 378pp; English.
XX
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or disregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholestorolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC can be used to control ApoB gene expression.
XX
SQ Sequence 19 BP; 13 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 43;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1575 ACTTCCAAAATATAAAAAT 1593
|||| ||||||||||||
Db 1 ACTTAAAAAATATAAAAAT 19

RESULT 41
ADR80521
ID ADR80521 standard; DNA; 19 BP.
XX
AC ADR80521;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 5018.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
OS Homo sapiens.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
DR WPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 5018; 378pp; English.
XX
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)

```
CC   is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC   The subject is suffering from a disorder characterised by elevated or
CC   otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC   levels of cholesterol, and/or disregulation of lipid metabolism. The
CC   disorder is chosen from the HDL/LDL cholesterol imbalance,
CC   dyslipidaemias, hypercholestorolaemia, statin-resistant
CC   hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC   disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC   inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC   treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC   lung cancer), neurological disease (e.g., Huntington disease or
CC   spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC   represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC   can be used to control ApoB gene expression.
XX
SQ   Sequence 19 BP; 13 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 43;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1575 ACTTCCAAAATATAAAAAT 1593
              ||||  ||||||||||||
Db          1 ACTTAAAAAATATAAAAAT 19


RESULT 42
ADR80559
ID   ADR80559 standard; DNA; 19 BP.
XX
AC   ADR80559;
XX
DT   16-DEC-2004  (first entry)
XX
DE   Human apolipoprotein B (ApoB) oligonucleotide seqid 5056.
XX
KW   antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW   cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW   RNA interference; iRNA; antisense technology; lipid metabolism;
KW   cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW   coronary artery disease; CAD; coronary heart disease; CHD;
KW   atherosclerosis; hepatic glucose production;
KW   glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW   colon cancer; lung cancer; neurological disease; Huntington disease;
KW   spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004080406-A2.
XX
PD   23-SEP-2004.
XX
PF   08-MAR-2004; 2004WO-US007070.
XX
PR   07-MAR-2003; 2003US-0452682P.
PR   12-MAR-2003; 2003US-0454265P.
PR   13-MAR-2003; 2003US-0454962P.
PR   13-MAR-2003; 2003US-0455050P.
PR   14-APR-2003; 2003US-0462894P.
PR   17-APR-2003; 2003US-0463772P.
PR   25-APR-2003; 2003US-0465665P.
PR   25-APR-2003; 2003US-0465802P.
PR   09-MAY-2003; 2003US-0469612P.
PR   08-AUG-2003; 2003US-0493986P.
PR   11-AUG-2003; 2003US-0494597P.
PR   26-SEP-2003; 2003US-0506341P.
PR   09-OCT-2003; 2003US-0510246P.
PR   10-OCT-2003; 2003US-0510318P.
PR   07-NOV-2003; 2003US-0518453P.
XX
PA   (ALNY-) ALNYLAM PHARM.
XX
PI   Manoharan M,  Bumcrot D;
XX
DR   WPI; 2004-677362/66.
XX
PT   Interference RNA agent useful for treating dyslipidemias, coronary artery
PT   disease, diabetes, cancer or neurological disease, comprises sense
PT   sequence and antisense sequence which has specific modifications.
XX
PS   Example 5; SEQ ID NO 5056; 378pp; English.
XX
CC   The invention describes a RNA interference (iRNA) agent (I) comprising a
CC   sense sequence and an antisense sequence, where the sense sequences have
CC   one or more asymmetrical 2'-O alkyl modifications, the antisense
CC   sequences have one or more asymmetrical phosphorothioate modifications
CC   and the antisense sequence targets a human gene sequence. Also described
CC   are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC   levels or glucose-6-phosphatase levels in a subject; producing (I);
CC   stabilising (I), involves selecting a sequence with activity and
CC   introducing one or more asymmetrical modification in the sequence, where
CC   the modification decreases nuclease sensitivity while not decreasing its
CC   activity; a kit comprising (I) and instruction for its use; and a device
CC   that can be dispense or administer a composition comprising (I). (I) is
CC   useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC   is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC   The subject is suffering from a disorder characterised by elevated or
CC   otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC   levels of cholesterol, and/or disregulation of lipid metabolism. The
CC   disorder is chosen from the HDL/LDL cholesterol imbalance,
CC   dyslipidaemias, hypercholestorolaemia, statin-resistant
CC   hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC   disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC   inhibit hepatic glucose production or for treating glucose-metabolism-
CC   related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC   treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC   lung cancer), neurological disease (e.g., Huntington disease or
CC   spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC   represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC   can be used to control ApoB gene expression.
XX
SQ   Sequence 19 BP; 13 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 43;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1575 ACTTCCAAAATATAAAAAT 1593
              ||||  ||||||||||||
Db          1 ACTTAAAAAATATAAAAAT 19


RESULT 43
ADC05056/c
ID   ADC05056 standard; DNA; 17 BP.
XX
AC   ADC05056;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #1503.
XX
KW   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW   NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS   Homo sapiens.
XX
PN   EP1273660-A2.
XX
PD   08-JAN-2003.
XX
PF   25-JAN-2002; 2002EP-00001160.
XX
PR   30-JAN-2001; 2001WO-US000666.
PR   23-MAY-2001; 2001US-00864761.
```

PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y;
XX
DR WPI; 2003-302724/30.
XX
PT New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHELP1.
XX
PS Example 2; SEQ ID NO 1543; 468pp; English.
XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHELP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1747 TCTGATCTGAAGCCCAG 1763
||||||||||||||| ||
Db 17 TCTGATCTGAAGCCAAG 1

RESULT 44
ADC05057/c
ID ADC05057 standard; DNA; 17 BP.
XX
AC ADC05057;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1504.
XX
KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS Homo sapiens.
XX
PN EP1273660-A2.
XX
PD 08-JAN-2003.
XX
PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y;
XX
DR WPI; 2003-302724/30.
XX
PT New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHELP1.
XX
PS Example 2; SEQ ID NO 1544; 468pp; English.
XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHELP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1746 CTCTGATCTGAAGCCCA 1762
||||||||||||||| |
Db 17 CTCTGATCTGAAGCCAA 1

RESULT 45
ADO15165/c
ID ADO15165 standard; RNA; 19 BP.
XX
AC ADO15165;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human PDGFr-targeted siNA lower strand SEQ ID NO:596.
XX
KW cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human;
KW platelet derived growth factor receptor; PDGFr; ss.
XX
OS Homo sapiens.
XX
PN WO2003072704-A2.
XX
PD 04-SEP-2003.
XX
PF 05-FEB-2003; 2003WO-US003473.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B;
XX
DR WPI; 2003-731605/69.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and

PT diagnosis of tumors, downregulates expression of the platelet-derived
PT growth factor receptor gene.
XX
PS Example 3; SEQ ID NO 596; 148pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human platelet-derived growth factor
CC receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA, double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC modulate expression of the PDGFr gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating leukaemia and solid tumours, restenosis, polycystic kidney
CC disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC useful for drug screening, diagnosis, therapeutic target identification
CC and validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human PDGFr-
CC targeted double-stranded siNA, which is identical to the PDGFr transcript
CC target sequence.
XX
SQ Sequence 19 BP; 2 A; 8 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 1.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 48;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2197 AAGAAGTATGTGAGAGG 2213
              ||||||  ||||||||||
Db         17 AAGAAGGATGTGAGAGG 1
```

RESULT 46
ADO14854
ID ADO14854 standard; RNA; 19 BP.
XX
AC ADO14854;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human PDGFr-targeted siNA upper strand SEQ ID NO:285.
XX
KW cytostatic; vasotropic; nephrotropic; cerebroprotective;
KW treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
KW bronchiolitis; glomerulonephritis; stroke; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human;
KW platelet derived growth factor receptor; PDGFr; ss.
XX
OS Homo sapiens.
XX
PN WO2003072704-A2.
XX
PD 04-SEP-2003.
XX
PF 05-FEB-2003; 2003WO-US003473.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B;
XX
DR WPI; 2003-731605/69.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of tumors, downregulates expression of the platelet-derived
PT growth factor receptor gene.
XX
PS Example 3; SEQ ID NO 285; 148pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human platelet-derived growth factor
CC receptor (PDGFr) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA, double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siRNA; conjugates and/or
CC complexes of siRNA; and vectors that express siNA. The siNAs are used to
CC modulate expression of the PDGFr gene in cells, tissue explants or
CC organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC for the treatment of a variety of conditions. They may be used for
CC treating leukaemia and solid tumours, restenosis, polycystic kidney
CC disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also
CC useful for drug screening, diagnosis, therapeutic target identification
CC and validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human PDGFr-
CC targeted double-stranded siNA, which is identical to the PDGFr transcript
CC target sequence.
XX
SQ Sequence 19 BP; 7 A; 2 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 1.7%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 48;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2197 AAGAAGTATGTGAGAGG 2213
              ||||||  |:|:||||||
Db          3 AAGAAGGAUGUGAGAGG 19
```

RESULT 47
ADC05060/c
ID ADC05060 standard; DNA; 17 BP.
XX
AC ADC05060;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1507.
XX
KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS Homo sapiens.
XX
PN EP1273660-A2.
XX
PD 08-JAN-2003.
XX
PF 25-JAN-2002; 2002EP-00001160.
XX

PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y;
XX
DR WPI; 2003-302724/30.
XX
PT New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHELP1.
XX
PS Example 2; SEQ ID NO 1547; 468pp; English.
XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHELP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

```
  Query Match             1.6%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 45;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAGC 1759
              |||||||||||||||
Db         15 ACTCTGATCTGAAGC 1
```

RESULT 48
ABL45402
ID ABL45402 standard; DNA; 18 BP.
XX
AC ABL45402;
XX
DT 11-APR-2002 (first entry)
XX
DE Human chromosome 21q22.1 PCR primer SEQ ID NO:2446.
XX
KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.
XX
OS Homo sapiens.
XX
PN JP2001321190-A.
XX
PD 20-NOV-2001.
XX
PF 12-MAR-2001; 2001JP-00068285.
XX
PR 10-MAR-2000; 2000JP-00066716.
XX
PA (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
XX
DR WPI; 2002-144136/19.
XX
PT Arraying genome clones.
XX
PS Claim 6; Page 53; 528pp; Japanese.
XX
CC The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
SQ Sequence 18 BP; 7 A; 5 C; 1 G; 5 T; 0 U; 0 Other;

```
  Query Match             1.6%;  Score 15;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1955 AAAATCCTATTAGTC 1969
              |||||||||||||||
Db          4 AAAATCCTATTAGTC 18
```

RESULT 49
ADH36295/c
ID ADH36295 standard; DNA; 18 BP.
XX
AC ADH36295;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human purinergic receptor P2X4-related PCR primer 71.
XX
KW fat deposition; leanness; non-insulin dependent diabetes mellitus; NIDDM;
KW purinergic receptor; P2X4; antidiabetic; anorectic; diabetes; obesity;
KW human; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003101177-A2.
XX
PD 11-DEC-2003.
XX
PF 04-JUN-2003; 2003WO-US017676.
XX
PR 04-JUN-2002; 2002US-0386012P.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Adam GIR, Langdown ML, Roth RB, Denissenko MF, Smylie KJ;
XX
DR WPI; 2004-053318/05.
XX
PT Diagnosing predisposition to fat deposition, leanness or non-insulin
PT dependent diabetes mellitus (NIDDM) comprises detecting the presence or
PT absence of a polymorphic variation in a purinergic receptor.
XX
PS Example 3; Page 70; 154pp; English.
XX
CC This invention relates to a novel method of diagnosing a predisposition
CC to fat deposition, leanness or non-insulin dependent diabetes mellitus
CC (NIDDM) in a subject. The method comprises detecting the presence or

```
CC   absence of a polymorphic variation associated with fat deposition,
CC   leanness or NIDDM at a polymorphic site in a purinergic receptor (P2X4)
CC   nucleotide sequence in a nucleic acid sample from a subject. The
CC   invention may be useful for the development of compounds with an
CC   antidiabetic or anorectic activity. The method is useful for diagnosing a
CC   predisposition to fat deposition, leanness or NIDDM. The nucleic acid
CC   encoding the polypeptide is useful for diagnosing conditions or diseases
CC   including fat deposition or NIDDM, also in treating diabetes and obesity.
CC   The present sequence is that of a PCR primer which was used for
CC   amplification of a region of the human purinergic receptor (P2X4) gene
CC   sequence in the exemplification of the invention.
XX
SQ   Sequence 18 BP; 3 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 53;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2374 TGATAACCACAGCCTGGG 2391
              | | ||||||||||||||
Db         18 TTAAAACCACAGCCTGGG 1


RESULT 50
ADB43841
ID   ADB43841 standard; DNA; 17 BP.
XX
AC   ADB43841;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #4164.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 518; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1750 GATCTGAAGCCCAGCT 1765
              ||||||||||||||| |
Db          1 GATCTGAAGCCCAGGT 16


RESULT 51
ADC05055/c
ID   ADC05055 standard; DNA; 17 BP.
XX
AC   ADC05055;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #1502.
XX
KW   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW   NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS   Homo sapiens.
XX
PN   EP1273660-A2.
XX
PD   08-JAN-2003.
XX
PF   25-JAN-2002; 2002EP-00001160.
XX
PR   30-JAN-2001; 2001WO-US000666.
PR   23-MAY-2001; 2001US-00864761.
PR   21-DEC-2001; 2001US-0343331P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y;
XX
DR   WPI; 2003-302724/30.
XX
PT   New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT   passive replacement therapy or as a vaccine for treating or preventing
PT   disorders associated with aberrant expression or activity of human
PT   NHELP1.
XX
PS   Example 2; SEQ ID NO 1542; 468pp; English.
XX
CC   The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC   exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC   polypeptide, an antibody against the protein or its antigen-binding
CC   fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC   polypeptide and an agonist are particularly useful for manufacturing a
CC   medicament for treating or preventing a disorder associated with
CC   decreased expression or activity of human NHELP1. The antibody or its
CC   antigen-binding fragment, and an antagonist, are useful for manufacturing
CC   a medicament for treating or preventing a disorder associated with
CC   increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC   or protein is useful as passive replacement therapy, as a vaccine, or in
CC   diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC   spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ   Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
```

```
  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CTGATCTGAAGCCCAG 1763
              ||||||||||||| ||
Db         17 CTGATCTGAAGCCAAG 2


RESULT 52
ADB44962
ID   ADB44962 standard; DNA; 17 BP.
XX
AC   ADB44962;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #5285.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 649; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1750 GATCTGAAGCCCAGCT 1765
              ||||| ||||||||||
Db          1 GATCTTAAGCCCAGCT 16


RESULT 53
ADI47575/c
ID   ADI47575 standard; DNA; 17 BP.
XX
AC   ADI47575;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID78.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 78; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 6 A; 2 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2016 AATATCCCTTGATGAT 2031
              ||||||| ||||||||
Db         17 AATATCCATTGATGAT 2


RESULT 54
ADI47517/c
```

```
ID   ADI47517 standard; DNA; 17 BP.
XX
AC   ADI47517;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID20.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 20; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 4 A; 1 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 54;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1583 AATATAAAAATAGAGC 1598
              ||||||||||||||| |
Db         16 AATATAAAAATAGATC 1


RESULT 55
AAX73192/c
ID   AAX73192 standard; RNA; 17 BP.
XX
AC   AAX73192;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #625.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 142; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 3 A; 2 C; 1 G; 0 T; 11 U; 0 Other;

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 56
AAX71637/c
ID   AAX71637 standard; RNA; 17 BP.
XX
AC   AAX71637;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human KDR VEGF receptor hammerhead ribozyme substrate #649.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
```

```
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 116; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 3 A; 3 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 57
ACC67935/c
ID   ACC67935 standard; DNA; 17 BP.
XX
AC   ACC67935;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 5182.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 636; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 3 A; 3 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2282 GGAAAAAAAAATTG 2295
              ||||||||||||||
Db         17 GGAAAAAAAAATTG 4


RESULT 58
ADC05061/c
ID   ADC05061 standard; DNA; 17 BP.
XX
AC   ADC05061;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #1508.
XX
KW   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW   NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS   Homo sapiens.
XX
PN   EP1273660-A2.
XX
PD   08-JAN-2003.
XX
PF   25-JAN-2002; 2002EP-00001160.
XX
PR   30-JAN-2001; 2001WO-US000666.
PR   23-MAY-2001; 2001US-00864761.
PR   21-DEC-2001; 2001US-0343331P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y;
XX
DR   WPI; 2003-302724/30.
XX
PT   New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT   passive replacement therapy or as a vaccine for treating or preventing
PT   disorders associated with aberrant expression or activity of human
PT   NHELP1.
XX
PS   Example 2; SEQ ID NO 1548; 468pp; English.
XX
CC   The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC   exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC   polypeptide, an antibody against the protein or its antigen-binding
CC   fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC   polypeptide and an agonist are particularly useful for manufacturing a
CC   medicament for treating or preventing a disorder associated with
CC   decreased expression or activity of human NHELP1. The antibody or its
CC   antigen-binding fragment, and an antagonist, are useful for manufacturing
```

```
CC   a medicament for treating or preventing a disorder associated with
CC   increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC   or protein is useful as passive replacement therapy, as a vaccine, or in
CC   diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC   spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ   Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAG 1758
              ||||||||||||||
Db         14 ACTCTGATCTGAAG 1


RESULT 59
ADI47840
ID   ADI47840 standard; DNA; 17 BP.
XX
AC   ADI47840;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID343.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 343; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 62;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1954 CAAAATCCTATTAG 1967
              ||||||||||||||
Db          4 CAAAATCCTATTAG 17


RESULT 60
ADL50250
ID   ADL50250 standard; RNA; 17 BP.
XX
AC   ADL50250;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PKR substrate sequence #1364.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 3783; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 6 A; 0 C; 3 G; 0 T; 8 U; 0 Other;
```

```
  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 62;
  Matches    7;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1905 TTTGTAAATTGTAA 1918
              :::|:|||::|:||
Db          2 UUUGUAAAUUGUAA 15


RESULT 61
ADL48957
ID   ADL48957 standard; RNA; 17 BP.
XX
AC   ADL48957;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PKR substrate sequence #71.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 2490; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 6 A; 0 C; 4 G; 0 T; 7 U; 0 Other;

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 62;
  Matches    7;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1905 TTTGTAAATTGTAA 1918
              :::|:|||::|:||
Db          4 UUUGUAAAUUGUAA 17


RESULT 62
AAQ05540/c
ID   AAQ05540 standard; DNA; 15 BP.
XX
AC   AAQ05540;
XX
DT   25-MAR-2003  (revised)
DT   10-DEC-1990  (first entry)
XX
DE   Probe to sequence encoding homing receptor unit mLHRc.
XX
KW   Alpha 4m; core protein gp. 90ME1-14; metastasis; cancer;
KW   regional ileitis; ulcerative colitis; lymphadenitides.
XX
OS   Synthetic.
XX
PN   WO9007321-A.
XX
PD   12-JUL-1990.
XX
PF   23-DEC-1988;   88US-00289201.
XX
PR   23-DEC-1988;   88US-00289201.
PR   24-FEB-1989;   89US-00315736.
XX
PA   (STRD ) UNIV LELAND STANFORD JUNIOR.
XX
PI   Weismann IL,  Holzmann B,  Siegelman MH;
XX
DR   WPI; 1990-238876/31.
XX
PT   DNA sequence for encoding homing receptor - of e.g. alpha 4m or core
PT   protein gp. 90ME1-14 free of ubiquitin.
XX
PS   Example 1; Page 23; 60pp; English.
XX
CC   Probe is to the degenerate code of five amino terminal residues of the
CC   mature ubiquitin homing receptor unit protein. Receptor unit may be used
CC   in directing a component to a homing ligand of a high endothelial venule
CC   associated with a mucosal membrane, lymphoid organ, tissue or lymph node
CC   in the mammalian host. Homing may be inhibited in treatment of
CC   inflamatory bowel diseases such as regional ileitis, ulcerative colitis,
CC   lymphadenitides, histiocytic disorders or other inflamatory conditions.
CC   (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ   Sequence 15 BP; 4 A; 2 C; 2 G; 4 T; 0 U; 3 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 52;
  Matches   12;  Conservative    3;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2038 ATAATGATATGTCCA 2052
              |||:||:||:|||||
Db         15 ATARTGRTAYGTCCA 1


RESULT 63
AAT12725
ID   AAT12725 standard; DNA; 17 BP.
XX
AC   AAT12725;
XX
DT   04-SEP-1996  (first entry)
XX
```

```
DE   Human Calpain I gene PCR primer, SM-37.
XX
KW   Polymerase chain reaction; recombinant calpain I; calpain inhibitor;
KW   meat tenderising; thrombosis; blood clot dissolving; primer; ss.
XX
OS   Synthetic.
XX
PN   WO9602634-A1.
XX
PD   01-FEB-1996.
XX
PF   06-JUL-1995;   95WO-US008487.
XX
PR   15-JUL-1994;   94US-00275683.
XX
PA   (CEPH-) CEPHALON INC.
XX
PI   Meyer SL,  Scott RW,  Siman R;
XX
DR   WPI; 1996-105900/11.
XX
PT   Recombinant mammalian calpain and vectors encoding it - useful for
PT   screening potential calpain inhibitors, and to tenderise meat and
PT   dissolve blood clots.
XX
PS   Disclosure; Page 15; 59pp; English.
XX
CC   AAT12724-T12735 are PCR primers used to produce a recombinant human
CC   calpain I, produced by infecting insect cells (partic. Spodoptera
CC   frugisperda) with a recombinant virus (e.g. baculovirus Autographa
CC   californica). Recombinant calpain can be expressed at high levels in the
CC   baculovirus/insect cell system and loses no enzymatic activity. Calpain
CC   produced can be used in assays to screen for potential calpain
CC   inhibitors, to treat diseases in which calpain is implicated, as a meat
CC   tenderiser and for dissolving blood clots
XX
SQ   Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 CACTCTGATCTGAAGCC 1760
              ||| |||||||||||| |
Db          1 CACCCTGATCTGAAGAC 17


RESULT 64
AAT81498/c
ID   AAT81498 standard; RNA; 17 BP.
XX
AC   AAT81498;
XX
DT   07-DEC-1997  (first entry)
XX
DE   Human c-myb hammerhead ribozyme target sequence (nt. position 2690).
XX
KW   Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW   smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW   coronary angioplasty; ss.
XX
OS   Homo sapiens.
XX
PN   WO9531541-A2.
XX
PD   23-NOV-1995.
XX
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 76; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
CC   line. The c-myb sequence was screened for optimal ribozyme target sites
CC   using a computer folding algorithm, and regions of the mRNA which did not
CC   form secondary folding structures and contained potential ribozyme
CC   cleavage sites were identified. Ribozymes were synthesised and their
CC   activities optimised by either varying the length of the binding arms or
CC   by modification to prevent degradation by nucleases. The ribozymes cleave
CC   the c-myb sequence and can be used to prevent smooth muscle cell
CC   hyperproliferation in restenosis, especially after coronary angioplasty,
CC   and in cancers
XX
SQ   Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1638 CCAGTTCTTACAGTAAT 1654
              | | ||||||||||||||
Db         17 CTATTTCTTACAGTAAT 1


RESULT 65
AAT81623/c
ID   AAT81623 standard; RNA; 17 BP.
XX
AC   AAT81623;
XX
DT   21-DEC-1997  (first entry)
XX
DE   Human c-myb hammerhead ribozyme target sequence (nt. position 3079).
XX
KW   Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW   smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW   coronary angioplasty; ss.
XX
OS   Homo sapiens.
XX
PN   WO9531541-A2.
XX
PD   23-NOV-1995.
XX
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 80; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
```

CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX
SQ Sequence 17 BP; 4 A; 0 C; 4 G; 0 T; 9 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1574 AACTTCCAAAATATAAA 1590
||||| ||||| ||||||
Db 17 AACTCCCAAATTATAAA 1

RESULT 66
AAT81624/c
ID AAT81624 standard; RNA; 17 BP.
XX
AC AAT81624;
XX
DT 21-DEC-1997 (first entry)
XX
DE Human c-myb hammerhead ribozyme target sequence (nt. position 3080).
XX
KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
XX
OS Homo sapiens.
XX
PN WO9531541-A2.
XX
PD 23-NOV-1995.
XX
PF 18-MAY-1995; 95WO-US006368.
XX
PR 18-MAY-1994; 94US-00245466.
PR 13-JAN-1995; 95US-00373124.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
XX
DR WPI; 1996-010927/01.
XX
PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
XX
PS Claim 1; Page 80; 128pp; English.
XX
CC The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX
SQ Sequence 17 BP; 4 A; 1 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1573 GAACTTCCAAAATATAA 1589
||||| ||||| |||||
Db 17 GAACTCCCAAATTATAA 1

RESULT 67
AAX71636/c
ID AAX71636 standard; RNA; 17 BP.
XX
AC AAX71636;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human KDR VEGF receptor hammerhead ribozyme substrate #648.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 116; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 3 A; 4 C; 3 G; 0 T; 7 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1871 TGAAAATCAAATGATGC 1887
||||||||||||| ||
Db 17 TGAAAATCAAATGCGGC 1

RESULT 68
AAX73191/c
ID AAX73191 standard; RNA; 17 BP.

```
XX
AC   AAX73191;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #624.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 142; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 4 A; 4 C; 2 G; 0 T; 7 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              ||||||||||||||  ||
Db         17 TGAAAATCAAATGTGGC 1

RESULT 69
AAV49159/c
ID   AAV49159 standard; DNA; 17 BP.
XX
AC   AAV49159;
XX
DT   15-OCT-1998  (first entry)
XX
DE   rb gene antisense oligonucleotide rb-N-107.
XX
KW   rb gene; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Example 7; Fig 9c; 286pp; English.
XX
CC   AAV49008-236 represent antisense oligonucleotides directed against the rb
CC   gene. Of these, only oligonucleotides AAV49008-52 resulted in effective
CC   downregulation of negative growth control by rb, while oligonucleotides
CC   AAV49052-236 had little effect. The oligonucleotides exemplify the
CC   invention. The specification describes oligonucleotides that contain 8-30
CC   nucleotides, which contain at most 8 nucleotides that can each form three
CC   hydrogen bonds to cytosine; do not contain four consecutive nucleotides
CC   able to form three H-bonds each to four consecutive cytosines; do not
CC   contain two sequences of three consecutive nucleotides each able to form
CC   three H-bonds to three consecutive cytosines, and the ratio between
CC   residues able to form two H-bonds each (2R) or three such bonds (3R) is
CC   given by 2R/3R = 0.33-0.72. The oligonucleotides are used to modulate
CC   expression of genes, particularly the genes for p53, ErB-2, junB, junD,
CC   TGF-beta 1 or beta 2 to control proliferation of primary cell cultures
CC   (e.g. bone marrow stem, liver or kidney cells, osteoclasts, osteoblasts
CC   and/or keratinocytes). The oligonucleotides can also be used to analyse
CC   function of proteins (by altering their expression or activity) and
CC   therapeutically, e.g. in cases of cancer or (targeting TGF) for
CC   stimulating the immune system
XX
SQ   Sequence 17 BP; 5 A; 1 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1918 AAATGATACAAAATTTA 1934
              ||||||||  ||  |||||
Db         17 AAATGATAAAACATTTA 1

RESULT 70
AAV91108/c
ID   AAV91108 standard; RNA; 17 BP.
XX
AC   AAV91108;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human C-raf target site nucleotide position 1199.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
```

```
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
PI   Parry T, Beigelman L, Mcswiggen JA, Karpeisky A, Burgin A;
PI   Thompson J, Workman CT, Beaudry A, Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 149; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2138 AAGGGCCTGACCTAATC 2154
              ||| |||||||| ||||
Db         17 AAGAGCCTGACCCAATC 1


RESULT 71
AAV91107/c
ID   AAV91107 standard; RNA; 17 BP.
XX
AC   AAV91107;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human C-raf target site nucleotide position 1194.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
PI   Parry T, Beigelman L, Mcswiggen JA, Karpeisky A, Burgin A;
PI   Thompson J, Workman CT, Beaudry A, Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 149; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2143 CCTGACCTAATCCAAGT 2159
              ||||||| ||||| |||
Db         17 CCTGACCCAATCCGAGT 1


RESULT 72
AAA25079
ID   AAA25079 standard; DNA; 17 BP.
XX
AC   AAA25079;
XX
DT   19-JUL-2000  (first entry)
```

XX
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1577.
XX
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX
OS Homo sapiens.
XX
PN WO9954459-A2.
XX
PD 28-OCT-1999.
XX
PF 19-APR-1999; 99WO-US008547.
XX
PR 20-APR-1998; 98US-0082404P.
PR 23-JUN-1998; 98US-00103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeberli P;
PI Matulic-Adamic J;
XX
DR WPI; 2000-013248/01.
XX
PT New nucleic acids that interact, and optionally cleave, target sequences,
PT used to treat cancer.
XX
PS Claim 77; Page 67; 148pp; English.
XX
CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphoro(di)thioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 3 G; 6 T; 0 U; 0 Other;

```
  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1899 AAGCACTTTGTAAATTG 1915
              ||||||||| ||||| |
Db          1 AAGCACTTTTTAAATGG 17
```

RESULT 73
ABN02789
ID ABN02789 standard; DNA; 17 BP.
XX
AC ABN02789;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2781.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 2781; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 5 A; 9 C; 1 G; 2 T; 0 U; 0 Other;

```
  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1666 CTCCTTCAAGCATCACC 1682
              | |||||||||| ||||
Db          1 CACCTTCAAGCACCACC 17
```

```
RESULT 74
AAS17003/c
ID   AAS17003 standard; DNA; 17 BP.
XX
AC   AAS17003;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Human p21 sense PCR primer 1A.
XX
KW   Human; ss; PCR primer; p53; 1A; p16; p21; ovarian carcinoma;
KW   ovarian tumour; cystadenoma.
XX
OS   Homo sapiens.
XX
PN   US6287775-B1.
XX
PD   11-SEP-2001.
XX
PF   01-JUL-1999;   99US-00346200.
XX
PR   21-MAR-1996;   96US-0041554P.
PR   21-MAR-1996;   96US-00621180.
PR   17-MAR-1997;   97US-00819358.
XX
PA   (UYAR-) UNIV ARKANSAS.
XX
PI   O'brien TJ,  Shigemasa K;
XX
DR   WPI; 2002-048215/06.
XX
PT   Detecting changes in ovarian epithelium, especially for early diagnosis
PT   of ovarian carcinomas, comprises quantifying p16 gene products.
XX
PS   Disclosure; Col 6; 16pp; English.
XX
CC   The invention relates to detecting changes in the ovarian epithelium of a
CC   test subject, comprising removing a sample from the subject's ovarian
CC   epithelium, quantifying p16 gene products in the sample, and comparing
CC   the amount of p16 gene products with a known control. An increase or
CC   decrease in the amount of p16 gene products relative to the control
CC   indicates a change in the subject's ovarian epithelium. The method is
CC   used for early diagnosis of ovarian carcinomas on the basis of increased
CC   p16 gene expression. Increased p16 expression is a sensitive marker for
CC   ovarian tumours. In a study on 38 ovarian epithelium samples, p16
CC   overexpression (at least 2 standard deviations) was observed in 0/6
CC   normal samples, 1/2 benign cystadenoma samples, 5/6 cystadenoma samples
CC   of low malignant potential and 22/24 carcinoma samples. The present
CC   sequence represents a quantitative PCR primer for human p21 used in an
CC   experiment comparing levels of p16, p53 and p21 ovarian samples
XX
SQ   Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2315 AAGGAACTGAATTCTGC 2331
              ||||||||||  ||| ||
Db         17 AAGGAACTGACTTCGGC 1


RESULT 75
ABV89984/c
ID   ABV89984 standard; DNA; 17 BP.
XX
AC   ABV89984;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 697.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 697; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2042 TGATATGTCCATTATTA 2058
              ||||||  |||  ||||||
Db         17 TGATATCTCCCTTATTA 1


RESULT 76
ABV89985/c
ID   ABV89985 standard; DNA; 17 BP.
XX
AC   ABV89985;
XX
```

DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 698.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 698; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2041 ATGATATGTCCATTATT 2057
||||||| ||| |||||
Db 17 ATGATATCTCCCTTATT 1

RESULT 77
ACD00758
ID ACD00758 standard; DNA; 17 BP.
XX
AC ACD00758;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1231.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO2003031621-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032599.
XX
PR 12-OCT-2001; 2001US-0329000P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
DR WPI; 2003-381720/36.
XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 1255; 156pp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 3 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1655 CCCTGAGAAATCTCCTT 1671
||||||||| | |||||
Db 1 CCCTGAGAAGTTTCCTT 17

RESULT 78
ABZ60839/c
ID ABZ60839 standard; RNA; 17 BP.
XX
AC ABZ60839;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNAzyme substrate #951.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX

PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 103; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1877 TCAAATGATGCAAAATA 1893
              ||||||||| ||| |||
Db         17 TCAAATGATACAATATA 1
```

RESULT 79
ACD54840/c
ID ACD54840 standard; RNA; 17 BP.
XX
AC ACD54840;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV DNAzyme substrate sequence #144.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Example 1; Page 189; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 5 A; 4 C; 1 G; 0 T; 7 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1824 TAATAACATTGGGCTAA 1840
              || |||||||||| |||
Db         17 TAGTAACATTGGGATAA 1
```

RESULT 80
ACD51179
ID ACD51179 standard; RNA; 17 BP.
XX
AC ACD51179;
XX
DT 23-SEP-2003 (first entry)
XX
DE HBV hammerhead ribozyme substrate sequence #441.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.

```
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 144; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 7 A; 0 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 66;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2081 GAAGGAATTTGGCAGAT 2097
              |||| ||:::|| |||:
Db          1 GAAGUAAUUUGGAAGAU 17


RESULT 81
ADB42393
ID   ADB42393 standard; DNA; 17 BP.
XX
AC   ADB42393;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #2716.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 349; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2095 GATGCAGTTAAGGTTCC 2111
              ||| ||||| |||||||
Db          1 GATCCAGTTCAGGTTCC 17


RESULT 82
ADC04546/c
ID   ADC04546 standard; DNA; 17 BP.
XX
AC   ADC04546;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #993.
XX
```

KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS Homo sapiens.
XX
PN EP1273660-A2.
XX
PD 08-JAN-2003.
XX
PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y;
XX
DR WPI; 2003-302724/30.
XX
PT New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHELP1.
XX
PS Example 2; SEQ ID NO 1033; 468pp; English.
XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHELP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 0 A; 4 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2274 AGCAAGCAGGAAAAAAA 2290
|| |||||||||||| |
Db 17 AGAAAGCAGGAAAAACA 1

RESULT 83
ADL46517
ID ADL46517 standard; RNA; 17 BP.
XX
AC ADL46517;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor hammerhead ribozyme substrate sequence #50.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor hammerhead ribozyme; substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 50; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor hammerhead ribozyme substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 66;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 2428 ATGAGAATCTATCTGTT 2444
|:|| | :|:|:|:|::
Db 1 AUGACACUCUAUCUGUU 17

RESULT 84
ADL50306/c
ID ADL50306 standard; RNA; 17 BP.
XX
AC ADL50306;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1420.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

```
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 3839; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1657 CTGAGAAATCTCCTTCA 1673
              ||||||| || ||||||
Db         17 CTGAGAAGTCACCTTCA 1

RESULT 85
ADM59993/c
ID   ADM59993 standard; RNA; 17 BP.
XX
AC   ADM59993;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #2127.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 2127; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 5 A; 4 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 66;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1824 TAATAACATTGGGCTAA 1840
              || |||||||||| |||
Db         17 TAGTAACATTGGGATAA 1

RESULT 86
ADM58340
ID   ADM58340 standard; RNA; 17 BP.
XX
AC   ADM58340;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #474.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
```

PF 15-JAN-2003; 2003US-00342902.
XX
PR 14-MAY-1992; 92US-00882712.
PR 07-FEB-1994; 94US-00193627.
PR 08-NOV-1999; 99US-00436430.
PR 20-MAR-2000; 2000US-00531025.
PR 09-AUG-2000; 2000US-00636385.
PR 24-OCT-2000; 2000US-00696347.
PR 08-JUN-2001; 2001US-00877478.
XX
PA (DRAP/) DRAPER K.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
PA (MORR/) MORRISSEY D.
XX
PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX
DR WPI; 2004-247781/23.
XX
PT Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT specifically cleaving RNA derived from hepatitis B virus and comprising
PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS Disclosure; SEQ ID NO 474; 122pp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule that
CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC comprising one or more binding arms, without requiring the presence of a
CC 2'-OH group within the molecule for activity. The nucleic acids are
CC useful for treating hepatitis B virus infection, hepatitis,
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC combination with other therapies such as lamivudine and interferons. The
CC nucleic acids are useful as diagnostic tools to examine genetic drift and
CC mutations within diseased cells, for detecting the presence of HBV RNA in
CC a cell, for the study of RNA and for down-regulating gene expression of
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC sequence represents an HBV RNA target sequence, used in the scope of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 17 BP; 7 A; 0 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 66;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2081 GAAGGAATTTGGCAGAT 2097
|||| ||:::|| |||:
Db 1 GAAGUAAUUUGGAAGAU 17

RESULT 87
ACN65879
ID ACN65879 standard; DNA; 17 BP.
XX
AC ACN65879;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:2781.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUYY/) GU Y.
PA (JIYY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
DR WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 2781; 0pp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SQ Sequence 17 BP; 5 A; 9 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1666 CTCCTTCAAGCATCACC 1682
| |||||||||| ||||
Db 1 CACCTTCAAGCACCACC 17

RESULT 88
ACF57579/c
ID ACF57579 standard; DNA; 15 BP.
XX
AC ACF57579;
XX
DT 22-APR-2004 (first entry)
XX
DE Human ALDOB gene allele-specific primer SEQ ID NO: 30.
XX
KW Human; ALDOB; fructose-bisphosphate aldolase B; SNP;
KW single nucleotide polymorphism; primer; probe; ss.
XX
OS Homo sapiens.

XX
PN WO2003091454-A1.
XX
PD 06-NOV-2003.
XX
PF 26-APR-2002; 2002WO-US013328.
XX
PR 26-APR-2002; 2002WO-US013328.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Chew A, Kazemi A, Koshy B;
XX
DR WPI; 2003-877338/81.
XX
PS Claim 39; Page 14; 0pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC fructose-bisphosphate aldolase B (ALDOB) and single nucleotide
CC polymorphisms (SNPs) which have been identified in each sequence. The
CC method of haplotyping the sequences is useful for haplotyping the
CC fructose-biphosphate aldose B (ALDOB) gene of an individual or for
CC validating the ALDOB protein as a candidate target for treating a medical
CC condition predicted to be associated with ALDOB activity. The present
CC sequence is an allele-specific primer/probe used to identify the
CC haplotype of the human ALDOB gene in the exemplification of the invention
XX
SQ Sequence 15 BP; 6 A; 1 C; 3 G; 4 T; 0 U; 1 Other;

Query Match 1.5%; Score 13.6; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 56;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1960 CCTATTAGTCATAT 1973
:||||||||||||
Db 14 YCTATTAGTCATAT 1

RESULT 89
AAF47767
ID AAF47767 standard; DNA; 15 BP.
XX
AC AAF47767;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #1187.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 7; Page 51; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 59;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2263 TTCCAGTTGTCAGCA 2277
||||||| |||||||
Db 1 TTCCAGTAGTCAGCA 15

RESULT 90
AAF47768
ID AAF47768 standard; DNA; 15 BP.
XX
AC AAF47768;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP3 oligonucleotide #1188.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.

XX
PS Example 7; Page 51; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 59;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2264 TCCAGTTGTCAGCAA 2278
||||||| |||||||
Db 1 TCCAGTAGTCAGCAA 15

RESULT 91
ABZ33935/c
ID ABZ33935 standard; DNA; 16 BP.
XX
AC ABZ33935;
XX
DT 31-JAN-2003 (first entry)
XX
DE HIV-1 reverse transcriptase mutation detection probe SEQ ID NO:177.
XX
KW Human immunodeficiency virus; HIV; reverse transcriptase; RT; enzyme;
KW detection; mutation; anti-HIV drug resistance; polymorphism; resistance;
KW probe; ss.
XX
OS Human immunodeficiency virus 1.
OS Synthetic.
XX
PN WO200255741-A2.
XX
PD 18-JUL-2002.
XX
PF 09-JAN-2002; 2002WO-EP000153.
XX
PR 11-JAN-2001; 2001EP-00870005.
PR 20-APR-2001; 2001EP-00870085.
PR 24-APR-2001; 2001US-0286102P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI De Smet K, Stuyver L;
XX
DR WPI; 2002-590680/63.
XX
PT Detecting mutations associated with anti-HIV drug resistance comprises
PT detecting at least one of the mutations in the HIV reverse transcriptase
PT gene by using probes optimized to function together in a reverse-
PT hybridization assay.
XX
PS Claim 2; Page 15; 117pp; English.
XX
CC The present invention describes a method for detecting mutations
CC associated with anti-HIV drug resistance in a patient by detecting at
CC least one of the mutations K103N/R, V106A/I/L, Y181C/I, M184V/I, Y188L,
CC G190A/S/R, T215Y/F/D/S/A and/or Q151M/L in the reverse transcriptase (RT)
CC of HIV strains in a biological sample using a specific set of probes
CC optimised to function together in a reverse-hybridisation assay. The
CC method and the nucleic acid sequences used in the method are useful for
CC determining viral mutations and/or polymorphisms in the HIV RT gene
CC associated with resistance. The probes are useful for the genetic
CC detection, preferably in vitro detection of the mutations K103N/R,
CC V106A/I/L, Y181C/I, Q151M/L, M184V/I, Y188L, G190A/S/R and/or
CC T215Y/F/D/S/A in the RT of HIV strains in a biological sample, where the
CC mutation is associated with anti-HIV drug resistance. The method provides
CC a rapid, reliable and precise assay or determination and monitoring of
CC antiviral drug resistance or mutations associated with drug resistance of
CC viruses containing RT genes. ABZ33759 to ABZ34642 represent HIV RT
CC sequences and probes which are used in the exemplification of the present
CC invention
XX
SQ Sequence 16 BP; 6 A; 3 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 67;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1969 CATATATTTATAGAT 1983
||||||| ||||||
Db 16 CATATATTGATAGAT 2

RESULT 92
ADQ30355/c
ID ADQ30355 standard; DNA; 16 BP.
XX
AC ADQ30355;
XX
DT 09-SEP-2004 (first entry)
XX
DE Human VR1 exon 1d transcription factor binding fragment #74.
XX
KW ds; VR1 receptor; vanilloid receptor type 1; modulator;
KW pain transmission; primary sensory neuron; transcription factor;
KW detection; MZF1; NFkappaB; NFAT; GATA1; sensitivity disorder; analgesia;
KW hypalgesia; hyperalgesia; neuralgia; myalgia; human.
XX
OS Homo sapiens.
XX
PN WO2004053120-A2.
XX
PD 24-JUN-2004.
XX
PF 01-DEC-2003; 2003WO-EP013522.
XX
PR 09-DEC-2002; 2002DE-01057421.
XX
PA (CHEF) GRUENENTHAL GMBH.
XX
PI Weihe E, Bieller A, Schaefer MKH;
XX
DR WPI; 2004-468868/44.
XX
PT New nucleic acid that modulates expression of the vanilloid receptor-1,
PT useful for control of pain or sensitivity disorders, comprises sequences
PT from control regions of the receptor gene.
XX
PS Disclosure; Page 53; 68pp; German.
XX
CC This invention describes a novel nucleic acid containing a specific
CC segment having at least one region that modulates expression of the VR1
CC (vanilloid receptor type 1) receptor, or a functional derivative, allele
CC or fragment of this region, or a sequence that hybridises to it under
CC standard conditions. The VR1 modulator is derived from one or more of
CC positions 221931-223344 of GenBank AL670399, 31673-36359 of AL663116, or
CC 44731-43231 or 36616-33151 of AF168787 and is involved in transmission of
CC pain, particularly in primary sensory neurons. The invention also
CC describes a vector that contains the VR1 modulator, host cells containing

CC this vector (other than human germ or embryonal stem cells) and a method
CC for modulating expression of the VR1 receptor by introducing the
CC modulator or the vector into a cell that contains the VR1 gene. The
CC products of the invention are used for detecting a transcription factor
CC from its binding to a regulatory sequence (or a double-stranded
CC oligonucleotide fragment of it), e.g. by Western blotting or enzyme-
CC linked immunosorbant assay, particularly for diagnosis of diseases
CC associated with overexpression or underexpression of the transcription
CC factor. The region that modulates VR1 receptor expression includes a
CC binding site for a transcription factor, e.g. MZF1, NFkappaB, NFAT or
CC GATA1. The nucleic acids of the invention, or vectors containing them,
CC are used for prevention or treatment of pain, also for treating
CC sensitivity disorders, e.g. analgesia, hypalgesia or hyperalgesia, also
CC neuralgia and myalgia, that are associated with activity of the VR1
CC receptor. This sequence represents a fragment of human VR1 exon 1d DNA
CC which is capable of binding to a transcription factor.
XX
SQ Sequence 16 BP; 10 A; 0 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 67;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1970 ATATATTTATAGATT 1984
||||||||||| |||
Db 15 ATATATTTATATATT 1

RESULT 93
ABZ03275/c
ID ABZ03275 standard; DNA; 50 BP.
XX
AC ABZ03275;
XX
DT 09-JAN-2003 (first entry)
XX
DE Human leukocyte gene expression profiling probe SEQ ID NO 3266.
XX
KW T7; leukocyte; gene expression profiling; allograft rejection;
KW atherosclerosis; congestive heart failure; systemic lupus erythematosus;
KW rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
KW ss.
XX
OS Homo sapiens.
XX
PN WO200257414-A2.
XX
PD 25-JUL-2002.
XX
PF 22-OCT-2001; 2001WO-US047856.
XX
PR 20-OCT-2000; 2000US-0241994P.
PR 08-JUN-2001; 2001US-0296764P.
XX
PA (BIOC-) BIOCARDIA INC.
XX
PI Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;
PI Ly N, Woodward R, Quertermous T, Johnson F;
XX
DR WPI; 2002-636525/68.
XX
PT New system for leukocyte expression profiling, diagnosing a disease, or
PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
PT or congestive heart failure, comprises diagnostic oligonucleotides.
XX
PS Claim 1; Page 431; 0pp; English.
XX
CC The invention relates to a system for detecting gene expression, which
CC comprises one or two isolated DNA molecules that detect expression of a
CC gene, where the gene corresponds to any of 8143 oligonucleotides
CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
CC for leukocyte expression profiling. It is particularly useful for
CC diagnosing a disease, monitoring (rate of) progression of a disease,
CC predicting therapeutic outcome, determining prognosis for a patient,
CC predicting disease complications in an individual or monitoring response
CC to treatment in an individual. The diseases include cardiac allograft
CC rejection, kidney allograft rejection, liver allograft rejection,
CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
XX
SQ Sequence 50 BP; 12 A; 11 C; 11 G; 16 T; 0 U; 0 Other;

Query Match 1.4%; Score 13.2; DB 1; Length 50;
Best Local Similarity 61.8%; Pred. No. 98;
Matches 21; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1883 GATGCAAAATATATACAAGCACTTTGTAAATTGT 1916
|| ||| | | ||| ||| | ||| | | ||
Db 37 GAAGCACAGCAGATATTAGCCCAATGTTATTAGT 4

RESULT 94
ABC12913/c
ID ABC12913 standard; DNA; 13 BP.
XX
AC ABC12913;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 12920 for detecting SNP TSC0003014.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 12920; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1582 AAATATAAAAATA 1594
              |||||||||||||
Db         13 AAATATAAAAATA 1

RESULT 95
ABH02414/c
ID   ABH02414 standard; DNA; 13 BP.
XX
AC   ABH02414;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 202391 for detecting SNP TSC0008339.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 202391; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1887 CAAAATATATACA 1899
              |||||||||||||
Db         13 CAAAATATATACA 1

RESULT 96
ABC12912
ID   ABC12912 standard; DNA; 13 BP.
XX
AC   ABC12912;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 12919 for detecting SNP TSC0003014.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 12919; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 10 A; 0 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1582 AAATATAAAAATA 1594
              |||||||||||||
Db          1 AAATATAAAAATA 13

RESULT 97
ABH53074
ID   ABH53074 standard; DNA; 13 BP.
XX
AC   ABH53074;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 253051 for detecting SNP TSC0006570.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
```

```
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 253051; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 0 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1908 GTAAATTGTAAAA 1920
              |||||||||||||
Db          1 GTAAATTGTAAAA 13


RESULT 98
ABC23754/c
ID   ABC23754 standard; DNA; 13 BP.
XX
AC   ABC23754;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 23771 for detecting SNP TSC0005308.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 23771; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 0 G; 10 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAAT 1593
              |||||||||||||
Db         13 AAAATATAAAAAT 1


RESULT 99
ABH02415
ID   ABH02415 standard; DNA; 13 BP.
XX
AC   ABH02415;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 202392 for detecting SNP TSC0008339.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 202392; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
```

```
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1887 CAAAATATATACA 1899
              |||||||||||||
Db          1 CAAAATATATACA 13


RESULT 100
ABF62300/c
ID   ABF62300 standard; DNA; 13 BP.
XX
AC   ABF62300;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 162297 for detecting SNP TSC0009377.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 162297; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1770 CCACTACTAATTT 1782
              |||||||||||||
Db         13 CCACTACTAATTT 1


RESULT 101
ABH47035/c
ID   ABH47035 standard; DNA; 13 BP.
XX
AC   ABH47035;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 247012 for detecting SNP TSC0060369.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 247012; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 ATTTATAGATTGT 1986
              |||||||||||||
Db         13 ATTTATAGATTGT 1


RESULT 102
ABC50481
ID   ABC50481 standard; DNA; 13 BP.
XX
AC   ABC50481;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 50498 for detecting SNP TSC0014187.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 50498; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1888 AAAATATATACAA 1900
              |||||||||||||
Db          1 AAAATATATACAA 13


RESULT 103
ABH15319
ID   ABH15319 standard; DNA; 13 BP.
XX
AC   ABH15319;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 215296 for detecting SNP TSC0006400.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 215296; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1821 CACTAATAACATT 1833
              |||||||||||||
Db          1 CACTAATAACATT 13


RESULT 104
ABF79796
ID   ABF79796 standard; DNA; 13 BP.
XX
AC   ABF79796;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 179793 for detecting SNP TSC0044520.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 179793; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
```

```
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1585 TATAAAAATAGAG 1597
             |||||||||||||
Db          1 TATAAAAATAGAG 13


RESULT 105
ABF79797/c
ID   ABF79797 standard; DNA; 13 BP.
XX
AC   ABF79797;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 179794 for detecting SNP TSC0044520.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 179794; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 2 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1585 TATAAAAATAGAG 1597
             |||||||||||||
Db          13 TATAAAAATAGAG 1


RESULT 106
ABF00805/c
ID   ABF00805 standard; DNA; 13 BP.
XX
AC   ABF00805;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 100802 for detecting SNP TSC0025074.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 100802; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1972 ATATTTATAGATT 1984
             |||||||||||||
Db          13 ATATTTATAGATT 1


RESULT 107
ABF32140/c
ID   ABF32140 standard; DNA; 13 BP.
XX
AC   ABF32140;
```

XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 132137 for detecting SNP TSC0032979.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 132137; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1580 CAAAATATAAAAA 1592
||||||||||||||
Db 13 CAAAATATAAAAA 1

RESULT 108
ABC50480/c
ID ABC50480 standard; DNA; 13 BP.
XX
AC ABC50480;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 50497 for detecting SNP TSC0014187.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 50497; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1888 AAAATATATACAA 1900
||||||||||||||
Db 13 AAAATATATACAA 1

RESULT 109
ABC52298/c
ID ABC52298 standard; DNA; 13 BP.
XX
AC ABC52298;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 52315 for detecting SNP TSC0014536.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 52315; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2008 ACAAATAAAATAT 2020
||||||||||||
Db 13 ACAAATAAAATAT 1

RESULT 110
ABC52299
ID ABC52299 standard; DNA; 13 BP.
XX
AC ABC52299;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 52316 for detecting SNP TSC0014536.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 52316; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 1 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2008 ACAAATAAAATAT 2020
||||||||||||
Db 1 ACAAATAAAATAT 13

RESULT 111
ABH47034
ID ABH47034 standard; DNA; 13 BP.
XX
AC ABH47034;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 247011 for detecting SNP TSC0060369.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 247011; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1974 ATTTATAGATTGT 1986
||||||||||||

```
Db          1 ATTTATAGATTGT 13


RESULT 112
ABC23755
ID   ABC23755 standard; DNA; 13 BP.
XX
AC   ABC23755;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 23772 for detecting SNP TSC0005308.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 23772; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 10 A; 0 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAAT 1593
              |||||||||||||
Db          1 AAAATATAAAAAT 13


RESULT 113
ABF32141
ID   ABF32141 standard; DNA; 13 BP.
XX
AC   ABF32141;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 132138 for detecting SNP TSC0032979.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 132138; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 10 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1580 CAAAATATAAAAA 1592
              |||||||||||||
Db          1 CAAAATATAAAAA 13


RESULT 114
ABF93762/c
ID   ABF93762 standard; DNA; 13 BP.
XX
AC   ABF93762;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 193759 for detecting SNP TSC0047657.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
```

```
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 193759; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1951 TTACAAAATCCTA 1963
              |||||||||||||
Db         13 TTACAAAATCCTA 1


RESULT 115
ABH53075/c
ID   ABH53075 standard; DNA; 13 BP.
XX
AC   ABH53075;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 253052 for detecting SNP TSC0006570.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 253052; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 2 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1908 GTAAATTGTAAAA 1920
              |||||||||||||
Db         13 GTAAATTGTAAAA 1


RESULT 116
ABF93763
ID   ABF93763 standard; DNA; 13 BP.
XX
AC   ABF93763;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 193760 for detecting SNP TSC0047657.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 193760; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
```

```
SQ   Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1951 TTACAAAATCCTA 1963
              |||||||||||||
Db          1 TTACAAAATCCTA 13


RESULT 117
ABF62301
ID   ABF62301 standard; DNA; 13 BP.
XX
AC   ABF62301;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 162298 for detecting SNP TSC0009377.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 162298; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1770 CCACTACTAATTT 1782
              |||||||||||||
Db          1 CCACTACTAATTT 13


RESULT 118
ABF00804
ID   ABF00804 standard; DNA; 13 BP.
XX
AC   ABF00804;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 100801 for detecting SNP TSC0025074.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 100801; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 52;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1972 ATATTTATAGATT 1984
              |||||||||||||
Db          1 ATATTTATAGATT 13


RESULT 119
ABH15318/c
ID   ABH15318 standard; DNA; 13 BP.
XX
AC   ABH15318;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 215295 for detecting SNP TSC0006400.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
```

XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 215295; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1821 CACTAATAACATT 1833
||||||||||||||
Db 13 CACTAATAACATT 1

RESULT 120
ADF61903
ID ADF61903 standard; RNA; 14 BP.
XX
AC ADF61903;
XX
DT 12-FEB-2004 (first entry)
XX
DE Ribosome binding site RNA SEQ ID 56 located downstream of promoter.
XX
KW artificial promoter; bacterial clone; strain performance;
KW fermentation process; cell viability; ss; RBS; ribosome binding site.
XX
OS Unidentified.
XX
PN WO2003089605-A2.
XX
PD 30-OCT-2003.
XX
PF 18-APR-2003; 2003WO-US012045.
XX
PR 22-APR-2002; 2002US-0374627P.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Soucaille P;
XX
DR WPI; 2003-854112/79.
XX
PT Creating a library of artificial promoters comprises mixing
PT oligonucleotides in a polymerase chain reaction with an insertion DNA
PT cassette to obtain a library of double-stranded amplified products
PT comprising artificial promoters.
XX
PS Claim 15; SEQ ID NO 56; 44pp; English.
XX
CC The invention relates to a novel method for creating a library of
CC artificial promoters comprising mixing a first oligonucleotide and a
CC second oligonucleotide in an amplification reaction with an insertion DNA
CC cassette to obtain a library of double-stranded amplified products
CC comprising artificial promoters. The method of the invention may be
CC useful in creating a library of bacterial clones with varying levels of
CC gene expression and in developing a quick and efficient means of
CC determining the optimum expression level of a gene in a metabolic pathway
CC which, in turn, results in an optimisation of strain performance for a
CC desired product. A direct advantage of the method is that a bacterial
CC clone may be selected based on the expression level obtained from DNA
CC libraries and then be ready for use in a fermentation process where cell
CC viability is not negatively affected by expression of the gene of
CC interest. The current sequence is that of the ribosome biding site (RBS)
CC RNA of the invention which is located downstream of precursor promoter.
XX
SQ Sequence 14 BP; 11 A; 0 C; 2 G; 0 T; 1 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 60;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2281 AGGAAAAAAAAAT 2293
||||||||||||:
Db 2 AGGAAAAAAAAAU 14

RESULT 121
AAT55633/c
ID AAT55633 standard; RNA; 15 BP.
XX
AC AAT55633;
XX
DT 25-MAR-2003 (revised)
DT 21-MAR-1997 (first entry)
XX
DE Human TNF-alpha hammerhead ribozyme target sequence (nt position 39).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
OS Homo sapiens.
XX
PN WO9523225-A2.
XX
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.
XX
PR 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.

PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Chowrira B, Direnzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX
DR WPI; 1995-351090/45.
XX
PT Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
PS Claim 2; Page 241; 407pp; English.
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves TNF-alpha mRNA at
CC the nucleotide base position indicated in the DE line. Regions of the
CC mRNA that do not form secondary folding structures and that contain
CC potential hammerhead and hairpin ribozyme cleavage sites were identified
CC by computer analysis. Ribozymes directed against these mRNA sequences
CC were designed and synthesised with modifications that improve their
CC nuclease resistance. The ribozymes are designed to cleave the target
CC sequences and thereby inhibit TNF-alpha expression, making them
CC potentially useful for treating rheumatoid arthritis, septic shock and
CC other inflammatory disorders including psoriasis, as well as for
CC treatment of AIDS. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 15 BP; 3 A; 6 C; 0 G; 0 T; 6 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2201 AGTATGTGAGAGG 2213
||||||||||||
Db 15 AGTATGTGAGAGG 3

RESULT 122
ABS51921/c
ID ABS51921 standard; DNA; 15 BP.
XX
AC ABS51921;
XX
DT 05-NOV-2002 (first entry)
XX
DE Human FMO2 gene polymorphism detection ASO primer #42.
XX
KW Human; flavin containing monooxygenase-2; FMO2; isogene; drugs targeting;
KW drug toxicity; bone disorder; gene therapy; polymorphism; chromosome 1q;
KW allele-specific oligonucleotide; ASO; primer; ss.
XX
OS Homo sapiens.

XX
PN WO200253579-A2.
XX
PD 11-JUL-2002.
XX
PF 18-DEC-2001; 2001WO-US049059.
XX
PR 29-DEC-2000; 2000US-0259062P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Bentivegna SC, Duda A, Kazemi A, Lee HH, Messer C, Parks KE;
XX
DR WPI; 2002-590627/63.
XX
PT Novel genetic variants of Flavin Containing Monooxygenase 2 isogenes,
PT useful for improving efficiency and reliability in drug development for
PT treating developmental bone disorders.
XX
PS Claim 15; Page 16; 140pp; English.
XX
CC The present invention relates to a new polynucleotide which comprises
CC flavin containing monooxygenase-2 (FMO2) isogenes. The invention is
CC useful in screening for drugs that are useful for treating drug toxicity.
CC The methods of the invention are useful for improving the efficiency and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with FMO2 activity. The methods are also
CC used by the pharmaceutical research scientist to validate FMO2 as a
CC candidate target for treating a specific condition or disease predicted
CC to be associated with FMO2 activity, e.g. drug toxicity, and in the
CC design of clinical trials for treating a specific condition of disease
CC associated with FMO2 activity. The methods are also useful for screening
CC compounds targeting FMO2. The nucleic acid of the invention is useful in
CC studying the expression and function of FMO2, and in expressing FMO2
CC protein for use in screening for candidate drugs to treat diseases
CC related to FMO2 activity. It is also useful in studying the effect of the
CC variation on the biological activity of FMO2 as well as on the binding
CC affinity of candidate drugs targeting FMO2 for the treatment of drug
CC toxicity. The invention is useful for studying the expression of FMO2
CC isogenes in vivo, for in vivo screening and testing of drugs targeted
CC against FMO2 protein, and for testing the efficacy of therapeutic agents
CC and compounds for treating drug toxicity in a biological system. The
CC present nucleic acid sequence represents an allele-specific
CC oligonucleotide (ASO) primer that was used in the methods of the
CC invention to detect polymorphisms in the human FMO2 gene located on
CC chromosome 1q
XX
SQ Sequence 15 BP; 2 A; 3 C; 0 G; 9 T; 0 U; 1 Other;

Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 67;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2281 AGGAAAAAAAAATTG 2295
|:||||||| |||||
Db 15 AKGAAAAAAGAATTG 1

RESULT 123
ABI99114
ID ABI99114 standard; DNA; 15 BP.
XX
AC ABI99114;
XX
DT 27-FEB-2002 (first entry)
XX
DE Human PCDH2 ASO PCR primer SEQ ID NO 71.
XX
KW Human; PCDH2; protocadherin 2; haplotyping; polymorphic variant; SNP;
KW single nucleotide polymorphism; cytostatic; cancer; chromosome 5q31;
KW allele-specific oligonucleotide; ASO; PCR primer; ss.
XX
OS Homo sapiens.

XX
PN WO200194361-A2.
XX
PD 13-DEC-2001.
XX
PF 06-JUN-2001; 2001WO-US018321.
XX
PR 06-JUN-2000; 2000US-0209564P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Kliem SE, Koshy B, Tanguay DA;
XX
DR WPI; 2002-097928/13.
XX
PT New protocadherin 2 (PCDH2) polymorphic variants and encoding genes,
PT useful in expressing PCDH2 protein for screening candidate drugs to treat
PT diseases related to PCDH2 activity.
XX
PS Claim 16; Page 14; 127pp; English.
XX
CC The invention relates to haplotyping the protocadherin 2 (PCDH2) gene,
CC comprising determining which of the haplotypes given in the specification
CC defines one or both copies of the individual's pCDH2 gene. The
CC polymorphisms are within a 30244 base pair sequence (ABA05413), fully
CC defined in the specification. The polymorphic variants are useful in
CC studying the expression and function of PCDH2, in expressing PCDH2
CC protein for use in screening for candidate drugs to treat diseases such
CC as cancer, related to PCDH2 activity, in studying the effect of the
CC variation on the biological activity of PCDH2 and the binding affinity of
CC candidate drugs targeting PCDH2. The haplotyping methods are useful in
CC validating PCDH2 as a candidate target for treating a specific condition
CC or disease predicted to be associated with PCDH2 activity or in the
CC design of clinical trials of candidate drugs for treating a specific
CC condition or disease associated with PCDH2 activity. The present sequence
CC is that of a PCDH2 allele-specific oligonucleotide (ASO) PCR primer of
CC the invention
XX
SQ Sequence 15 BP; 2 A; 4 C; 5 G; 3 T; 0 U; 1 Other;

Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 67;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2386 CCTGGGCTGACACCT 2400
||||||||||:||
Db 1 CCTGGGCTGAGACYT 15

RESULT 124
ADR74580/c
ID ADR74580 standard; DNA; 16 BP.
XX
AC ADR74580;
XX
DT 16-DEC-2004 (first entry)
XX
DE Allele specific primer A for human stenosis marker hCV15850923.
XX
KW Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
KW angina; ischaemic chest pain; myocardial infarction;
KW sudden cardiac death; SNP; single nucleotide polymorphism.
XX
OS Homo sapiens.
XX
PN WO2004081186-A2.
XX
PD 23-SEP-2004.
XX
PF 10-MAR-2004; 2004WO-US007140.
XX
PR 10-MAR-2003; 2003US-0453050P.
PR 30-APR-2003; 2003US-0466437P.
XX
PA (APPL-) APPLERA CORP.
XX
PI Cargill M, Devlin JJ, Luke MM;
XX
DR WPI; 2004-668949/65.
XX
PT Identifying an individual who has altered risk for developing stenosis
PT comprises detecting single nucleotide polymorphism (SNP), in the
PT individual's nucleic acids.
XX
PS Claim 19; SEQ ID NO 67892; 146pp; English.
XX
CC The invention relates to identifying an individual who has altered risk
CC for developing coronary stenosis comprising detecting a single nucleotide
CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not
CC given in the specification), in the individual's nucleic acids, where the
CC presence of the SNP is correlated with an altered risk for stenosis in
CC the individual. Also included are an isolated nucleic acid molecule
CC (comprising at least 8 contiguous nucleotides where one of the
CC nucleotides is an SNP as cited above, or their complement), an isolated
CC polypeptide comprising an amino acid sequence selected from any of the
CC 696 amino acid sequences (not defined in the specification), an antibody
CC that specifically binds to the polypeptide (or its antigen-binding
CC fragment), an amplified polynucleotide containing the SNP as cited (where
CC the amplified polynucleotide is between about 16 and about 1,000
CC nucleotides in length), an isolated polynucleotide which specifically
CC hybridises to a nucleic acid molecule containing the SNP, a kit for
CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid
CC molecule, detecting a variant polypeptide and identifying an agent useful
CC in therapeutically or prophylactically treating stenosis. The detection
CC step of the method is carried out by a process selected from allele-
CC specific probe hybridisation, allele-specific primer extension, allele-
CC specific amplification, sequencing, 5' nuclease digestion, molecular
CC beacon assay, oligonucleotide ligation assay, size analysis, and single-
CC stranded conformation polymorphism. The method is useful for identifying
CC an individual who has altered risk for developing coronary stenosis,
CC which can lead to angina (ischaemic chest pain), myocardial infarction
CC and ultimately sudden cardiac death. The present sequence is an allele
CC specific primer for amplifying a SNP-containing region of a human marker
CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the
CC specification but are provided on a CD-R named CL001510CDR which was not
CC supplied with the specification.
XX
SQ Sequence 16 BP; 2 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2302 CAGTTGCAACCAC 2314
||||||||||||
Db 13 CAGTTGCAACCAC 1

RESULT 125
ADR74581/c
ID ADR74581 standard; DNA; 16 BP.
XX
AC ADR74581;
XX
DT 16-DEC-2004 (first entry)
XX
DE Allele specific primer B for human stenosis marker hCV15850923.
XX
KW Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
KW angina; ischaemic chest pain; myocardial infarction;
KW sudden cardiac death; SNP; single nucleotide polymorphism.
XX
OS Homo sapiens.
XX
PN WO2004081186-A2.
XX

PD 23-SEP-2004.
XX
PF 10-MAR-2004; 2004WO-US007140.
XX
PR 10-MAR-2003; 2003US-0453050P.
PR 30-APR-2003; 2003US-0466437P.
XX
PA (APPL-) APPLERA CORP.
XX
PI Cargill M, Devlin JJ, Luke MM;
XX
DR WPI; 2004-668949/65.
XX
PT Identifying an individual who has altered risk for developing stenosis
PT comprises detecting single nucleotide polymorphism (SNP), in the
PT individual's nucleic acids.
XX
PS Claim 19; SEQ ID NO 67893; 146pp; English.
XX
CC The invention relates to identifying an individual who has altered risk
CC for developing coronary stenosis comprising detecting a single nucleotide
CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not
CC given in the specification), in the individual's nucleic acids, where the
CC presence of the SNP is correlated with an altered risk for stenosis in
CC the individual. Also included are an isolated nucleic acid molecule
CC (comprising at least 8 contiguous nucleotides where one of the
CC nucleotides is an SNP as cited above, or their complement), an isolated
CC polypeptide comprising an amino acid sequence selected from any of the
CC 696 amino acid sequences (not defined in the specification), an antibody
CC that specifically binds to the polypeptide (or its antigen-binding
CC fragment), an amplified polynucleotide containing the SNP as cited (where
CC the amplified polynucleotide is between about 16 and about 1,000
CC nucleotides in length), an isolated polynucleotide which specifically
CC hybridises to a nucleic acid molecule containing the SNP, a kit for
CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid
CC molecule, detecting a variant polypeptide and identifying an agent useful
CC in therapeutically or prophylactically treating stenosis. The detection
CC step of the method is carried out by a process selected from allele-
CC specific probe hybridisation, allele-specific primer extension, allele-
CC specific amplification, sequencing, 5' nuclease digestion, molecular
CC beacon assay, oligonucleotide ligation assay, size analysis, and single-
CC stranded conformation polymorphism. The method is useful for identifying
CC an individual who has altered risk for developing coronary stenosis,
CC which can lead to angina (ischaemic chest pain), myocardial infarction
CC and ultimately sudden cardiac death. The present sequence is an allele
CC specific primer for amplifying a SNP-containing region of a human marker
CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the
CC specification but are provided on a CD-R named CL001510CDR which was not
CC supplied with the specification.
XX
SQ Sequence 16 BP; 2 A; 2 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2302 CAGTTGCAACCAC 2314
||||||||||||
Db 13 CAGTTGCAACCAC 1

RESULT 126
AAQ05541/c
ID AAQ05541 standard; DNA; 15 BP.
XX
AC AAQ05541;
XX
DT 25-MAR-2003 (revised)
DT 10-DEC-1990 (first entry)
XX
DE Probe to sequence encoding homing receptor unit mLHRc.
XX
KW Alpha 4m; core protein gp. 90ME1-14; metastasis; cancer;
KW regional ileitis; ulcerative colitis; lymphadenitides.
XX
OS Synthetic.
XX
PN WO9007321-A.
XX
PD 12-JUL-1990.
XX
PF 23-DEC-1988; 88US-00289201.
XX
PR 23-DEC-1988; 88US-00289201.
PR 24-FEB-1989; 89US-00315736.
XX
PA (STRD) UNIV LELAND STANFORD JUNIOR.
XX
PI Weismann IL, Holzmann B, Siegelman MH;
XX
DR WPI; 1990-238876/31.
XX
PT DNA sequence for encoding homing receptor - of e.g. alpha 4m or core
PT protein gp. 90ME1-14 free of ubiquitin.
XX
PS Example 1; Page 23; 60pp; English.
XX
CC Probe is to the degenerate code of five amino terminal residues of the
CC mature ubiquitin homing receptor unit protein. Receptor unit may be used
CC in directing a component to a homing ligand of a high endothelial venule
CC associated with a mucosal membrane, lymphoid organ, tissue or lymph node
CC in the mammalian host. Homing may be inhibited in treatment of
CC inflamatory bowel diseases such as regional ileitis, ulcerative colitis,
CC lymphadenitides, histiocytic disorders or other inflamatory conditions.
CC (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 15 BP; 4 A; 3 C; 2 G; 3 T; 0 U; 3 Other;

Query Match 1.4%; Score 12.8; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 72;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2039 TAATGATATGTCCA 2052
||:||:||:|||||
Db 14 TARTGRTAYGTCCA 1

RESULT 127
AAQ50518/c
ID AAQ50518 standard; DNA; 16 BP.
XX
AC AAQ50518;
XX
DT 25-MAR-2003 (revised)
DT 25-MAY-1994 (first entry)
XX
DE tRNAtyr/CAT chimeric tRNA gene primer #1.
XX
KW H1 DNA; transcription; H1 RNA; RNase P; RNAase P; cleavage; enzyme;
KW external guide sequence; EGS; prevention; expression; viral gene;
KW disease causing genes; oncogene; tumour suppressor gene; antibody;
KW cellular mRNA; hormone; co-factors; growth factor;
KW chloramphenicol acetyltransferase; CAT; ss.
XX
OS Synthetic.
XX
PN WO9322434-A2.
XX
PD 11-NOV-1993.
XX
PF 28-APR-1993; 93WO-US003961.
XX
PR 28-APR-1992; 92US-00875099.
PR 18-AUG-1992; 92US-00931937.
XX
PA (UYYA) UNIV YALE.

```
XX
PI   Yuan Y,  Guerrier-Takada CL,  Altman S;
XX
DR   WPI; 1993-368793/46.
XX
PT   Targetted RNA cleavage with ribonuclease P and external guide sequence -
PT   forms a hybrid with the target RNA used for inactivating oncogene(s),
PT   viral genes, etc.
XX
PS   Example 5; Page 27; 40pp; English.
XX
CC   The sequences given in AAQ50518-19 are primers which were used in the
CC   construction a chimeric tRNA gene that contains sequences from the
CC   chloramphenicol acetyltransferase (CAT) mRNA and tRNATyr from E. coli.
CC   These sequences were used in the production of the composition of the
CC   invention. The composition targets an RNA substrate for cleavage by RNase
CC   P and comprises a recombinant external guide sequence (EGS), which
CC   includes a targetting site for cleavage by RNase P and a nucleotide
CC   sequence complementary to the substrate. This composition is useful for
CC   preventing the expression of disease causing genes in vivo, eg. to
CC   inactivate RNA from oncogenes, tumour suppressor genes, viral genes or
CC   cellular mRNAs encoding proteins such as enzymes, hormones, co-factors,
CC   antibodies or growth factors. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 16 BP; 4 A; 1 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CCTTCAAGCATCACCA 1683
              |||||| || ||||||
Db         16 CCTTCATGCCTCACCA 1


RESULT 128
AAQ98791/c
ID   AAQ98791 standard; DNA; 16 BP.
XX
AC   AAQ98791;
XX
DT   29-AUG-1996  (first entry)
XX
DE   CAT mRNA/E.coli tRNA-Tyr RNase P product PCR primer SEC-1C.
XX
KW   external guide sequence; EGS; messenger RNA cleavage;
KW   chloramphenicol acetyltransferase; RNase P; ribonuclease; PCR;
KW   polymerase chain reaction; chimeric tRNA; ss.
XX
OS   Synthetic.
XX
PN   WO9524489-A1.
XX
PD   14-SEP-1995.
XX
PF   07-MAR-1995;   95WO-US002816.
XX
PR   07-MAR-1994;   94US-00207547.
PR   18-MAR-1994;   94US-00215082.
XX
PA   (UYYA ) UNIV YALE.
XX
PI   Yuan Y,  Guerrier-Takada C,  Altman S,  Liu F;
XX
DR   WPI; 1995-328280/42.
XX
PT   Targetted ribonuclease P cleavage of RNA using an oligo:nucleotide -
PT   comprising a target recognition sequence and a RNase P binding sequence,
PT   useful for treating cancers and viral and bacterial infections.
XX
PS   Example 5; Page 31; 94pp; English.
XX
CC   Any RNA can be targetted for cleavage by RNase P, using a suitably
CC   designed oligonucleotide as "external guide sequence" (EGS) to form a
CC   hybrid with the target RNA and create a substrate for RNase P cleavage.
CC   The EGSs contain sequences which are complementary to the target RNA and
CC   which form secondary and tertiary structure similar to portions of a tRNA
CC   molecule. A chimeric tRNA gene which contains sequences from CAT mRNA and
CC   E.coli tRNA-Tyr as well as 9 randomised nucleotides was synthesised (see
CC   e.g. AAQ98567) and was used to select for EGS sequences that guide RNase
CC   P to target chloramphenicol acetyltransferase (CAT) mRNA. In the in vitro
CC   selection procedure, ds DNA templates for chimeric CAT mRNA-EGS sequences
CC   were constructed using two overlapping oligonucleotides SEC-1A and SEC-1B
CC   (AAQ98568 and AAQ98569, respectively). SEC-1A was also used as the 5'-
CC   primer for PCR in order to restore the T7 promoter and the leader
CC   sequence of the RNase P-cleaved chimeric RNA for the next cycle of
CC   selection. The present sequence is that of the 3'-primer SEC-1C used for
CC   this amplification
XX
SQ   Sequence 16 BP; 4 A; 1 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CCTTCAAGCATCACCA 1683
              |||||| || ||||||
Db         16 CCTTCATGCCTCACCA 1


RESULT 129
AAV49158/c
ID   AAV49158 standard; DNA; 16 BP.
XX
AC   AAV49158;
XX
DT   15-OCT-1998  (first entry)
XX
DE   rb gene antisense oligonucleotide rb-N-106.
XX
KW   rb gene; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Example 7; Fig 9c; 286pp; English.
XX
CC   AAV49008-236 represent antisense oligonucleotides directed against the rb
CC   gene. Of these, only oligonucleotides AAV49008-52 resulted in effective
CC   downregulation of negative growth control by rb, while oligonucleotides
CC   AAV49052-236 had little effect. The oligonucleotides exemplify the
CC   invention. The specification describes oligonucleotides that contain 8-30
CC   nucleotides, which contain at most 8 nucleotides that can each form three
CC   hydrogen bonds to cytosine; do not contain four consecutive nucleotides
CC   able to form three H-bonds each to four consecutive cytosines; do not
```

```
CC   contain two sequences of three consecutive nucleotides each able to form
CC   three H-bonds to three consecutive cytosines, and the ratio between
CC   residues able to form two H-bonds each (2R) or three such bonds (3R) is
CC   given by 2R/3R = 0.33-0.72. The oligonucleotides are used to modulate
CC   expression of genes, particularly the genes for p53, ErB-2, junB, junD,
CC   TGF-beta 1 or beta 2 to control proliferation of primary cell cultures
CC   (e.g. bone marrow stem, liver or kidney cells, osteoclasts, osteoblasts
CC   and/or keratinocytes). The oligonucleotides can also be used to analyse
CC   function of proteins (by altering their expression or activity) and
CC   therapeutically, e.g. in cases of cancer or (targeting TGF) for
CC   stimulating the immune system
XX
SQ   Sequence 16 BP; 5 A; 1 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1918 AAATGATACAAAATTT 1933
              ||||||| || ||||
Db         16 AAATGATAAAACATTT 1


RESULT 130
AAZ23160/c
ID   AAZ23160 standard; DNA; 16 BP.
XX
AC   AAZ23160;
XX
DT   17-JAN-2000  (first entry)
XX
DE   p21 gene amplifying sense primer 1A.
XX
KW   Ovarian carcinoma; p16 gene; ovarian epithelium; detection; diagnosis;
KW   p53 gene; p21 gene; beta-tubulin gene; tumor; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5976799-A.
XX
PD   02-NOV-1999.
XX
PF   17-MAR-1997;   97US-00819358.
XX
PR   21-MAR-1996;   96US-0041554P.
XX
PA   (UYAR-) UNIV ARKANSAS.
XX
PI   Shiqemasa K,  O'brien TJ;
XX
DR   WPI; 1999-619647/53.
XX
PT   Early detection of ovarian carcinoma.
XX
PS   Disclosure; Col 6; 18pp; English.
XX
CC   The invention provides a method for early detection of ovarian carcinoma
CC   that comprises detecting overexpression of p16 mRNA in a sample derived
CC   from ovarian epithelium. The method comprises: (a) taking a sample
CC   containing p16 mRNA derived from the subject's ovarian epithelium; (b)
CC   isolating the p16 mRNA from the sample; (c) preparing cDNA to the p16
CC   mRNA; (d) combining the cDNA with primers complementary to p16 DNA target
CC   sequences and to control DNA sequences; (e) amplifying the DNA in the
CC   sample; (f) quantifying the amplification products; and (g) comparing the
CC   amount of p16 amplification product with the amount of p16 amplification
CC   product from a similarly treated reference sample. p16 mRNA is
CC   overexpressed in ovarian tumors but not in normal ovaries. The methods
CC   are useful for early diagnosis of ovarian carcinoma. Sequences AAZ23160-
CC   61 represent primers for amplifying the p21 gene. This is used to
CC   demonstrate the mRNA expression levels of p53, p21 and p16 genes relative
CC   to a beta-tubulin gene. Most tumors investigated showed an elevated p53
CC   expression, low p21 expression and a very high p16 expression
XX
SQ   Sequence 16 BP; 3 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2315 AAGGAACTGAATTCTG 2330
              |||||||||| ||| |
Db         16 AAGGAACTGACTTCGG 1


RESULT 131
AAZ48622
ID   AAZ48622 standard; DNA; 16 BP.
XX
AC   AAZ48622;
XX
DT   03-MAR-2000  (first entry)
XX
DE   PCR primer for human prolactin gene.
XX
KW   PCR primer; prolactin; human; proliferation inhibitor; breast cancer;
KW   prostate cancer; prolactin receptor; therapy; proliferative disorder;
KW   apoptosis induction; therapy; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9958142-A1.
XX
PD   18-NOV-1999.
XX
PF   11-MAY-1999;   99WO-US010232.
XX
PR   12-MAY-1998;   98US-0085128P.
PR   05-FEB-1999;   99US-00246041.
XX
PA   (CHEN/) CHEN W Y.
PA   (WAGN/) WAGNER T E.
XX
PI   Chen WY,  Wagner TE;
XX
DR   WPI; 2000-062263/05.
XX
PT   Use of human prolactin variants to treat breast or prostate cancer,
PT   methods of inducing apoptosis.
XX
PS   Example; Page 30; 77pp; English.
XX
CC   This sequence represents a PCR primer for the human prolactin gene. The
CC   invention relates to a method of inhibiting the proliferation of a breast
CC   or prostate cancer cell which expresses a prolactin receptor comprises
CC   exposing the cell to an effective concentration of a variant of human
CC   prolactin having a substitution of the glycine at position 129 or a cell-
CC   free truncated prolactin receptor. The method is used to treat human
CC   breast and prostate cancer and proliferative disorders. The method is
CC   also useful for inducing apoptosis in cells expressing the prolactin
CC   receptor. The prolactin variants act as antagonists at the prolactin
CC   receptor. Also provided is a cell-based assay system that can be used to
CC   identify compounds that modulate prolactin receptor activity
XX
SQ   Sequence 16 BP; 8 A; 2 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATGAT 1885
              ||||| |||||| |||
Db          1 ATGAACATCAAAGGAT 16
```

RESULT 132
AAZ48617
ID AAZ48617 standard; DNA; 16 BP.
XX
AC AAZ48617;
XX
DT 03-MAR-2000 (first entry)
XX
DE PCR primer for human prolactin gene.
XX
KW PCR primer; prolactin; human; proliferation inhibitor; breast cancer;
KW prostate cancer; prolactin receptor; therapy; proliferative disorder;
KW apoptosis induction; therapy; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9958142-A1.
XX
PD 18-NOV-1999.
XX
PF 11-MAY-1999; 99WO-US010232.
XX
PR 12-MAY-1998; 98US-0085128P.
PR 05-FEB-1999; 99US-00246041.
XX
PA (CHEN/) CHEN W Y.
PA (WAGN/) WAGNER T E.
XX
PI Chen WY, Wagner TE;
XX
DR WPI; 2000-062263/05.
XX
PT Use of human prolactin variants to treat breast or prostate cancer,
PT methods of inducing apoptosis.
XX
PS Example; Page 23; 77pp; English.
XX
CC This sequence represents a PCR primer for the human prolactin gene. The
CC invention relates to a method of inhibiting the proliferation of a breast
CC or prostate cancer cell which expresses a prolactin receptor comprises
CC exposing the cell to an effective concentration of a variant of human
CC prolactin having a substitution of the glycine at position 129 or a cell-
CC free truncated prolactin receptor. The method is used to treat human
CC breast and prostate cancer and proliferative disorders. The method is
CC also useful for inducing apoptosis in cells expressing the prolactin
CC receptor. The prolactin variants act as antagonists at the prolactin
CC receptor. Also provided is a cell-based assay system that can be used to
CC identify compounds that modulate prolactin receptor activity
XX
SQ Sequence 16 BP; 8 A; 2 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1870 ATGAAAATCAAATGAT 1885
||||| |||||| |||
Db 1 ATGAACATCAAAGGAT 16

RESULT 133
AAL46073
ID AAL46073 standard; DNA; 16 BP.
XX
AC AAL46073;
XX
DT 19-JUL-2002 (first entry)
XX
DE Human prolactin coding sequence PCR primer #2.
XX
KW Human; prolactin; prolactin variant; cancer; breast cancer; cytostatic;
KW antiproliferative; prostate cancer; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO9958097-A2.
XX
PD 18-NOV-1999.
XX
PF 12-MAY-1999; 99WO-US010545.
XX
PR 12-MAY-1998; 98US-0085128P.
XX
PA (GREE-) GREENVILLE HOSPITAL SYSTEM.
XX
PI Chen WY, Wagner TE;
XX
DR WPI; 2000-038947/03.
XX
PT Human prolactin variants and their use in treating breast or prostate
PT cancer, and in methods of inducing apoptosis.
XX
PS Example; Page 31; 84pp; English.
XX
CC The present invention relates to a method of inhibiting the proliferation
CC of a breast or prostate cancer cell which expresses a prolactin receptor
CC comprising exposing the cell to a G129 substituted variant of human
CC prolactin or a cell-free truncated prolactin receptor. The methods and
CC variants are used to treat human breast and prostate cancer and
CC proliferative disorders, inducing apoptosis in cells expressing the
CC prolactin receptor and the prolactin variants also act as antagonists at
CC the prolactin receptor. The present sequence is a PCR primer used to
CC isolate the human prolactin cDNA
XX
SQ Sequence 16 BP; 8 A; 2 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1870 ATGAAAATCAAATGAT 1885
||||| |||||| |||
Db 1 ATGAACATCAAAGGAT 16

RESULT 134
AAS56909/c
ID AAS56909 standard; DNA; 16 BP.
XX
AC AAS56909;
XX
DT 16-JAN-2002 (first entry)
XX
DE Validation ribozyme DNA sequence #83.
XX
KW Human; BRCA-1 regulator; ribozyme; BR1; RNA target recognition; probe;
KW cytostatic; RNA cleavage; tumour suppressor; PCR primer; CHLR2; AF6; BR2;
KW inhibitor dominant negative 4; breast basic conserved protein 1; BBC1;
KW BR3; ID4; cancer; proliferative disorder; tumour proliferation; ss.
XX
OS Homo sapiens.
XX
PN WO200170982-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US009559.
XX
PR 23-MAR-2000; 2000US-00536058.
XX
PA (IMMU-) IMMUSOL INC.
PA (BEGE/) BEGER C.
XX
PI Beger C, Barber J, Wong-Staal F;
XX

```
DR   WPI; 2001-611503/70.
XX
PT   Novel polypeptides that are the regulators of BRCA-1, useful for treating
PT   cancer and diagnosing the presence of neoplastic cells in biological
PT   sample.
XX
PS   Disclosure; Fig 8; 97pp; English.
XX
CC   Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators,
CC   ribozyme target recognition RNA sequences, DNA fragments encoding the RNA
CC   and primers used in the methods of the invention. Hybridisation of
CC   ribozymes to their targets results in cleavage of the RNA target. The
CC   ribozymes can be used to cleave regulators of the tumour suppressor BRCA-
CC   1, resulting in upregulation or downregulation of BRCA-1 in a cell. The
CC   mRNA targets include those encoding the BRCA-1 regulator BR1, inhibitor
CC   dominant negative 4 (ID4), breast basic conserved protein 1 (BBC1),
CC   CHLR2, AF6, BR2 and BR3. Regulation of BRCA-1 is useful for treating and
CC   diagnosing cancer and other proliferative disorders. The severity of an
CC   incidence of cancer can be lessened by regulating tumour proliferation
CC   through modulation of BRCA-1 expression. The sequences of the invention
CC   are useful in the development of anti-cancer drugs
XX
SQ   Sequence 16 BP; 1 A; 4 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2289 AAAATTGGGACCTCAG 2304
              ||||| |||||| |||
Db         16 AAAATAGGGACCACAG 1


RESULT 135
ACA60933
ID   ACA60933 standard; DNA; 16 BP.
XX
AC   ACA60933;
XX
DT   11-AUG-2003  (first entry)
XX
DE   Human prolactin sense RT-PCR primer.
XX
KW   Human; prolactin; antagonist; cancer cell proliferation; breast cancer;
KW   prostate cancer; cellular apoptosis; primer; ss; reverse transcriptase;
KW   RT-PCR.
XX
OS   Homo sapiens.
XX
PN   US2003022833-A1.
XX
PD   30-JAN-2003.
XX
PF   08-MAY-2002; 2002US-00140293.
XX
PR   13-MAY-1998;   98US-0085228P.
PR   05-FEB-1999;   99US-00246041.
XX
PA   (GREE-) GREENVILLE HOSPITAL SYSTEM.
XX
PI   Chen WY,  Wagner TE;
XX
DR   WPI; 2003-438990/41.
XX
PT   Use of a variant of human prolactin for inhibiting the proliferation of
PT   breast and prostate cancer cells.
XX
PS   Example 7; Page 8; 68pp; English.
XX
CC   The invention relates to a method of inhibiting the proliferation of
CC   breast and prostate cancer cells expressing a prolactin receptor which
CC   involves exposing the cell to a variant of human prolactin having a
CC   substitution of the glycine at position 129, or a cell-free truncated
CC   prolactin receptor. The method is useful for inhibiting the proliferation
CC   of a breast cancer and prostate cancer cells; and for inducing cellular
CC   apoptosis in a cell expressing the prolactin receptor. The human
CC   prolactin variant in combination with an anti-oestrogen induces a
CC   synergistic inhibitory effect on cell proliferation. The present sequence
CC   represents the human prolactin sense reverse transcriptase (RT)-PCR
CC   primer
XX
SQ   Sequence 16 BP; 8 A; 2 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 80;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATGAT 1885
              ||||| |||||| |||
Db          1 ATGAACATCAAAGGAT 16


RESULT 136
ABF11493/c
ID   ABF11493 standard; DNA; 13 BP.
XX
AC   ABF11493;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 111490 for detecting SNP TSC0027841.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 111490; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 2 C; 0 G; 9 T; 0 U; 1 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2282 GGAAAAAAAAATT 2294
              |||||||||||:
Db         13 GGAAAAAAAAATY 1


RESULT 137
ABC14272/c
ID   ABC14272 standard; DNA; 13 BP.
XX
AC   ABC14272;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 14279 for detecting SNP TSC0003242.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 14279; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1888 AAAATATATACAA 1900
              :|||||||||||||
Db         13 RAAATATATACAA 1


RESULT 138
ABC31897
ID   ABC31897 standard; DNA; 13 BP.
XX
AC   ABC31897;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31914 for detecting SNP TSC0009939.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 31914; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 4 C; 0 G; 4 T; 0 U; 1 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1997 ATCATTTAACCAC 2009
              :|||||||||||||
Db          1 RTCATTTAACCAC 13


RESULT 139
ABC04860
ID   ABC04860 standard; DNA; 13 BP.
XX
AC   ABC04860;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 4851 for detecting SNP TSC0001714.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
```

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 4851; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2057 TAGATTATGTTAC 2069
||||||||||||:
Db 1 TAGATTATGTTAY 13

RESULT 140
ABF11492
ID ABF11492 standard; DNA; 13 BP.
XX
AC ABF11492;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 111489 for detecting SNP TSC0027841.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 111489; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 1 Other;

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2282 GGAAAAAAAAATT 2294
||||||||||||:
Db 1 GGAAAAAAAAATY 13

RESULT 141
ABC14273
ID ABC14273 standard; DNA; 13 BP.
XX
AC ABC14273;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 14280 for detecting SNP TSC0003242.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 14280; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

```
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1888 AAAATATATACAA 1900
              :||||||||||||
Db          1 RAAATATATACAA 13


RESULT 142
ABC59749
ID   ABC59749 standard; DNA; 13 BP.
XX
AC   ABC59749;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 59766 for detecting SNP TSC0015985.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 59766; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 0 C; 0 G; 3 T; 0 U; 1 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1582 AAATATAAAAATA 1594
              :||||||||||||
Db          1 RAATATAAAAATA 13


RESULT 143
ABC31896/c
ID   ABC31896 standard; DNA; 13 BP.
XX
AC   ABC31896;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 31913 for detecting SNP TSC0009939.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 31913; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 1 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1997 ATCATTTAACCAC 2009
              :||||||||||||
Db         13 RTCATTTAACCAC 1


RESULT 144
ABC59748/c
ID   ABC59748 standard; DNA; 13 BP.
XX
AC   ABC59748;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 59765 for detecting SNP TSC0015985.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 59765; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 0 G; 9 T; 0 U; 1 Other;

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1582 AAATATAAAAATA 1594
:||||||||||||
Db 13 RAATATAAAAATA 1

RESULT 145
ABC38162/c
ID ABC38162 standard; DNA; 13 BP.
XX
AC ABC38162;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 38179 for detecting SNP TSC0011829.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 38179; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 0 G; 9 T; 0 U; 1 Other;

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1581 AAAATATAAAAAT 1593
:||||||||||||
Db 13 RAAATATAAAAAT 1

RESULT 146
ABC38163
ID ABC38163 standard; DNA; 13 BP.
XX
AC ABC38163;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 38180 for detecting SNP TSC0011829.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 38180; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

```
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 9 A; 0 C; 0 G; 3 T; 0 U; 1 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAAT 1593
              :||||||||||||
Db          1 RAAATATAAAAAT 13


RESULT 147
ABC04861/c
ID   ABC04861 standard; DNA; 13 BP.
XX
AC   ABC04861;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 4852 for detecting SNP TSC0001714.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 4852; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 59;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2057 TAGATTATGTTAC 2069
              |||||||||||:
Db         13 TAGATTATGTTAY 1


RESULT 148
AAQ05538/c
ID   AAQ05538 standard; DNA; 15 BP.
XX
AC   AAQ05538;
XX
DT   25-MAR-2003  (revised)
DT   10-DEC-1990  (first entry)
XX
DE   Probe to sequence encoding homing receptor unit mLHRc.
XX
KW   Alpha 4m; core protein gp. 90ME1-14; metastasis; cancer;
KW   regional ileitis; ulcerative colitis; lymphadenitides.
XX
OS   Synthetic.
XX
PN   WO9007321-A.
XX
PD   12-JUL-1990.
XX
PF   23-DEC-1988;   88US-00289201.
XX
PR   23-DEC-1988;   88US-00289201.
PR   24-FEB-1989;   89US-00315736.
XX
PA   (STRD ) UNIV LELAND STANFORD JUNIOR.
XX
PI   Weismann IL,  Holzmann B,  Siegelman MH;
XX
DR   WPI; 1990-238876/31.
XX
PT   DNA sequence for encoding homing receptor - of e.g. alpha 4m or core
PT   protein gp. 90ME1-14 free of ubiquitin.
XX
PS   Example 1; Page 23; 60pp; English.
XX
CC   Probe is to the degenerate code of five amino terminal residues of the
CC   mature ubiquitin homing receptor unit protein. Receptor unit may be used
CC   in directing a component to a homing ligand of a high endothelial venule
CC   associated with a mucosal membrane, lymphoid organ, tissue or lymph node
CC   in the mammalian host. Homing may be inhibited in treatment of
CC   inflamatory bowel diseases such as regional ileitis, ulcerative colitis,
CC   lymphadenitides, histiocytic disorders or other inflamatory conditions.
CC   (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ   Sequence 15 BP; 4 A; 2 C; 2 G; 4 T; 0 U; 3 Other;

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 76;
  Matches   12;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2038 ATAATGATATGTCCA 2052
              |||:||:|| |||||
Db         15 ATARTGRTARGTCCA 1


RESULT 149
ABL01281
ID   ABL01281 standard; DNA; 15 BP.
XX
AC   ABL01281;
XX
DT   12-MAR-2002  (first entry)
XX
```

DE Human MMP3 gene polymorphism detection ASO primer SEQ ID NO:60.
XX
KW Human; matrix metalloproteinase 3; MMP3; chromosome 11q22.3; SNP;
KW haplotype; polymorphism; polymorphic; single nucleotide polymorphism;
KW probe; primer; detection; genotyping; vulnerary; cytostatic; cancer;
KW antiarteriosclerotic; gene therapy; coronary atherosclerosis;
KW wound healing; ss.
XX
OS Homo sapiens.
XX
PN WO200179238-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012452.
XX
PR 17-APR-2000; 2000US-0197911P.
PR 13-JUL-2000; 2000US-0218092P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
XX
DR WPI; 2002-075067/10.
XX
PT Genotyping human matrix metalloproteinase 3 gene of an individual for
PT determining the haplotype of the individual, comprises determining the
PT identity of a nucleotide pair at specific polymorphic sites for two
PT copies of the gene.
XX
PS Claim 15; Page 15; 83pp; English.
XX
CC The present invention describes a method for genotyping a human matrix
CC metalloproteinase 3 (MMP3) gene of an individual. MMP3 has vulnerary,
CC cytostatic and antiarteriosclerotic activity, and can be used in gene
CC therapy. The method can be used: for improving the efficacy and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with MMP3 activity, e.g., wound healing,
CC cancer and coronary atherosclerosis; to validate MMP3 as a candidate
CC agent for treating a specific condition or disease predicted to be
CC associated with MMP3 activity; and in the design of clinical trials of
CC candidate drugs for treating a specific condition or disease predicted to
CC be associated with MMP3 activity. Polymorphic variants of a reference
CC sequence for MMP3 (see ABL01223) are useful in studying the expression
CC and function of MMP3, and in expressing MMP3 protein for use in screening
CC for candidate drugs to treat diseases related to MMP3 activity. ABL01225
CC to ABL01246 and ABL01247 to ABL01290 represent allele-specific
CC oligonucleotide (ASO) probes and primers used in the detection of
CC polymorphisms in the human MMP3 gene. ABL01291 to ABL01334 represent
CC preferred primers used in the detection of polymorphisms in the human
CC MMP3 gene
XX
SQ Sequence 15 BP; 8 A; 3 C; 1 G; 2 T; 0 U; 1 Other;

Query Match 1.4%; Score 12.6; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 76;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1869 CATGAAAATCAAA 1881
||||||||||:|
Db 3 CATGAAAATCAWA 15

Search completed: April 6, 2005, 15:54:27
Job time : 2 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 7, 2005, 05:57:40 ; Search time 1 Seconds
(without alignments)
2.840 Million cell updates/sec

Title: US-10-630-399-3
Perfect score: 922
Sequence: 1 gacagtggttattaaagcat.....ctggacttctaatatataga 922

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 89 seqs, 1540 residues

Total number of hits satisfying chosen parameters: 178

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 89 summaries

Database : rni3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
c 1	20	2.2	20	1	US-09-966-451-52	Sequence 52, Appl
c 2	20	2.2	20	1	US-09-966-451-53	Sequence 53, Appl
c 3	20	2.2	20	1	US-09-966-451-54	Sequence 54, Appl
c 4	20	2.2	20	1	US-09-966-451-55	Sequence 55, Appl
c 5	20	2.2	20	1	US-09-966-451-56	Sequence 56, Appl
c 6	20	2.2	20	1	US-09-966-451-57	Sequence 57, Appl
c 7	20	2.2	20	1	US-09-966-451-58	Sequence 58, Appl
c 8	20	2.2	20	1	US-09-966-451-59	Sequence 59, Appl
c 9	20	2.2	20	1	US-09-966-451-60	Sequence 60, Appl
c 10	20	2.2	20	1	US-09-966-451-61	Sequence 61, Appl
c 11	20	2.2	20	1	US-09-966-451-62	Sequence 62, Appl
c 12	20	2.2	20	1	US-09-966-451-63	Sequence 63, Appl
c 13	20	2.2	20	1	US-09-966-451-64	Sequence 64, Appl
c 14	20	2.2	20	1	US-09-966-451-65	Sequence 65, Appl
c 15	20	2.2	20	1	US-09-966-451-66	Sequence 66, Appl
c 16	20	2.2	20	1	US-09-966-451-67	Sequence 67, Appl
c 17	20	2.2	20	1	US-09-966-451-68	Sequence 68, Appl
c 18	20	2.2	20	1	US-09-966-451-69	Sequence 69, Appl
c 19	20	2.2	20	1	US-09-966-451-70	Sequence 70, Appl
c 20	20	2.2	20	1	US-09-966-451-71	Sequence 71, Appl
c 21	20	2.2	20	1	US-09-966-451-72	Sequence 72, Appl
c 22	20	2.2	20	1	US-09-966-451-73	Sequence 73, Appl
c 23	20	2.2	20	1	US-09-966-451-74	Sequence 74, Appl
c 24	20	2.2	20	1	US-09-966-451-75	Sequence 75, Appl
c 25	20	2.2	20	1	US-09-966-451-76	Sequence 76, Appl
c 26	20	2.2	20	1	US-09-966-451-77	Sequence 77, Appl
c 27	20	2.2	20	1	US-09-966-451-78	Sequence 78, Appl
c 28	20	2.2	20	1	US-09-966-451-79	Sequence 79, Appl
29	18	2.0	20	1	US-09-418-640-80	Sequence 80, Appl
30	15.8	1.7	19	1	US-09-422-978-11728	Sequence 11728, A
c 31	15	1.6	16	1	US-09-371-772B-6036	Sequence 6036, Ap
c 32	14	1.5	17	1	US-08-584-040-4387	Sequence 4387, Ap
c 33	14	1.5	17	1	US-08-584-040-5942	Sequence 5942, Ap
c 34	14	1.5	17	1	US-09-371-772B-2154	Sequence 2154, Ap
c 35	14	1.5	17	1	US-09-371-772B-2779	Sequence 2779, Ap
c 36	14	1.5	17	1	US-09-685-664B-2154	Sequence 2154, Ap
c 37	14	1.5	17	1	US-09-685-664B-2779	Sequence 2779, Ap
c 38	13.8	1.5	17	1	US-08-373-124A-1168	Sequence 1168, Ap
c 39	13.8	1.5	17	1	US-08-373-124A-1170	Sequence 1170, Ap
c 40	13.8	1.5	17	1	US-08-435-628-1168	Sequence 1168, Ap
c 41	13.8	1.5	17	1	US-08-435-628-1170	Sequence 1170, Ap
42	13.8	1.5	17	1	US-08-896-116-2	Sequence 2, Appli
c 43	13.8	1.5	17	1	US-08-819-358-3	Sequence 3, Appli
44	13.8	1.5	17	1	US-08-896-122-2	Sequence 2, Appli
c 45	13.8	1.5	17	1	US-09-346-200A-3	Sequence 3, Appli
c 46	13.8	1.5	17	1	US-08-584-040-4386	Sequence 4386, Ap
c 47	13.8	1.5	17	1	US-08-584-040-5941	Sequence 5941, Ap
c 48	13.8	1.5	17	1	US-09-371-772B-2153	Sequence 2153, Ap
c 49	13.8	1.5	17	1	US-09-371-772B-2778	Sequence 2778, Ap
c 50	13.8	1.5	17	1	US-09-371-772B-5483	Sequence 5483, Ap
51	13.8	1.5	17	1	US-09-866-108A-2781	Sequence 2781, Ap
c 52	13.8	1.5	17	1	US-09-685-664B-2153	Sequence 2153, Ap
c 53	13.8	1.5	17	1	US-09-685-664B-2778	Sequence 2778, Ap
54	13.8	1.5	17	1	PCT-US95-08487-2	Sequence 2, Appli
c 55	13.4	1.5	16	1	US-07-971-978-22	Sequence 22, Appl
c 56	13.4	1.5	16	1	US-07-971-978-23	Sequence 23, Appl
c 57	13.4	1.5	16	1	US-07-971-978-52	Sequence 52, Appl
c 58	13.4	1.5	16	1	US-07-971-978-58	Sequence 58, Appl
c 59	13	1.4	15	1	US-08-311-486C-21	Sequence 21, Appl
c 60	13	1.4	16	1	US-09-479-005A-70	Sequence 70, Appl
c 61	12.8	1.4	16	1	US-08-207-547A-15	Sequence 15, Appl
c 62	12.8	1.4	16	1	US-08-215-082-15	Sequence 15, Appl
c 63	12.8	1.4	16	1	US-08-702-652-15	Sequence 15, Appl
c 64	12.8	1.4	16	1	US-09-371-772B-6037	Sequence 6037, Ap
65	12.8	1.4	16	1	US-09-371-772B-7113	Sequence 7113, Ap
c 66	12.8	1.4	16	1	US-09-479-005A-209	Sequence 209, App
c 67	12.4	1.3	14	1	PCT-US94-08023-24	Sequence 24, Appl
c 68	12.4	1.3	15	1	US-08-182-968A-88	Sequence 88, Appl
69	12.4	1.3	15	1	US-08-292-620A-214	Sequence 214, App
c 70	12.4	1.3	15	1	US-08-774-306A-88	Sequence 88, Appl
c 71	12.4	1.3	15	1	US-09-064-156A-88	Sequence 88, Appl
72	12.4	1.3	15	1	US-09-071-845-214	Sequence 214, App
c 73	12.4	1.3	15	1	US-09-180-437-137	Sequence 137, App
c 74	12	1.3	14	1	US-08-535-249-120	Sequence 120, App
c 75	12	1.3	15	1	US-08-585-684B-630	Sequence 630, App
c 76	12	1.3	15	1	US-08-585-684B-631	Sequence 631, App
c 77	12	1.3	15	1	US-08-585-684B-632	Sequence 632, App
c 78	12	1.3	15	1	US-08-585-684B-633	Sequence 633, App
c 79	12	1.3	15	1	US-08-585-684B-634	Sequence 634, App
c 80	12	1.3	15	1	US-08-585-684B-2056	Sequence 2056, Ap
c 81	12	1.3	15	1	US-08-585-684B-2330	Sequence 2330, Ap
c 82	12	1.3	15	1	US-08-832-021-36	Sequence 36, Appl
c 83	12	1.3	15	1	US-09-038-073-630	Sequence 630, App
c 84	12	1.3	15	1	US-09-038-073-631	Sequence 631, App
c 85	12	1.3	15	1	US-09-038-073-632	Sequence 632, App
c 86	12	1.3	15	1	US-09-038-073-633	Sequence 633, App
c 87	12	1.3	15	1	US-09-038-073-634	Sequence 634, App
c 88	12	1.3	15	1	US-09-038-073-2056	Sequence 2056, Ap
c 89	12	1.3	15	1	US-09-038-073-2330	Sequence 2330, Ap

ALIGNMENTS

RESULT 1
US-09-966-451-52/c
; Sequence 52, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-52

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1548 GACAGTGGTTATTAAAGCAT 1567
||||||||||||||||||||
Db 20 GACAGTGGTTATTAAAGCAT 1

RESULT 2
US-09-966-451-53/c
; Sequence 53, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-53

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1560 TAAAGCATGGGTTGAACTTC 1579
||||||||||||||||||||
Db 20 TAAAGCATGGGTTGAACTTC 1

RESULT 3
US-09-966-451-54/c
; Sequence 54, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-54

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1646 TACAGTAATCCCTGAGAAAT 1665
||||||||||||||||||||
Db 20 TACAGTAATCCCTGAGAAAT 1

RESULT 4
US-09-966-451-55/c
; Sequence 55, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-55

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1674 AGCATCACCAAACACAGTTT 1693
||||||||||||||||||||
Db 20 AGCATCACCAAACACAGTTT 1

RESULT 5
US-09-966-451-56/c
; Sequence 56, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-56

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1711 CAAAAAGAGCCTGGGCTGTA 1730
||||||||||||||||||||
Db 20 CAAAAAGAGCCTGGGCTGTA 1

RESULT 6
US-09-966-451-57/c
; Sequence 57, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 57

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-57

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1720 CCTGGGCTGTATGTAGGGTG 1739
              ||||||||||||||||||||
Db         20 CCTGGGCTGTATGTAGGGTG 1


RESULT 7
US-09-966-451-58/c
; Sequence 58, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 58
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-58

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1737 GTGGAAACACTCTGATCTGA 1756
              ||||||||||||||||||||
Db         20 GTGGAAACACTCTGATCTGA 1


RESULT 8
US-09-966-451-59/c
; Sequence 59, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 59
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-59

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1756 AAGCCCAGCTGACTCCACTA 1775
              ||||||||||||||||||||
Db         20 AAGCCCAGCTGACTCCACTA 1


RESULT 9
US-09-966-451-60/c
; Sequence 60, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-60

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1810 CTGCTGTGAGCCACTAATAA 1829
              ||||||||||||||||||||
Db         20 CTGCTGTGAGCCACTAATAA 1


RESULT 10
US-09-966-451-61/c
; Sequence 61, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 61
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-61

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1829 ACATTGGGCTAATATCTGCT 1848
              ||||||||||||||||||||
Db         20 ACATTGGGCTAATATCTGCT 1


RESULT 11
US-09-966-451-62/c
; Sequence 62, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
;   LENGTH: 20
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-62

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1846 GCTGTGCTTCTCTGACAGGT 1865
              ||||||||||||||||||||
Db         20 GCTGTGCTTCTCTGACAGGT 1


RESULT 12
US-09-966-451-63/c
; Sequence 63, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 63
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-63

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1854 TCTCTGACAGGTAGTCATGA 1873
              ||||||||||||||||||||
Db         20 TCTCTGACAGGTAGTCATGA 1


RESULT 13
US-09-966-451-64/c
; Sequence 64, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 64
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-64

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1894 TATACAAGCACTTTGTAAAT 1913
              ||||||||||||||||||||
Db         20 TATACAAGCACTTTGTAAAT 1


RESULT 14
US-09-966-451-65/c
; Sequence 65, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 65
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-65

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1951 TTACAAAATCCTATTAGTCA 1970
              ||||||||||||||||||||
Db         20 TTACAAAATCCTATTAGTCA 1


RESULT 15
US-09-966-451-66/c
; Sequence 66, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 66
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-66

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1985 GTGTTCACAGCAATCATTTA 2004
              ||||||||||||||||||||
Db         20 GTGTTCACAGCAATCATTTA 1


RESULT 16
US-09-966-451-67/c
; Sequence 67, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 67
;   LENGTH: 20
;   TYPE: DNA
```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-67

  Query Match 2.2%; Score 20; DB 1; Length 20;
  Best Local Similarity 100.0%; Pred. No. 1;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2066 TTACATGACAAAGTTGAAGG 2085
         ||||||||||||||||||||
Db 20 TTACATGACAAAGTTGAAGG 1

RESULT 17
US-09-966-451-68/c
; Sequence 68, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-68

  Query Match 2.2%; Score 20; DB 1; Length 20;
  Best Local Similarity 100.0%; Pred. No. 1;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2089 TTGGCAGATGCAGTTAAGGT 2108
         ||||||||||||||||||||
Db 20 TTGGCAGATGCAGTTAAGGT 1

RESULT 18
US-09-966-451-69/c
; Sequence 69, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-69

  Query Match 2.2%; Score 20; DB 1; Length 20;
  Best Local Similarity 100.0%; Pred. No. 1;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2137 AAAGGGCCTGACCTAATCCA 2156
         ||||||||||||||||||||
Db 20 AAAGGGCCTGACCTAATCCA 1

RESULT 19
US-09-966-451-70/c
; Sequence 70, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-70

  Query Match 2.2%; Score 20; DB 1; Length 20;
  Best Local Similarity 100.0%; Pred. No. 1;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2191 GCCTTGAAGAAGTATGTGAG 2210
         ||||||||||||||||||||
Db 20 GCCTTGAAGAAGTATGTGAG 1

RESULT 20
US-09-966-451-71/c
; Sequence 71, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-71

  Query Match 2.2%; Score 20; DB 1; Length 20;
  Best Local Similarity 100.0%; Pred. No. 1;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2211 AGGGCCACATTGGCTAAAAC 2230
         ||||||||||||||||||||
Db 20 AGGGCCACATTGGCTAAAAC 1

RESULT 21
US-09-966-451-72/c
; Sequence 72, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-72

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 CATTGGCTAAAACCTAAAGG 2237
              ||||||||||||||||||||
Db         20 CATTGGCTAAAACCTAAAGG 1


RESULT 22
US-09-966-451-73/c
; Sequence 73, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 73
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-73

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2223 GCTAAAACCTAAAGGTGGCC 2242
              ||||||||||||||||||||
Db         20 GCTAAAACCTAAAGGTGGCC 1


RESULT 23
US-09-966-451-74/c
; Sequence 74, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 74
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-74

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2236 GGTGGCCTCTAGGAGATGAG 2255
              ||||||||||||||||||||
Db         20 GGTGGCCTCTAGGAGATGAG 1


RESULT 24
US-09-966-451-75/c
; Sequence 75, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 75
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-75

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2256 ACCTACCTTCCAGTTGTCAG 2275
              ||||||||||||||||||||
Db         20 ACCTACCTTCCAGTTGTCAG 1


RESULT 25
US-09-966-451-76/c
; Sequence 76, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-76

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2267 AGTTGTCAGCAAGCAGGAAA 2286
              ||||||||||||||||||||
Db         20 AGTTGTCAGCAAGCAGGAAA 1


RESULT 26
US-09-966-451-77/c
; Sequence 77, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 77
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-77

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2364 AAGCTTCAGATGATAACCAC 2383
              ||||||||||||||||||||
Db         20 AAGCTTCAGATGATAACCAC 1


RESULT 27
US-09-966-451-78/c
; Sequence 78, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 78
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-78

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2377 TAACCACAGCCTGGGCTGAC 2396
              ||||||||||||||||||||
Db         20 TAACCACAGCCTGGGCTGAC 1


RESULT 28
US-09-966-451-79/c
; Sequence 79, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 79
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-79

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2419 ATCCTCAGTATGAGAATCTA 2438
              ||||||||||||||||||||
Db         20 ATCCTCAGTATGAGAATCTA 1


RESULT 29
US-09-418-640-80
; Sequence 80, Application US/09418640
; Patent No. 6140125
; GENERAL INFORMATION:
;  APPLICANT: Jennifer K. Taylor
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF BCL-6 EXPRESSION
;  FILE REFERENCE: RTS-0102
;  CURRENT APPLICATION NUMBER: US/09/418,640
;  CURRENT FILING DATE: 1999-10-15
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 80
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-418-640-80

  Query Match             2.0%;  Score 18;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.6;
  Matches   18;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1902 CACTTTGTAAATTGTAAA 1919
              ||||||||||||||||||
Db          3 CACTTTGTAAATTGTAAA 20


RESULT 30
US-09-422-978-11728
; Sequence 11728, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11728
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-3884 for SEQ 3863, in complemer
US-09-422-978-11728

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 7.5;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2146 GACCTAATCCAAGTGAACC 2164
              || | ||||||||||||||
Db          1 GAACAAATCCAAGTGAACC 19


RESULT 31
US-09-371-772B-6036/c
; Sequence 6036, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
```

```
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6036
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6036

  Query Match             1.6%;  Score 15;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 13;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1897 ACAAGCACTTTGTAA 1911
              |||||||||||||||
Db         16 ACAAGCACTTTGTAA 2


RESULT 32
US-08-584-040-4387/c
; Sequence 4387, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4387:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-4387

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 33
US-08-584-040-5942/c
; Sequence 5942, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5942:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5942

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
```

```
Db         14 ATGAAAATCAAATG 1


RESULT 34
US-09-371-772B-2154/c
; Sequence 2154, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2154
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-2154

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
             ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 35
US-09-371-772B-2779/c
; Sequence 2779, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2779
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2779

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
             ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 36
US-09-685-664B-2154/c
; Sequence 2154, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2154
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-685-664B-2154

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
             ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 37
US-09-685-664B-2779/c
; Sequence 2779, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2779
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-09-685-664B-2779

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1

RESULT 38
US-08-373-124A-1168/c
; Sequence 1168, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1168:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-1168

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1574 AACTTCCAAAATATAAA 1590
              |||| ||||| ||||||
Db         17 AACTCCCAAATTATAAA 1

RESULT 39
US-08-373-124A-1170/c
; Sequence 1170, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1170:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-1170

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1573 GAACTTCCAAAATATAA 1589
              ||||| ||||| |||||
Db         17 GAACTCCCAAATTATAA 1

RESULT 40
US-08-435-628-1168/c
; Sequence 1168, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
```

```
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/435,628
;       FILING DATE:  05-MAY-1995
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/373,124
;       FILING DATE:  January 13, 1995
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1168:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-435-628-1168

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1574 AACTTCCAAAATATAAA 1590
              |||| ||||| ||||||
Db         17 AACTCCCAAATTATAAA 1


RESULT 41
US-08-435-628-1170/c
; Sequence 1170, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;     APPLICANT:  Stinchcomb, Dan T.
;     APPLICANT:  Draper, Kenneth
;     APPLICANT:  McSwiggen, James
;     APPLICANT:  Jarvis, Thale
;     TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;     TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;     TITLE OF INVENTION:  CANCER USING RIBOZYMES
;     NUMBER OF SEQUENCES:  2627
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/435,628
;       FILING DATE:  05-MAY-1995
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/373,124
;       FILING DATE:  January 13, 1995
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1170:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-435-628-1170

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1573 GAACTTCCAAAATATAA 1589
              ||||| ||||| |||||
Db         17 GAACTCCCAAATTATAA 1


RESULT 42
US-08-896-116-2
; Sequence 2, Application US/08896116
; Patent No. 5869336
;  GENERAL INFORMATION:
;     APPLICANT:  Meyer, Sheryl L.
;     APPLICANT:  Scott, Richard W.
;     APPLICANT:  Siman, Robert
;     TITLE OF INVENTION:  Recombinant Enzymatically Active Calpain
;     TITLE OF INVENTION:  Expressed in a Baculovirus System
;     NUMBER OF SEQUENCES:  12
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz & No. 5869336ris
;       STREET:  One Liberty Place, 46th floor
;       CITY:  Philadelphia
;       STATE:  PA
;       COUNTRY:  USA
;       ZIP:  19103
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/896,116
```

```
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/275,683
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Trujillo, Doreen Y.
;       REGISTRATION NUMBER:  35,719
;       REFERENCE/DOCKET NUMBER:  CEPH-013
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (215) 568-3100
;       TELEFAX:  (215) 568-3439
;   INFORMATION FOR SEQ ID NO:  2:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
;     HYPOTHETICAL:  NO
;     ANTI-SENSE:  NO
US-08-896-116-2

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 CACTCTGATCTGAAGCC 1760
              ||| |||||||||||  |
Db          1 CACCCTGATCTGAAGAC 17


RESULT 43
US-08-819-358-3/c
; Sequence 3, Application US/08819358
; Patent No. 5976799
;  GENERAL INFORMATION:
;    APPLICANT:  O'BRIEN, TIMOTHY J.
;    APPLICANT:  SHIGEMASA, KAZUSHI
;    TITLE OF INVENTION:  EARLY DETECTION OF OVARIAN CARCINOMA
;    TITLE OF INVENTION:  USING p16 GENE PRODUCTS
;    NUMBER OF SEQUENCES:  18
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MARTIN L. MCGREGOR
;      STREET:  5380  WEST 34TH STREET, #345
;      CITY:  HOUSTON
;      STATE:  TEXAS
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE 3.5 INCH 1.44 MB STORAGE
;      COMPUTER:  IBM COMPATIBLE
;      OPERATING SYSTEM:  MS-DOS
;      SOFTWARE:  WORDPERFECT 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/819,358
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/621,180
;      FILING DATE:  MARCH 21, 1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MCGREGOR, MARTIN L.
;      REGISTRATION NUMBER:  29,329
;      REFERENCE/DOCKET NUMBER:  1-2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  713-682-1213
;      TELEFAX:  713-682-5807
;      TELEX:  NONE
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 BASE PAIRS
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  SINGLE
;      TOPOLOGY:  LINEAR
;    MOLECULE TYPE:  OTHER NUCLEIC ACID
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-819-358-3

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2315 AAGGAACTGAATTCTGC 2331
              |||||||||| ||| ||
Db         17 AAGGAACTGACTTCGGC 1


RESULT 44
US-08-896-122-2
; Sequence 2, Application US/08896122
; Patent No. 6057143
;  GENERAL INFORMATION:
;    APPLICANT:  Meyer, Sheryl L.
;    APPLICANT:  Scott, Richard W.
;    APPLICANT:  Siman, Robert
;    TITLE OF INVENTION:  Recombinant Enzymatically Active Calpain
;    TITLE OF INVENTION:  Expressed in a Baculovirus System
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz & No. 6057143ris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/896,122
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/275,683
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Trujillo, Doreen Y.
;      REGISTRATION NUMBER:  35,719
;      REFERENCE/DOCKET NUMBER:  CEPH-013
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-896-122-2

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 CACTCTGATCTGAAGCC 1760
              ||| |||||||||||  |
Db          1 CACCCTGATCTGAAGAC 17
```

```
RESULT 45
US-09-346-200A-3/c
; Sequence 3, Application US/09346200A
; Patent No. 6287775
; GENERAL INFORMATION:
;  APPLICANT: O'Brien, Timothy J.
;  APPLICANT:  Shigemasa, Kazushi
;  TITLE OF INVENTION: Early Detection of Ovarian Carcinoma Using p16 Gene Products
;  FILE REFERENCE: D6222D
;  CURRENT APPLICATION NUMBER: US/09/346,200A
;  CURRENT FILING DATE:  1999-07-01
;  PRIOR APPLICATION NUMBER: US 08/819,358
;  PRIOR FILING DATE: 1997-03-17
;  NUMBER OF SEQ ID NOS: 18
; SEQ ID NO 3
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   NAME/KEY: primer_bind
;   OTHER INFORMATION: p21 sense primer 1A
US-09-346-200A-3

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2315 AAGGAACTGAATTCTGC 2331
              ||||||||||  ||| ||
Db         17 AAGGAACTGACTTCGGC 1


RESULT 46
US-08-584-040-4386/c
; Sequence 4386, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4386:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-4386

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              |||||||||||||  ||
Db         17 TGAAAATCAAATGCGGC 1


RESULT 47
US-08-584-040-5941/c
; Sequence 5941, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5941:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5941
```

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1871 TGAAAATCAAATGATGC 1887
              ||||||||||||| ||
Db         17 TGAAAATCAAATGTGGC 1
```

RESULT 48
US-09-371-772B-2153/c
; Sequence 2153, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2153
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2153

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1871 TGAAAATCAAATGATGC 1887
              ||||||||||||| ||
Db         17 TGAAAATCAAATGCGGC 1
```

RESULT 49
US-09-371-772B-2778/c
; Sequence 2778, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2778
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2778

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1871 TGAAAATCAAATGATGC 1887
              ||||||||||||| ||
Db         17 TGAAAATCAAATGTGGC 1
```

RESULT 50
US-09-371-772B-5483/c
; Sequence 5483, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5483
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5483

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1899 AAGCACTTTGTAAATTG 1915
              ||||||||||||| | |
Db         17 AAGCACTTTGTAACTAG 1
```

RESULT 51
US-09-866-108A-2781
; Sequence 2781, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2781
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2781

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1666 CTCCTTCAAGCATCACC 1682
              | |||||||||| ||||
Db          1 CACCTTCAAGCACCACC 17


RESULT 52
US-09-685-664B-2153/c
; Sequence 2153, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2153
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-685-664B-2153

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              |||||||||||||  ||
Db         17 TGAAAATCAAATGCGGC 1


RESULT 53
US-09-685-664B-2778/c
; Sequence 2778, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Recptor
;  FILE REFERENCE: MBHB00-876-K (400/021)
;  CURRENT APPLICATION NUMBER: US/09/685,664B
;  CURRENT FILING DATE:  2000-10-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  NUMBER OF SEQ ID NOS: 8231
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2778
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-09-685-664B-2778

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              |||||||||||||  ||
Db         17 TGAAAATCAAATGTGGC 1


RESULT 54
PCT-US95-08487-2
; Sequence 2, Application PC/TUS9508487
;  GENERAL INFORMATION:
;    APPLICANT:  Meyer, Sheryl L.
;    APPLICANT:  Scott, Richard W.
;    APPLICANT:  Siman, Robert
;    TITLE OF INVENTION:  Recombinant Enzymatically Active
;    TITLE OF INVENTION:  Calpain Expressed IN A Baculovirus System
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewicz &
;      ADDRESSEE:  Norris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/08487
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Trujillo, Doreen Y.
;      REGISTRATION NUMBER:  35,719
;      REFERENCE/DOCKET NUMBER:  CEPH-013
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
PCT-US95-08487-2
```

```
  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 21;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1744 CACTCTGATCTGAAGCC 1760
              ||| |||||||||||  |
Db          1 CACCCTGATCTGAAGAC 17


RESULT 55
US-07-971-978-22/c
; Sequence 22, Application US/07971978
; Patent No. 5614617
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Sanghvi
;    TITLE OF INVENTION:  Nuclease Resistant, Pyrimidine
;    TITLE OF INVENTION:  Modified Oligonucleotides that Detect and Modulate
;    TITLE OF INVENTION:  Gene Expression
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5614617ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,978
;      FILING DATE:  February 18, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/558,806
;      FILING DATE:  July 27, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0333
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  13
;      OTHER INFORMATION:  6-aza-cytidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  14
;      OTHER INFORMATION:  6-aza-cytidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  15
;      OTHER INFORMATION:  6-aza-cytidine substitution
US-07-971-978-22

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 26;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2389 GGGCTGACACCTGGA 2403
              |||| ||||||||||
Db         15 GGGCGGACACCTGGA 1


RESULT 56
US-07-971-978-23/c
; Sequence 23, Application US/07971978
; Patent No. 5614617
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Sanghvi
;    TITLE OF INVENTION:  Nuclease Resistant, Pyrimidine
;    TITLE OF INVENTION:  Modified Oligonucleotides that Detect and Modulate
;    TITLE OF INVENTION:  Gene Expression
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5614617ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,978
;      FILING DATE:  February 18, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/558,806
;      FILING DATE:  July 27, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0333
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  14
;      OTHER INFORMATION:  6-aza-cytidine substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  15
;      OTHER INFORMATION:  6-aza-cytidine substitution
US-07-971-978-23

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 26;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2389 GGGCTGACACCTGGA 2403
              |||| ||||||||||
Db         15 GGGCGGACACCTGGA 1


RESULT 57
US-07-971-978-52/c
; Sequence 52, Application US/07971978
; Patent No. 5614617
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Sanghvi
```

```
;    TITLE OF INVENTION:  Nuclease Resistant, Pyrimidine
;    TITLE OF INVENTION:  Modified Oligonucleotides that Detect and Modulate
;    TITLE OF INVENTION:  Gene Expression
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5614617ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,978
;      FILING DATE:  February 18, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/558,806
;      FILING DATE:  July 27, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0333
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  52:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  13
;      OTHER INFORMATION:  5-bromo-2'-deoxycytidine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  14
;      OTHER INFORMATION:  5-bromo-2'-deoxycytidine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  15
;      OTHER INFORMATION:  5-bromo-2'-deoxycytidine
;      OTHER INFORMATION:  substitution
US-07-971-978-52

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 26;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2389 GGGCTGACACCTGGA 2403
             |||| ||||||||||
Db         15 GGGCGGACACCTGGA 1


RESULT 58
US-07-971-978-58/c
; Sequence 58, Application US/07971978
; Patent No. 5614617
;  GENERAL INFORMATION:
;    APPLICANT:  Cook and Sanghvi
;    TITLE OF INVENTION:  Nuclease Resistant, Pyrimidine
;    TITLE OF INVENTION:  Modified Oligonucleotides that Detect and Modulate
;    TITLE OF INVENTION:  Gene Expression
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5614617ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,978
;      FILING DATE:  February 18, 1993
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/558,806
;      FILING DATE:  July 27, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Joseph Lucci
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-0333
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  58:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  13
;      OTHER INFORMATION:  5-methyl-2'-deoxycytidine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  14
;      OTHER INFORMATION:  5-methyl-2'-deoxycytidine
;      OTHER INFORMATION:  substitution
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  15
;      OTHER INFORMATION:  5-methyl-2'-deoxycytidine
;      OTHER INFORMATION:  substitution
US-07-971-978-58

  Query Match             1.5%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 26;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2389 GGGCTGACACCTGGA 2403
             |||| ||||||||||
Db         15 GGGCGGACACCTGGA 1


RESULT 59
US-08-311-486C-21/c
; Sequence 21, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
```

```
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-`
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-21

  Query Match             1.4%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 33;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2201 AGTATGTGAGAGG 2213
             |||||||||||||
Db         15 AGTATGTGAGAGG 3


RESULT 60
US-09-479-005A-70/c
; Sequence 70, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 70
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-70

  Query Match             1.4%;  Score 13;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2278 AGCAGGAAAAAAA 2290
             |||||||||||||
Db         13 AGCAGGAAAAAAA 1


RESULT 61
US-08-207-547A-15/c
; Sequence 15, Application US/08207547A
; Patent No. 5624824
;  GENERAL INFORMATION:
;    APPLICANT:  Yuan, Yan
;    APPLICANT:  Guerrier-Takada, Cecilia
;    APPLICANT:  Altman, Sidney
;    APPLICANT:  Liu, Fenyong
;    TITLE OF INVENTION:  Targeted Cleavage of RNA Using
;    TITLE OF INVENTION:  Eukaryotic Ribonuclease P and External Guide Sequence
;    NUMBER OF SEQUENCES:  39
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Patrea L. Pabst
;      STREET:  2800 One Atlantic Center
;      STREET:  1201 West Peachtree Street
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30309-3450
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/207,547A
;      FILING DATE:  07-MAR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US PCT/US93/03961
;      FILING DATE:  28-APR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/054,892
;      FILING DATE:  29-APR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/931,837
;      FILING DATE:  18-AUG-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/875,099
;      FILING DATE:  28-APR-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/568,834
;      FILING DATE:  17-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/328,368
;      FILING DATE:  24-MAR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Pabst, Patrea L.
;      REGISTRATION NUMBER:  31,284
;      REFERENCE/DOCKET NUMBER:  YU100CIP(4)
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (404)-873-8794
;      TELEFAX:  (404)-873-8795
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
```

```
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-207-547A-15

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 34;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CCTTCAAGCATCACCA 1683
              |||||| || ||||||
Db         16 CCTTCATGCCTCACCA 1


RESULT 62
US-08-215-082-15/c
; Sequence 15, Application US/08215082
; Patent No. 5728521
;  GENERAL INFORMATION:
;    APPLICANT:  Yuan, Yan
;    APPLICANT:  Guerrier-Takada, Cecilia
;    APPLICANT:  Altman, Sidney
;    APPLICANT:  Liu, Fenyong
;    TITLE OF INVENTION:  Targeted Cleavage of RNA Using
;    TITLE OF INVENTION:  Eukaryotic Ribonuclease P and External Guide Sequence
;    NUMBER OF SEQUENCES:  39
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Patrea L. Pabst
;      STREET:  1100 Peachtree Street, Suite 2800
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30309-4530
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/215,082
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  YU100CIP(4)
;      FILING DATE:  07-MAR-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US PCT/US93/03961
;      FILING DATE:  28-APR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/054,892
;      FILING DATE:  29-APR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/931,837
;      FILING DATE:  18-AUG-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/875,099
;      FILING DATE:  28-APR-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/568,834
;      FILING DATE:  17-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/328,368
;      FILING DATE:  24-MAR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Pabst, Patrea L.
;      REGISTRATION NUMBER:  31,284
;      REFERENCE/DOCKET NUMBER:  YU100CIP(5)
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (404)-815-6508
;      TELEFAX:  (404)-815-6555
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-215-082-15

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 34;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 CCTTCAAGCATCACCA 1683
              |||||| || ||||||
Db         16 CCTTCATGCCTCACCA 1


RESULT 63
US-08-702-652-15/c
; Sequence 15, Application US/08702652
; Patent No. 5869248
;  GENERAL INFORMATION:
;    APPLICANT:  Yan Yuan, Cecilia Guerrier-Takada, and
;    APPLICANT:  Sidney Altman
;    TITLE OF INVENTION:  TARGETED CLEAVAGE OF RNA USING
;    TITLE OF INVENTION:  RIBONUCLEASE P TARGETING AND CLEAVAGE SEQUENCES
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Patrea L. Pabst
;      STREET:  2800 One Atlantic Center
;      STREET:  1201 West Peachtree Street
;      CITY:  Atlanta
;      STATE:  Georgia
;      COUNTRY:  USA
;      ZIP:  30309-3450
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/702,652
;      FILING DATE:  No. 5869248ember 6, 1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/02816
;      FILING DATE:  March 7, 1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/207,547
;      FILING DATE:  March 7, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Pabst, Patrea L.
;      REGISTRATION NUMBER:  31,284
;      REFERENCE/DOCKET NUMBER:  YU112
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (404)-873-8794
;      TELEFAX:  (404)-873-8795
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-08-702-652-15

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 34;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1668 CCTTCAAGCATCACCA 1683
              |||||| || ||||||
Db         16 CCTTCATGCCTCACCA 1


RESULT 64
US-09-371-772B-6037/c
; Sequence 6037, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6037
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6037

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 34;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1893 ATATACAAGCACTTTG 1908
              ||  ||||||||||||
Db         16 ATGAACAAGCACTTTG 1


RESULT 65
US-09-371-772B-7113
; Sequence 7113, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7113
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-7113

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 34;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 GAAATCTCCTTCAAGC 1676
              ||||:|:| : |||||
Db          1 GAAAUCUCUUGCAAGC 16


RESULT 66
US-09-479-005A-209/c
; Sequence 209, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 209
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-209

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 34;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1974 ATTTATAGATTGTGTT 1989
              ||||| |||||||| |
Db         16 ATTTACAGATTGTGCT 1


RESULT 67
PCT-US94-08023-24/c
; Sequence 24, Application PC/TUS9408023
;  GENERAL INFORMATION:
;    APPLICANT:  de Kloet, Siwo R.
;    TITLE OF INVENTION:  Sex-Specific DNA Probe For Parrots,
;    TITLE OF INVENTION:  Methods And Kits
;    NUMBER OF SEQUENCES:  44
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Ruden, Barnett, McClosky, Smith, Schuster &
;      ADDRESSEE:  Russell, P.A.
;      STREET:  200 East Broward Boulevard
;      CITY:  Fort Lauderdale
;      STATE:  FL
;      COUNTRY:  USA
;      ZIP:  33301
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/08023
;      FILING DATE:  15-JUL-1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/093,198
;      FILING DATE:  15-JUL-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Manso, Peter J.
;      REGISTRATION NUMBER:  32,264
;      REFERENCE/DOCKET NUMBER:  FL20979-34
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  305-527-2498
;      TELEFAX:  305-764-4996
;  INFORMATION FOR SEQ ID NO:  24:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US94-08023-24

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 46;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1704 GGGTTAGCAAAAAG 1717
              ||||||| ||||||
Db         14 GGGTTAGAAAAAAG 1

RESULT 68
US-08-182-968A-88/c
; Sequence 88, Application US/08182968A
; Patent No. 5610054
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/182,968A
;      FILING DATE:  13-JANUARY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  14-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  205/277
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  88:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-182-968A-88

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 43;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1597 GCCACCATATCAAC 1610
              |||||||||||  ||
Db         15 GCCACCATATCCAC 2

RESULT 69
US-08-292-620A-214
; Sequence 214, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  214:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-214

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   64.3%;  Pred. No. 43;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2019 ATCCCTTGATGATA 2032
              | |||::||:||:|
Db          2 AACCCUUGAUGAUA 15

RESULT 70
US-08-774-306A-88/c
; Sequence 88, Application US/08774306A
; Patent No. 5869253
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
```

```
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  497
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,306A
;      FILING DATE:  December 26, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/227
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  88:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-306A-88

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 43;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1597 GCCACCATATCAAC 1610
              ||||||||||| ||
Db         15 GCCACCATATCCAC 2


RESULT 71
US-09-064-156A-88/c
; Sequence 88, Application US/09064156A
; Patent No. 6132966
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING HEPATITIS C
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  498
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/064,156A
;      FILING DATE:  April 21, 1998
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/774,306
;      FILING DATE:  December 26, 1996
;      APPLICATION NUMBER:  08/182,968
;      FILING DATE:  January 13, 1994
;      APPLICATION NUMBER:  07/882,888
;      FILING DATE:  May 14, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  234/083
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  88:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-064-156A-88

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 43;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1597 GCCACCATATCAAC 1610
              ||||||||||| ||
Db         15 GCCACCATATCCAC 2


RESULT 72
US-09-071-845-214
; Sequence 214, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
```

```
;       FILING DATE:  January 19, 1993
;       APPLICATION NUMBER:  07/989,849
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  208/149
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  214:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-071-845-214

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   64.3%;  Pred. No. 43;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2019 ATCCCTTGATGATA 2032
              | |||::||:||:|
Db          2 AACCCUUGAUGAUA 15


RESULT 73
US-09-180-437-137/c
; Sequence 137, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
;  APPLICANT: FUKUSAKO, Shioji
;  APPLICANT: MORISAWA, Yoshifumi
;  APPLICANT: KUSUYAMA, Takeshi
;  TITLE OF INVENTION: Antisense Compounds to CD14
;  FILE REFERENCE: 1110-209P
;  CURRENT APPLICATION NUMBER: US/09/180,437
;  CURRENT FILING DATE: 1998-11-06
;  EARLIER APPLICATION NUMBER: PCT/JP98/00953
;  EARLIER FILING DATE: 1998-03-09
;  EARLIER APPLICATION NUMBER: 09-053518 JAPAN
;  EARLIER FILING DATE: 1997-03-07
;  NUMBER OF SEQ ID NOS: 289
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 137
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:other nucleic
;   OTHER INFORMATION: acid
US-09-180-437-137

  Query Match             1.3%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 43;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2311 CCACAAGGAACTGA 2324
              || ||||||||||||
Db         15 CCTCAAGGAACTGA 2


RESULT 74
US-08-535-249-120/c
; Sequence 120, Application US/08535249
; Patent No. 6455689
;  GENERAL INFORMATION:
;    APPLICANT:  Schlingensiepen, Georg-Ferdinand
;    APPLICANT:  Brysch, Wolfgang
;    APPLICANT:  Schlingensiepen, Karl-Hermann
;    APPLICANT:  Schlingensiepen, Reimar
;    APPLICANT:  Bogdahn, Ulrich
;    TITLE OF INVENTION:  Antisense-oligonucleotides for the treatment of
;    TITLE OF INVENTION:  immuno-suppressive effect of transforming-growth-factor beta (T
;    NUMBER OF SEQUENCES:  137
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jacobson, Price, Holman & Stern
;      STREET:  400 Seventh St. N.W.
;      CITY:  Washington D.C
;      COUNTRY:  U.S.A.
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/535,249
;      FILING DATE:
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 93 107 089.0
;      FILING DATE:  30-APR-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 93 107 849.7
;      FILING DATE:  13-MAY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Player, William E.
;      REGISTRATION NUMBER:  31,409
;      REFERENCE/DOCKET NUMBER:  10577/P58418
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)638-6666
;      TELEFAX:  (202) 393-5350
;      TELEX:  RCA 248593 IDEA UR
;  INFORMATION FOR SEQ ID NO:  120:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
;    ANTI-SENSE:  YES
US-08-535-249-120

  Query Match             1.3%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 54;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2443 TTCTGTGCTGGA 2454
              ||||||||||||
Db         12 TTCTGTGCTGGA 1


RESULT 75
US-08-585-684B-630/c
; Sequence 630, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
```

```
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  630:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-630

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
             ||||||||||||
Db         15 ATCCTATTAGTC 4


RESULT 76
US-08-585-684B-631/c
; Sequence 631, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  631:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-631

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
             ||||||||||||
Db         15 ATCCTATTAGTC 4


RESULT 77
US-08-585-684B-632/c
; Sequence 632, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  632:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-632

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
```

```
                    ||||||||||||
Db          15 ATCCTATTAGTC 4


RESULT 78
US-08-585-684B-633/c
; Sequence 633, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  633:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-633

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
                ||||||||||||
Db         12 ATCCTATTAGTC 1


RESULT 79
US-08-585-684B-634/c
; Sequence 634, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  634:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-634

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
                ||||||||||||
Db         12 ATCCTATTAGTC 1


RESULT 80
US-08-585-684B-2056/c
; Sequence 2056, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
```

```
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2056:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-2056

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2271 GTCAGCAAGCAG 2282
              ||||||||||||
Db         14 GTCAGCAAGCAG 3


RESULT 81
US-08-585-684B-2330/c
; Sequence 2330, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2330:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-2330

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2271 GTCAGCAAGCAG 2282
              ||||||||||||
Db         14 GTCAGCAAGCAG 3


RESULT 82
US-08-832-021-36/c
; Sequence 36, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
;  APPLICANT: Combates, N.
;  APPLICANT: Pardinas, J.
;  APPLICANT: Parimoo, S.
;  APPLICANT: Prouty, S.
;  APPLICANT: Stenn, K.
;  TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
;  FILE REFERENCE: JBP-382
;  CURRENT APPLICATION NUMBER: US/08/832,021
;  CURRENT FILING DATE: 1997-04-02
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-36

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2281 AGGAAAAAAAAA 2292
              ||||||||||||
Db         15 AGGAAAAAAAAA 4


RESULT 83
US-09-038-073-630/c
; Sequence 630, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  630:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-630

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
             ||||||||||||
Db         15 ATCCTATTAGTC 4


RESULT 84
US-09-038-073-631/c
; Sequence 631, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  631:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-631

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
             ||||||||||||
Db         15 ATCCTATTAGTC 4


RESULT 85
US-09-038-073-632/c
; Sequence 632, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  632:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-632

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
             ||||||||||||
Db         15 ATCCTATTAGTC 4


RESULT 86
US-09-038-073-633/c
```

```
; Sequence 633, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
;   APPLICANT: Stinchcomb, Daniel T.
;   APPLICANT: Jarvis, Thale
;   APPLICANT: McSwiggen, James
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
;   TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
;   NUMBER OF SEQUENCES: 2751
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: FastSEQ Version 1.5
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/038,073
;     FILING DATE:
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/585,684
;     FILING DATE:
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard
;     REGISTRATION NUMBER: 32,327
;     REFERENCE/DOCKET NUMBER: 218/078
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (213) 489-1600
;     TELEFAX: (213) 955-0440
;     TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 633:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 15 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
US-09-038-073-633

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
              ||||||||||||
Db         12 ATCCTATTAGTC 1


RESULT 87
US-09-038-073-634/c
; Sequence 634, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
;   APPLICANT: Stinchcomb, Daniel T.
;   APPLICANT: Jarvis, Thale
;   APPLICANT: McSwiggen, James
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
;   TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
;   NUMBER OF SEQUENCES: 2751
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: FastSEQ Version 1.5
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/038,073
;     FILING DATE:
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/585,684
;     FILING DATE:
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard
;     REGISTRATION NUMBER: 32,327
;     REFERENCE/DOCKET NUMBER: 218/078
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (213) 489-1600
;     TELEFAX: (213) 955-0440
;     TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 634:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 15 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
US-09-038-073-634

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1958 ATCCTATTAGTC 1969
              ||||||||||||
Db         12 ATCCTATTAGTC 1


RESULT 88
US-09-038-073-2056/c
; Sequence 2056, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
;   APPLICANT: Stinchcomb, Daniel T.
;   APPLICANT: Jarvis, Thale
;   APPLICANT: McSwiggen, James
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
;   TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
;   NUMBER OF SEQUENCES: 2751
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: FastSEQ Version 1.5
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/038,073
;     FILING DATE:
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/585,684
;     FILING DATE:
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard
```

```
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2056:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-2056

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2271 GTCAGCAAGCAG 2282
              ||||||||||||
Db         14 GTCAGCAAGCAG 3


RESULT 89
US-09-038-073-2330/c
; Sequence 2330, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2330:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-2330

  Query Match             1.3%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 50;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2271 GTCAGCAAGCAG 2282
              ||||||||||||
Db         14 GTCAGCAAGCAG 3


Search completed: April  7, 2005, 05:57:41
Job time : 1 secs
```

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 7, 2005, 05:59:31 ; Search time 2 Seconds
(without alignments)
2.572 Million cell updates/sec

Title: US-10-630-399-3
Perfect score: 922
Sequence: 1 gacagtggttattaaagcat.....ctggacttctaatatataga 922

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 161 seqs, 2790 residues

Total number of hits satisfying chosen parameters: 322

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 162 summaries

Database : rnpb3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	50	5.4	50	1	US-10-131-827-3266	Sequence 3266, Ap
c	2	20	2.2	20	1	US-09-966-451-52	Sequence 52, Appl
c	3	20	2.2	20	1	US-09-966-451-53	Sequence 53, Appl
c	4	20	2.2	20	1	US-09-966-451-54	Sequence 54, Appl
c	5	20	2.2	20	1	US-09-966-451-55	Sequence 55, Appl
c	6	20	2.2	20	1	US-09-966-451-56	Sequence 56, Appl
c	7	20	2.2	20	1	US-09-966-451-57	Sequence 57, Appl
c	8	20	2.2	20	1	US-09-966-451-58	Sequence 58, Appl
c	9	20	2.2	20	1	US-09-966-451-59	Sequence 59, Appl
c	10	20	2.2	20	1	US-09-966-451-60	Sequence 60, Appl
c	11	20	2.2	20	1	US-09-966-451-61	Sequence 61, Appl
c	12	20	2.2	20	1	US-09-966-451-62	Sequence 62, Appl
c	13	20	2.2	20	1	US-09-966-451-63	Sequence 63, Appl
c	14	20	2.2	20	1	US-09-966-451-64	Sequence 64, Appl
c	15	20	2.2	20	1	US-09-966-451-65	Sequence 65, Appl
c	16	20	2.2	20	1	US-09-966-451-66	Sequence 66, Appl
c	17	20	2.2	20	1	US-09-966-451-67	Sequence 67, Appl
c	18	20	2.2	20	1	US-09-966-451-68	Sequence 68, Appl
c	19	20	2.2	20	1	US-09-966-451-69	Sequence 69, Appl
c	20	20	2.2	20	1	US-09-966-451-70	Sequence 70, Appl
c	21	20	2.2	20	1	US-09-966-451-71	Sequence 71, Appl
c	22	20	2.2	20	1	US-09-966-451-72	Sequence 72, Appl
c	23	20	2.2	20	1	US-09-966-451-73	Sequence 73, Appl
c	24	20	2.2	20	1	US-09-966-451-74	Sequence 74, Appl
c	25	20	2.2	20	1	US-09-966-451-75	Sequence 75, Appl
c	26	20	2.2	20	1	US-09-966-451-76	Sequence 76, Appl
c	27	20	2.2	20	1	US-09-966-451-77	Sequence 77, Appl
c	28	20	2.2	20	1	US-09-966-451-78	Sequence 78, Appl
c	29	20	2.2	20	1	US-09-966-451-79	Sequence 79, Appl
c	30	20	2.2	20	1	US-10-630-399-52	Sequence 52, Appl
c	31	20	2.2	20	1	US-10-630-399-53	Sequence 53, Appl
c	32	20	2.2	20	1	US-10-630-399-54	Sequence 54, Appl
c	33	20	2.2	20	1	US-10-630-399-55	Sequence 55, Appl
c	34	20	2.2	20	1	US-10-630-399-56	Sequence 56, Appl
c	35	20	2.2	20	1	US-10-630-399-57	Sequence 57, Appl
c	36	20	2.2	20	1	US-10-630-399-58	Sequence 58, Appl
c	37	20	2.2	20	1	US-10-630-399-59	Sequence 59, Appl
c	38	20	2.2	20	1	US-10-630-399-60	Sequence 60, Appl
c	39	20	2.2	20	1	US-10-630-399-61	Sequence 61, Appl
c	40	20	2.2	20	1	US-10-630-399-62	Sequence 62, Appl
c	41	20	2.2	20	1	US-10-630-399-63	Sequence 63, Appl
c	42	20	2.2	20	1	US-10-630-399-64	Sequence 64, Appl
c	43	20	2.2	20	1	US-10-630-399-65	Sequence 65, Appl
c	44	20	2.2	20	1	US-10-630-399-66	Sequence 66, Appl
c	45	20	2.2	20	1	US-10-630-399-67	Sequence 67, Appl
c	46	20	2.2	20	1	US-10-630-399-68	Sequence 68, Appl
c	47	20	2.2	20	1	US-10-630-399-69	Sequence 69, Appl
c	48	20	2.2	20	1	US-10-630-399-70	Sequence 70, Appl
c	49	20	2.2	20	1	US-10-630-399-71	Sequence 71, Appl
c	50	20	2.2	20	1	US-10-630-399-72	Sequence 72, Appl
c	51	20	2.2	20	1	US-10-630-399-73	Sequence 73, Appl
c	52	20	2.2	20	1	US-10-630-399-74	Sequence 74, Appl
c	53	20	2.2	20	1	US-10-630-399-75	Sequence 75, Appl
c	54	20	2.2	20	1	US-10-630-399-76	Sequence 76, Appl
c	55	20	2.2	20	1	US-10-630-399-77	Sequence 77, Appl
c	56	20	2.2	20	1	US-10-630-399-78	Sequence 78, Appl
c	57	20	2.2	20	1	US-10-630-399-79	Sequence 79, Appl
	58	17.4	1.9	21	1	US-10-751-736-29540	Sequence 29540, A
c	59	16	1.7	17	1	US-10-060-998-1545	Sequence 1545, Ap
c	60	16	1.7	17	1	US-10-060-998-1546	Sequence 1546, Ap
	61	15.8	1.7	19	1	US-10-349-143-11728	Sequence 11728, A
c	62	15.8	1.7	19	1	US-10-665-951-369	Sequence 369, App
	63	15.8	1.7	19	1	US-10-665-951-796	Sequence 796, App
c	64	15.4	1.7	17	1	US-10-060-998-1543	Sequence 1543, Ap
c	65	15.4	1.7	17	1	US-10-060-998-1544	Sequence 1544, Ap
c	66	15	1.6	16	1	US-10-138-674-6036	Sequence 6036, Ap
c	67	15	1.6	16	1	US-10-287-949A-6036	Sequence 6036, Ap
c	68	15	1.6	17	1	US-10-060-998-1547	Sequence 1547, Ap
c	69	15	1.6	17	1	US-10-138-674-8189	Sequence 8189, Ap
c	70	15	1.6	17	1	US-10-287-949A-8189	Sequence 8189, Ap
c	71	15	1.6	17	1	US-10-712-633-1450	Sequence 1450, Ap
c	72	14.8	1.6	18	1	US-10-455-552-74	Sequence 74, Appl
	73	14.4	1.6	17	1	US-09-730-289B-1033	Sequence 1033, Ap
	74	14.4	1.6	17	1	US-09-730-289B-1122	Sequence 1122, Ap
c	75	14.4	1.6	17	1	US-10-060-998-1542	Sequence 1542, Ap
	76	14.4	1.6	18	1	US-09-969-373-1804	Sequence 1804, Ap
c	77	14	1.5	17	1	US-10-060-998-1548	Sequence 1548, Ap
	78	14	1.5	17	1	US-10-156-306-71	Sequence 71, Appl
	79	14	1.5	17	1	US-10-156-306-2713	Sequence 2713, Ap
c	80	14	1.5	17	1	US-10-138-674-2154	Sequence 2154, Ap
c	81	14	1.5	17	1	US-10-138-674-2779	Sequence 2779, Ap
c	82	14	1.5	17	1	US-10-138-674-8190	Sequence 8190, Ap
c	83	14	1.5	17	1	US-10-138-674-9127	Sequence 9127, Ap
c	84	14	1.5	17	1	US-10-287-949A-2154	Sequence 2154, Ap
c	85	14	1.5	17	1	US-10-287-949A-2779	Sequence 2779, Ap
c	86	14	1.5	17	1	US-10-287-949A-8190	Sequence 8190, Ap
c	87	14	1.5	17	1	US-10-287-949A-9127	Sequence 9127, Ap
c	88	14	1.5	17	1	US-10-712-633-1451	Sequence 1451, Ap
c	89	14	1.5	17	1	US-10-712-633-4397	Sequence 4397, Ap
	90	13.8	1.5	17	1	US-09-866-108-2781	Sequence 2781, Ap
	91	13.8	1.5	17	1	US-09-877-478-474	Sequence 474, App
c	92	13.8	1.5	17	1	US-09-877-478-2127	Sequence 2127, Ap
	93	13.8	1.5	17	1	US-09-848-754A-1182	Sequence 1182, Ap
	94	13.8	1.5	17	1	US-09-827-395A-50	Sequence 50, Appl
c	95	13.8	1.5	17	1	US-10-060-998-1033	Sequence 1033, Ap
c	96	13.8	1.5	17	1	US-10-156-306-2769	Sequence 2769, Ap
c	97	13.8	1.5	17	1	US-10-238-700-951	Sequence 951, App
c	98	13.8	1.5	17	1	US-10-061-201-697	Sequence 697, App
c	99	13.8	1.5	17	1	US-10-061-201-698	Sequence 698, App
	100	13.8	1.5	17	1	US-10-430-882-50	Sequence 50, Appl
	101	13.8	1.5	17	1	US-10-342-902-474	Sequence 474, App
c	102	13.8	1.5	17	1	US-10-342-902-2127	Sequence 2127, Ap
c	103	13.8	1.5	17	1	US-10-138-674-2153	Sequence 2153, Ap
c	104	13.8	1.5	17	1	US-10-138-674-2778	Sequence 2778, Ap
c	105	13.8	1.5	17	1	US-10-138-674-5483	Sequence 5483, Ap
	106	13.8	1.5	17	1	US-10-138-674-9343	Sequence 9343, Ap

	107	13.8	1.5	17	1	US-10-138-674-9377 Sequence 9377, Ap
c	108	13.8	1.5	17	1	US-10-287-949A-2153 Sequence 2153, Ap
c	109	13.8	1.5	17	1	US-10-287-949A-2778 Sequence 2778, Ap
c	110	13.8	1.5	17	1	US-10-287-949A-5483 Sequence 5483, Ap
	111	13.8	1.5	17	1	US-10-287-949A-9343 Sequence 9343, Ap
	112	13.8	1.5	17	1	US-10-287-949A-9377 Sequence 9377, Ap
	113	13.8	1.5	17	1	US-10-669-841-474 Sequence 474, App
c	114	13.8	1.5	17	1	US-10-669-841-1968 Sequence 1968, Ap
	115	13.8	1.5	17	1	US-10-723-361-2781 Sequence 2781, Ap
	116	13.8	1.5	17	1	US-10-712-633-4614 Sequence 4614, Ap
	117	13.8	1.5	17	1	US-10-712-633-4648 Sequence 4648, Ap
c	118	13.4	1.5	16	1	US-10-043-875-177 Sequence 177, App
c	119	13.2	1.4	50	1	US-10-131-827-3266 Sequence 3266, Ap
	120	13	1.4	13	1	US-10-257-017B-12919 Sequence 12919, A
c	121	13	1.4	13	1	US-10-257-017B-12920 Sequence 12920, A
c	122	13	1.4	13	1	US-10-257-017B-23771 Sequence 23771, A
	123	13	1.4	13	1	US-10-257-017B-23772 Sequence 23772, A
c	124	13	1.4	13	1	US-10-257-017B-50497 Sequence 50497, A
	125	13	1.4	13	1	US-10-257-017B-50498 Sequence 50498, A
c	126	13	1.4	13	1	US-10-257-017B-52315 Sequence 52315, A
	127	13	1.4	13	1	US-10-257-017B-52316 Sequence 52316, A
	128	13	1.4	13	1	US-10-257-017B-100801 Sequence 100801,
c	129	13	1.4	13	1	US-10-257-017B-100802 Sequence 100802,
c	130	13	1.4	13	1	US-10-257-017B-132137 Sequence 132137,
	131	13	1.4	13	1	US-10-257-017B-132138 Sequence 132138,
c	132	13	1.4	13	1	US-10-257-017B-162297 Sequence 162297,
	133	13	1.4	13	1	US-10-257-017B-162298 Sequence 162298,
	134	13	1.4	13	1	US-10-257-017B-179793 Sequence 179793,
c	135	13	1.4	13	1	US-10-257-017B-179794 Sequence 179794,
c	136	13	1.4	13	1	US-10-257-017B-193759 Sequence 193759,
	137	13	1.4	13	1	US-10-257-017B-193760 Sequence 193760,
c	138	13	1.4	13	1	US-10-257-017B-202391 Sequence 202391,
	139	13	1.4	13	1	US-10-257-017B-202392 Sequence 202392,
c	140	13	1.4	13	1	US-10-257-017B-215295 Sequence 215295,
	141	13	1.4	13	1	US-10-257-017B-215296 Sequence 215296,
	142	13	1.4	13	1	US-10-257-017B-247011 Sequence 247011,
c	143	13	1.4	13	1	US-10-257-017B-247012 Sequence 247012,
	144	13	1.4	13	1	US-10-257-017B-253051 Sequence 253051,
c	145	13	1.4	13	1	US-10-257-017B-253052 Sequence 253052,
	146	12.8	1.4	16	1	US-10-140-293-6 Sequence 6, Appli
c	147	12.8	1.4	16	1	US-10-138-674-6037 Sequence 6037, Ap
	148	12.8	1.4	16	1	US-10-138-674-7113 Sequence 7113, Ap
c	149	12.8	1.4	16	1	US-10-287-949A-6037 Sequence 6037, Ap
	150	12.8	1.4	16	1	US-10-287-949A-7113 Sequence 7113, Ap
	151	12.6	1.4	13	1	US-10-257-017B-4851 Sequence 4851, Ap
c	152	12.6	1.4	13	1	US-10-257-017B-4852 Sequence 4852, Ap
c	153	12.6	1.4	13	1	US-10-257-017B-14279 Sequence 14279, A
	154	12.6	1.4	13	1	US-10-257-017B-14280 Sequence 14280, A
c	155	12.6	1.4	13	1	US-10-257-017B-31913 Sequence 31913, A
	156	12.6	1.4	13	1	US-10-257-017B-31914 Sequence 31914, A
c	157	12.6	1.4	13	1	US-10-257-017B-38179 Sequence 38179, A
	158	12.6	1.4	13	1	US-10-257-017B-38180 Sequence 38180, A
c	159	12.6	1.4	13	1	US-10-257-017B-59765 Sequence 59765, A
	160	12.6	1.4	13	1	US-10-257-017B-59766 Sequence 59766, A
	161	12.6	1.4	13	1	US-10-257-017B-111489 Sequence 111489,
c	162	12.6	1.4	13	1	US-10-257-017B-111490 Sequence 111490,

ALIGNMENTS

```
RESULT 1
US-10-131-827-3266
; Sequence 3266, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
;  APPLICANT: Wohlgemuth, Jay
;  APPLICANT:  Fry, Kirk
;  APPLICANT:  Woodward, Robert
;  APPLICANT:  Ly, Ngoc
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
;  TITLE OF INVENTION:  CHRONIC INFLAMMATORY DISEASES
;  FILE REFERENCE: 506612000120
;  CURRENT APPLICATION NUMBER: US/10/131,827
;  CURRENT FILING DATE:  2002-09-06
;  PRIOR APPLICATION NUMBER: US 10/006,290
;  PRIOR FILING DATE: 2001-10-22
;  PRIOR APPLICATION NUMBER: US 60/296,764
;  PRIOR FILING DATE: 2001-06-08
;  NUMBER OF SEQ ID NOS: 9090
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3266
;   LENGTH: 50
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-131-827-3266

  Query Match             5.4%;  Score 50;  DB 1;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 0.001;
  Matches   50;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1819 GCCACTAATAACATTGGGCTAATATCTGCTGTGCTTCTCTGACAGGTAGT 1868
             ||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GCCACTAATAACATTGGGCTAATATCTGCTGTGCTTCTCTGACAGGTAGT 50


RESULT 2
US-09-966-451-52/c
; Sequence 52, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 52
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-52

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1548 GACAGTGGTTATTAAAGCAT 1567
             ||||||||||||||||||||
Db         20 GACAGTGGTTATTAAAGCAT 1


RESULT 3
US-09-966-451-53/c
; Sequence 53, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 53
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-53

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
```

Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1560 TAAAGCATGGGTTGAACTTC 1579
              ||||||||||||||||||||
Db         20 TAAAGCATGGGTTGAACTTC 1
```

RESULT 4
US-09-966-451-54/c
; Sequence 54, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-54

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1646 TACAGTAATCCCTGAGAAAT 1665
              ||||||||||||||||||||
Db         20 TACAGTAATCCCTGAGAAAT 1
```

RESULT 5
US-09-966-451-55/c
; Sequence 55, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-55

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1674 AGCATCACCAAACACAGTTT 1693
              ||||||||||||||||||||
Db         20 AGCATCACCAAACACAGTTT 1
```

RESULT 6
US-09-966-451-56/c
; Sequence 56, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-56

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1711 CAAAAAGAGCCTGGGCTGTA 1730
              ||||||||||||||||||||
Db         20 CAAAAAGAGCCTGGGCTGTA 1
```

RESULT 7
US-09-966-451-57/c
; Sequence 57, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-57

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1720 CCTGGGCTGTATGTAGGGTG 1739
              ||||||||||||||||||||
Db         20 CCTGGGCTGTATGTAGGGTG 1
```

RESULT 8
US-09-966-451-58/c
; Sequence 58, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-58

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;

```
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1737 GTGGAAACACTCTGATCTGA 1756
              ||||||||||||||||||||
Db         20 GTGGAAACACTCTGATCTGA 1

RESULT 9
US-09-966-451-59/c
; Sequence 59, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 59
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-59

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1756 AAGCCCAGCTGACTCCACTA 1775
              ||||||||||||||||||||
Db         20 AAGCCCAGCTGACTCCACTA 1

RESULT 10
US-09-966-451-60/c
; Sequence 60, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-60

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1810 CTGCTGTGAGCCACTAATAA 1829
              ||||||||||||||||||||
Db         20 CTGCTGTGAGCCACTAATAA 1

RESULT 11
US-09-966-451-61/c
; Sequence 61, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 61
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-61

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1829 ACATTGGGCTAATATCTGCT 1848
              ||||||||||||||||||||
Db         20 ACATTGGGCTAATATCTGCT 1

RESULT 12
US-09-966-451-62/c
; Sequence 62, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-62

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1846 GCTGTGCTTCTCTGACAGGT 1865
              ||||||||||||||||||||
Db         20 GCTGTGCTTCTCTGACAGGT 1

RESULT 13
US-09-966-451-63/c
; Sequence 63, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 63
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-63

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1854 TCTCTGACAGGTAGTCATGA 1873
              ||||||||||||||||||||
Db         20 TCTCTGACAGGTAGTCATGA 1


RESULT 14
US-09-966-451-64/c
; Sequence 64, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 64
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-64

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1894 TATACAAGCACTTTGTAAAT 1913
              ||||||||||||||||||||
Db         20 TATACAAGCACTTTGTAAAT 1


RESULT 15
US-09-966-451-65/c
; Sequence 65, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 65
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-65

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1951 TTACAAAATCCTATTAGTCA 1970
              ||||||||||||||||||||
Db         20 TTACAAAATCCTATTAGTCA 1


RESULT 16
US-09-966-451-66/c
; Sequence 66, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 66
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-66

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1985 GTGTTCACAGCAATCATTTA 2004
              ||||||||||||||||||||
Db         20 GTGTTCACAGCAATCATTTA 1


RESULT 17
US-09-966-451-67/c
; Sequence 67, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 67
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-67

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2066 TTACATGACAAAGTTGAAGG 2085
              ||||||||||||||||||||
Db         20 TTACATGACAAAGTTGAAGG 1


RESULT 18
US-09-966-451-68/c
; Sequence 68, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 68
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-68

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2089 TTGGCAGATGCAGTTAAGGT 2108
              ||||||||||||||||||||
Db         20 TTGGCAGATGCAGTTAAGGT 1


RESULT 19
US-09-966-451-69/c
; Sequence 69, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 69
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-69

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2137 AAAGGGCCTGACCTAATCCA 2156
              ||||||||||||||||||||
Db         20 AAAGGGCCTGACCTAATCCA 1


RESULT 20
US-09-966-451-70/c
; Sequence 70, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-70

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2191 GCCTTGAAGAAGTATGTGAG 2210
              ||||||||||||||||||||
Db         20 GCCTTGAAGAAGTATGTGAG 1


RESULT 21
US-09-966-451-71/c
; Sequence 71, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 71
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-71

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2211 AGGGCCACATTGGCTAAAAC 2230
              ||||||||||||||||||||
Db         20 AGGGCCACATTGGCTAAAAC 1


RESULT 22
US-09-966-451-72/c
; Sequence 72, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 72
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-72

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 CATTGGCTAAAACCTAAAGG 2237
              ||||||||||||||||||||
Db         20 CATTGGCTAAAACCTAAAGG 1


RESULT 23
US-09-966-451-73/c
; Sequence 73, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 73
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-73

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2223 GCTAAAACCTAAAGGTGGCC 2242
```

```
                    ||||||||||||||||||||
Db         20 GCTAAAACCTAAAGGTGGCC 1


RESULT 24
US-09-966-451-74/c
; Sequence 74, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 74
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-74

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2236 GGTGGCCTCTAGGAGATGAG 2255
                ||||||||||||||||||||
Db         20 GGTGGCCTCTAGGAGATGAG 1


RESULT 25
US-09-966-451-75/c
; Sequence 75, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 75
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-75

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2256 ACCTACCTTCCAGTTGTCAG 2275
                ||||||||||||||||||||
Db         20 ACCTACCTTCCAGTTGTCAG 1


RESULT 26
US-09-966-451-76/c
; Sequence 76, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-76

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2267 AGTTGTCAGCAAGCAGGAAA 2286
                ||||||||||||||||||||
Db         20 AGTTGTCAGCAAGCAGGAAA 1


RESULT 27
US-09-966-451-77/c
; Sequence 77, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 77
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-77

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2364 AAGCTTCAGATGATAACCAC 2383
                ||||||||||||||||||||
Db         20 AAGCTTCAGATGATAACCAC 1


RESULT 28
US-09-966-451-78/c
; Sequence 78, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 78
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-78

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2377 TAACCACAGCCTGGGCTGAC 2396
                ||||||||||||||||||||
```

```
Db         20 TAACCACAGCCTGGGCTGAC 1


RESULT 29
US-09-966-451-79/c
; Sequence 79, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/09/966,451
;  CURRENT FILING DATE:  2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 79
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-79

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2419 ATCCTCAGTATGAGAATCTA 2438
             ||||||||||||||||||||
Db         20 ATCCTCAGTATGAGAATCTA 1


RESULT 30
US-10-630-399-52/c
; Sequence 52, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 52
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-52

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1548 GACAGTGGTTATTAAAGCAT 1567
             ||||||||||||||||||||
Db         20 GACAGTGGTTATTAAAGCAT 1


RESULT 31
US-10-630-399-53/c
; Sequence 53, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 53
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-53

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1560 TAAAGCATGGGTTGAACTTC 1579
             ||||||||||||||||||||
Db         20 TAAAGCATGGGTTGAACTTC 1


RESULT 32
US-10-630-399-54/c
; Sequence 54, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 54
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-54

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1646 TACAGTAATCCCTGAGAAAT 1665
             ||||||||||||||||||||
Db         20 TACAGTAATCCCTGAGAAAT 1


RESULT 33
US-10-630-399-55/c
; Sequence 55, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 55
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-55
```

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1674 AGCATCACCAAACACAGTTT 1693
||||||||||||||||||||
Db 20 AGCATCACCAAACACAGTTT 1

RESULT 34
US-10-630-399-56/c
; Sequence 56, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-56

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1711 CAAAAAGAGCCTGGGCTGTA 1730
||||||||||||||||||||
Db 20 CAAAAAGAGCCTGGGCTGTA 1

RESULT 35
US-10-630-399-57/c
; Sequence 57, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-57

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1720 CCTGGGCTGTATGTAGGGTG 1739
||||||||||||||||||||
Db 20 CCTGGGCTGTATGTAGGGTG 1

RESULT 36
US-10-630-399-58/c
; Sequence 58, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-58

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1737 GTGGAAACACTCTGATCTGA 1756
||||||||||||||||||||
Db 20 GTGGAAACACTCTGATCTGA 1

RESULT 37
US-10-630-399-59/c
; Sequence 59, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-59

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1756 AAGCCCAGCTGACTCCACTA 1775
||||||||||||||||||||
Db 20 AAGCCCAGCTGACTCCACTA 1

RESULT 38
US-10-630-399-60/c
; Sequence 60, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451

```
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-60

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1810 CTGCTGTGAGCCACTAATAA 1829
             ||||||||||||||||||||
Db         20 CTGCTGTGAGCCACTAATAA 1


RESULT 39
US-10-630-399-61/c
; Sequence 61, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 61
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-61

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1829 ACATTGGGCTAATATCTGCT 1848
             ||||||||||||||||||||
Db         20 ACATTGGGCTAATATCTGCT 1


RESULT 40
US-10-630-399-62/c
; Sequence 62, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-62

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1846 GCTGTGCTTCTCTGACAGGT 1865
             ||||||||||||||||||||
Db         20 GCTGTGCTTCTCTGACAGGT 1


RESULT 41
US-10-630-399-63/c
; Sequence 63, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS]
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 63
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-63

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1854 TCTCTGACAGGTAGTCATGA 1873
             ||||||||||||||||||||
Db         20 TCTCTGACAGGTAGTCATGA 1


RESULT 42
US-10-630-399-64/c
; Sequence 64, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS]
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 64
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-64

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1894 TATACAAGCACTTTGTAAAT 1913
             ||||||||||||||||||||
Db         20 TATACAAGCACTTTGTAAAT 1


RESULT 43
US-10-630-399-65/c
; Sequence 65, Application US/10630399
```

```
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 65
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-65

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1951 TTACAAAATCCTATTAGTCA 1970
             ||||||||||||||||||||
Db         20 TTACAAAATCCTATTAGTCA 1


RESULT 44
US-10-630-399-66/c
; Sequence 66, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 66
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-66

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1985 GTGTTCACAGCAATCATTTA 2004
             ||||||||||||||||||||
Db         20 GTGTTCACAGCAATCATTTA 1


RESULT 45
US-10-630-399-67/c
; Sequence 67, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 67
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-67

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2066 TTACATGACAAAGTTGAAGG 2085
             ||||||||||||||||||||
Db         20 TTACATGACAAAGTTGAAGG 1


RESULT 46
US-10-630-399-68/c
; Sequence 68, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 68
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-68

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2089 TTGGCAGATGCAGTTAAGGT 2108
             ||||||||||||||||||||
Db         20 TTGGCAGATGCAGTTAAGGT 1


RESULT 47
US-10-630-399-69/c
; Sequence 69, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 69
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-69

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2137 AAAGGGCCTGACCTAATCCA 2156
             ||||||||||||||||||||
Db         20 AAAGGGCCTGACCTAATCCA 1


RESULT 48
US-10-630-399-70/c
; Sequence 70, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 70
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-70

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2191 GCCTTGAAGAAGTATGTGAG 2210
             ||||||||||||||||||||
Db         20 GCCTTGAAGAAGTATGTGAG 1


RESULT 49
US-10-630-399-71/c
; Sequence 71, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 71
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-71

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2211 AGGGCCACATTGGCTAAAAC 2230
             ||||||||||||||||||||
Db         20 AGGGCCACATTGGCTAAAAC 1


RESULT 50
US-10-630-399-72/c
; Sequence 72, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS]
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 72
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-72

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2218 CATTGGCTAAAACCTAAAGG 2237
             ||||||||||||||||||||
Db         20 CATTGGCTAAAACCTAAAGG 1


RESULT 51
US-10-630-399-73/c
; Sequence 73, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS]
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 73
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-73

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2223 GCTAAAACCTAAAGGTGGCC 2242
             ||||||||||||||||||||
Db         20 GCTAAAACCTAAAGGTGGCC 1


RESULT 52
US-10-630-399-74/c
; Sequence 74, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS]
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 74
;   LENGTH: 20
```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-74

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2236 GGTGGCCTCTAGGAGATGAG 2255
||||||||||||||||||||
Db 20 GGTGGCCTCTAGGAGATGAG 1

RESULT 53
US-10-630-399-75/c
; Sequence 75, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-75

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2256 ACCTACCTTCCAGTTGTCAG 2275
||||||||||||||||||||
Db 20 ACCTACCTTCCAGTTGTCAG 1

RESULT 54
US-10-630-399-76/c
; Sequence 76, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-76

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2267 AGTTGTCAGCAAGCAGGAAA 2286
||||||||||||||||||||
Db 20 AGTTGTCAGCAAGCAGGAAA 1

RESULT 55
US-10-630-399-77/c
; Sequence 77, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-77

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2364 AAGCTTCAGATGATAACCAC 2383
||||||||||||||||||||
Db 20 AAGCTTCAGATGATAACCAC 1

RESULT 56
US-10-630-399-78/c
; Sequence 78, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-78

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2377 TAACCACAGCCTGGGCTGAC 2396
||||||||||||||||||||
Db 20 TAACCACAGCCTGGGCTGAC 1

RESULT 57
US-10-630-399-79/c
; Sequence 79, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier

```
;  TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
;  FILE REFERENCE: RTS-0324
;  CURRENT APPLICATION NUMBER: US/10/630,399
;  CURRENT FILING DATE:  2003-07-30
;  PRIOR APPLICATION NUMBER: US/09/966,451
;  PRIOR FILING DATE: 2001-09-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 79
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-79

  Query Match             2.2%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2419 ATCCTCAGTATGAGAATCTA 2438
             ||||||||||||||||||||
Db         20 ATCCTCAGTATGAGAATCTA 1


RESULT 58
US-10-751-736-29540
; Sequence 29540, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  Martinez, Robert
;  APPLICANT:  Brown, Eugene
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
;  TITLE OF INVENTION:  CANCERS
;  FILE REFERENCE: AM100927 (031896-002000)
;  CURRENT APPLICATION NUMBER: US/10/751,736
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
;  PRIOR FILING DATE: 2003-01-06
;  NUMBER OF SEQ ID NOS: 54873
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29540
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi
US-10-751-736-29540

  Query Match             1.9%;  Score 17.4;  DB 1;  Length 21;
  Best Local Similarity   57.9%;  Pred. No. 30;
  Matches   11;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1984 TGTGTTCACAGCAATCATT 2002
              :|:|::|||||||:| ::
Db          3 UGUGUUCACAGCAAUCUUU 21


RESULT 59
US-10-060-998-1545/c
; Sequence 1545, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1545
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-1545

  Query Match             1.7%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 54;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAGCC 1760
              ||||||||||||||||
Db         17 ACTCTGATCTGAAGCC 2


RESULT 60
US-10-060-998-1546/c
; Sequence 1546, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1546
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-1546

  Query Match             1.7%;  Score 16;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 54;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAGCC 1760
              ||||||||||||||||
Db         16 ACTCTGATCTGAAGCC 1


RESULT 61
US-10-349-143-11728
; Sequence 11728, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11728
;   LENGTH: 19
```

```
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-3884 for SEQ 3863, in compleme
US-10-349-143-11728

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2146 GACCTAATCCAAGTGAACC 2164
              || | ||||||||||||||||
Db          1 GAACAAATCCAAGTGAACC 19


RESULT 62
US-10-665-951-369/c
; Sequence 369, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 369
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-369

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   89.5%;  Pred. No. 51;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1893 ATATACAAGCACTTTGTAA 1911
              ||  ||||||||||||||||
Db         19 ATGAACAAGCACTTTGTAA 1


RESULT 63
US-10-665-951-796
; Sequence 796, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 796
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-796

  Query Match             1.7%;  Score 15.8;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 51;
  Matches   12;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1893 ATATACAAGCACTTTGTAA 1911
              |:  ||||||||:::|:||
Db          1 AUGAACAAGCACUUUGUAA 19


RESULT 64
US-10-060-998-1543/c
; Sequence 1543, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1543
```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1543

  Query Match 1.7%; Score 15.4; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 64;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1747 TCTGATCTGAAGCCCAG 1763
         ||||||||||||||| ||
Db 17 TCTGATCTGAAGCCAAG 1

RESULT 65
US-10-060-998-1544/c
; Sequence 1544, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1544
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1544

  Query Match 1.7%; Score 15.4; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 64;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1746 CTCTGATCTGAAGCCCA 1762
         |||||||||||||||| |
Db 17 CTCTGATCTGAAGCCAA 1

RESULT 66
US-10-138-674-6036/c
; Sequence 6036, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6036
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6036

  Query Match 1.6%; Score 15; DB 1; Length 16;
  Best Local Similarity 100.0%; Pred. No. 75;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1897 ACAAGCACTTTGTAA 1911
         |||||||||||||||
Db 16 ACAAGCACTTTGTAA 2

RESULT 67
US-10-287-949A-6036/c
; Sequence 6036, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6036
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6036

  Query Match 1.6%; Score 15; DB 1; Length 16;
  Best Local Similarity 100.0%; Pred. No. 75;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1897 ACAAGCACTTTGTAA 1911
         |||||||||||||||
Db 16 ACAAGCACTTTGTAA 2

RESULT 68
US-10-060-998-1547/c
; Sequence 1547, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1547
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1547

  Query Match 1.6%; Score 15; DB 1; Length 17;
  Best Local Similarity 100.0%; Pred. No. 71;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1745 ACTCTGATCTGAAGC 1759
         |||||||||||||||
Db 15 ACTCTGATCTGAAGC 1

RESULT 69
US-10-138-674-8189/c

; Sequence 8189, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8189
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8189

Query Match 1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1897 ACAAGCACTTTGTAA 1911
||||||||||||||||
Db 16 ACAAGCACTTTGTAA 2

RESULT 70
US-10-287-949A-8189/c
; Sequence 8189, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8189
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8189

Query Match 1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1897 ACAAGCACTTTGTAA 1911
||||||||||||||||
Db 16 ACAAGCACTTTGTAA 2

RESULT 71
US-10-712-633-1450/c
; Sequence 1450, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND (
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1450
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1450

Query Match 1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1897 ACAAGCACTTTGTAA 1911
||||||||||||||||
Db 16 ACAAGCACTTTGTAA 2

RESULT 72
US-10-455-552-74/c
; Sequence 74, Application US/10455552
; Publication No. US20040018533A1
; GENERAL INFORMATION:
; APPLICANT: Adam, Gail Isabel
; APPLICANT: Langdown, Maria
; APPLICANT: Roth, Richard
; APPLICANT: Denissenko, Mikhail
; APPLICANT: Smylie, Kevin
; TITLE OF INVENTION: DIAGNOSING PREDISPOSITION TO FAT
; TITLE OF INVENTION: DEPOSITION AND THERAPEUTIC METHODS FOR REDUCING FAT
; TITLE OF INVENTION: DEPOSITION AND TREATMENT OF ASSOCIATED CONDITIONS
; FILE REFERENCE: 52459-20030.00
; CURRENT APPLICATION NUMBER: US/10/455,552
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: US 60/386,012
; PRIOR FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 98
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-455-552-74

Query Match 1.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2374 TGATAACCACAGCCTGGG 2391
| | ||||||||||||||
Db 18 TTAAAACCACAGCCTGGG 1

```
RESULT 73
US-09-730-289B-1033
; Sequence 1033, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1033
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-1033

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 82;
  Matches    6;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2052 ATTATTAGATTATGTT 2067
              |::|::|||::|: ::
Db          1 AUUAUUAGAUUAUAUU 16


RESULT 74
US-09-730-289B-1122
; Sequence 1122, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1122
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-1122

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 82;
  Matches    6;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2052 ATTATTAGATTATGTT 2067
              |::|::|||::|: ::
Db          2 AUUAUUAGAUUAUAUU 17


RESULT 75
US-10-060-998-1542/c
; Sequence 1542, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1542
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-1542

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 82;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1748 CTGATCTGAAGCCCAG 1763
              |||||||||||||  ||
Db         17 CTGATCTGAAGCCAAG 2


RESULT 76
US-09-969-373-1804
; Sequence 1804, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1804
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-1804

  Query Match             1.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 78;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1597 GCCACCATATCAACAC 1612
              |||||||| |||||||
Db          3 GCCACCATCTCAACAC 18


RESULT 77
US-10-060-998-1548/c
; Sequence 1548, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
```

```
; SEQ ID NO 1548
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-1548

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 ACTCTGATCTGAAG 1758
              ||||||||||||||
Db         14 ACTCTGATCTGAAG 1


RESULT 78
US-10-156-306-71
; Sequence 71, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 71
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-71

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 91;
  Matches    7;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1905 TTTGTAAATTGTAA 1918
              :::|:|||::|:||
Db          4 UUUGUAAAUUGUAA 17


RESULT 79
US-10-156-306-2713
; Sequence 2713, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2713
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-2713

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 91;
  Matches    7;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1905 TTTGTAAATTGTAA 1918
              :::|:|||::|:||
Db          2 UUUGUAAAUUGUAA 15


RESULT 80
US-10-138-674-2154/c
; Sequence 2154, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2154
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-2154

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 81
US-10-138-674-2779/c
; Sequence 2779, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2779
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-2779

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 82
US-10-138-674-8190/c
; Sequence 8190, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
```

```
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8190
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-8190

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1897 ACAAGCACTTTGTA 1910
             ||||||||||||||
Db         14 ACAAGCACTTTGTA 1


RESULT 83
US-10-138-674-9127/c
; Sequence 9127, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9127
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-9127

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
             ||||||||||||||
Db         16 ATGAAAATCAAATG 3


RESULT 84
US-10-287-949A-2154/c
; Sequence 2154, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2154
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-2154

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
             ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 85
US-10-287-949A-2779/c
; Sequence 2779, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2779
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-2779

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
             ||||||||||||||
Db         14 ATGAAAATCAAATG 1


RESULT 86
US-10-287-949A-8190/c
; Sequence 8190, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8190
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-8190

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1897 ACAAGCACTTTGTA 1910
              ||||||||||||||
Db         14 ACAAGCACTTTGTA 1


RESULT 87
US-10-287-949A-9127/c
; Sequence 9127, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9127
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-9127

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         16 ATGAAAATCAAATG 3


RESULT 88
US-10-712-633-1451/c
; Sequence 1451, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Sandberg, Jennifer
;  APPLICANT:  Gordon, Gilad
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
;  TITLE OF INVENTION:  RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
;  FILE REFERENCE: MBHB02-325PCT (400/047)
;  CURRENT APPLICATION NUMBER: US/10/712,633
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  PRIOR APPLICATION NUMBER: US 09/708,690
;  PRIOR FILING DATE: 2000-11-07
;  PRIOR APPLICATION NUMBER: US 09/870,161
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 60/334,461
;  PRIOR FILING DATE: 2001-11-30
;  PRIOR APPLICATION NUMBER: US 10/138,674
;  PRIOR FILING DATE: 2002-05-03
;  NUMBER OF SEQ ID NOS: 5989
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1451
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-10-712-633-1451

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1897 ACAAGCACTTTGTA 1910
              ||||||||||||||
Db         14 ACAAGCACTTTGTA 1


RESULT 89
US-10-712-633-4397/c
; Sequence 4397, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Sandberg, Jennifer
;  APPLICANT:  Gordon, Gilad
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
;  TITLE OF INVENTION:  RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND C
;  FILE REFERENCE: MBHB02-325PCT (400/047)
;  CURRENT APPLICATION NUMBER: US/10/712,633
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  PRIOR APPLICATION NUMBER: US 09/371,772
;  PRIOR FILING DATE: 1999-08-10
;  PRIOR APPLICATION NUMBER: US 09/708,690
;  PRIOR FILING DATE: 2000-11-07
;  PRIOR APPLICATION NUMBER: US 09/870,161
;  PRIOR FILING DATE: 2001-05-29
;  PRIOR APPLICATION NUMBER: US 60/334,461
;  PRIOR FILING DATE: 2001-11-30
;  PRIOR APPLICATION NUMBER: US 10/138,674
;  PRIOR FILING DATE: 2002-05-03
;  NUMBER OF SEQ ID NOS: 5989
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4397
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-10-712-633-4397

  Query Match             1.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATG 1883
              ||||||||||||||
Db         16 ATGAAAATCAAATG 3


RESULT 90
US-09-866-108-2781
; Sequence 2781, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
```

; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2781
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2781

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1666 CTCCTTCAAGCATCACC 1682
| |||||||||| ||||
Db 1 CACCTTCAAGCACCACC 17

RESULT 91
US-09-877-478-474
; Sequence 474, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 474
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-474

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 96;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2081 GAAGGAATTTGGCAGAT 2097
|||| ||:::|| |||:
Db 1 GAAGUAAUUUGGAAGAU 17

RESULT 92
US-09-877-478-2127/c
; Sequence 2127, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2127
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2127

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1824 TAATAACATTGGGCTAA 1840
|| |||||||||| |||
Db 17 TAGTAACATTGGGATAA 1

RESULT 93
US-09-848-754A-1182
; Sequence 1182, Application US/09848754A
; Publication No. US20030073207A1

```
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1182
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-1182

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 96;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2280 CAGGAAAAAAAAATTGG 2296
              ||||||| |||||:: |
Db          1 CAGGAAACAAAAAUUUG 17


RESULT 94
US-09-827-395A-50
; Sequence 50, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;  FILE REFERENCE: MBHB00-878-C (400/017)
;  CURRENT APPLICATION NUMBER: US/09/827,395A
;  CURRENT FILING DATE:  2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 50
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-827-395A-50

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 96;
  Matches    8;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2428 ATGAGAATCTATCTGTT 2444
              |:|| | :|:|:|:|::
Db          1 AUGACACUCUAUCUGUU 17


RESULT 95
US-10-060-998-1033/c
; Sequence 1033, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1033
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-1033

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2274 AGCAAGCAGGAAAAAAA 2290
              || |||||||||||| |
Db         17 AGAAAGCAGGAAAAACA 1


RESULT 96
US-10-156-306-2769/c
; Sequence 2769, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2769
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-2769

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1657 CTGAGAAATCTCCTTCA 1673
              ||||||| || ||||||
Db         17 CTGAGAAGTCACCTTCA 1


RESULT 97
US-10-238-700-951/c
; Sequence 951, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 951
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-951

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1877 TCAAATGATGCAAAATA 1893
              ||||||||| ||| |||
Db         17 TCAAATGATACAATATA 1

RESULT 98
US-10-061-201-697/c
; Sequence 697, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 697
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-697

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2042 TGATATGTCCATTATTA 2058
              |||||| ||| ||||||
Db         17 TGATATCTCCCTTATTA 1

RESULT 99
US-10-061-201-698/c
; Sequence 698, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 698
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-698

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2041 ATGATATGTCCATTATT 2057
              ||||||| ||| |||||
Db         17 ATGATATCTCCCTTATT 1

RESULT 100
US-10-430-882-50
; Sequence 50, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  APPLICANT:  Peter Haeberli
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Ge
;  FILE REFERENCE: MBHB00-878-H (400/112)
;  CURRENT APPLICATION NUMBER: US/10/430,882
;  CURRENT FILING DATE:  2003-05-06
;  PRIOR APPLICATION NUMBER: 09/827,395
;  PRIOR FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: PCT/US01/04273
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  PRIOR APPLICATION NUMBER: PCT/US02/10512
;  PRIOR FILING DATE: 2002-04-03
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 50
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-430-882-50

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 96;
  Matches    8;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2428 ATGAGAATCTATCTGTT 2444
              |:|| | :|:|:|:|::
Db          1 AUGACACUCUAUCUGUU 17

RESULT 101
US-10-342-902-474
; Sequence 474, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 474
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-474

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 96;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2081 GAAGGAATTTGGCAGAT 2097
              |||| ||:::|| |||:
Db          1 GAAGUAAUUUGGAAGAU 17


RESULT 102
US-10-342-902-2127/c
; Sequence 2127, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2127
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-2127

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1824 TAATAACATTGGGCTAA 1840
              || |||||||||| |||
Db         17 TAGTAACATTGGGATAA 1


RESULT 103
US-10-138-674-2153/c
; Sequence 2153, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2153
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-2153

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              |||||||||||||  ||
Db         17 TGAAAATCAAATGCGGC 1


RESULT 104
US-10-138-674-2778/c
; Sequence 2778, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2778
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-2778

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              |||||||||||||  ||
```

```
Db         17 TGAAAATCAAATGTGGC 1


RESULT 105
US-10-138-674-5483/c
; Sequence 5483, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5483
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5483

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1899 AAGCACTTTGTAAATTG 1915
              ||||||||||||| | |
Db         17 AAGCACTTTGTAACTAG 1


RESULT 106
US-10-138-674-9343
; Sequence 9343, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9343
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-9343

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 96;
  Matches   10;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2453 GACTTCTAATATATAGA 2469
              |||:: :|| |:|:|||
Db          1 GACUUUUAACAUAUAGA 17


RESULT 107
US-10-138-674-9377
; Sequence 9377, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9377
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-9377

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 96;
  Matches    7;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1970 ATATATTTATAGATTGT 1986
              |:|:|:::|:||  :|:
Db          1 AUAUAUUUAUAGUCUGU 17


RESULT 108
US-10-287-949A-2153/c
; Sequence 2153, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2153
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-2153

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 TGAAAATCAAATGATGC 1887
              ||||||||||||||  ||
Db         17 TGAAAATCAAATGCGGC 1


RESULT 109
US-10-287-949A-2778/c
; Sequence 2778, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
```

; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2778
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2778

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1871 TGAAAATCAAATGATGC 1887
||||||||||||| ||
Db 17 TGAAAATCAAATGTGGC 1

RESULT 110
US-10-287-949A-5483/c
; Sequence 5483, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5483
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5483

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1899 AAGCACTTTGTAAATTG 1915
||||||||||||| | |
Db 17 AAGCACTTTGTAACTAG 1

RESULT 111
US-10-287-949A-9343
; Sequence 9343, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9343
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-9343

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 96;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2453 GACTTCTAATATATAGA 2469
||||: :|| |:|:|||
Db 1 GACUUUUAACAUAUAGA 17

RESULT 112
US-10-287-949A-9377
; Sequence 9377, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9377
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-9377

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 96;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 1970 ATATATTTATAGATTGT 1986
|:|:|:::|:|| :|:
Db 1 AUAUAUUUAUAGUCUGU 17

RESULT 113
US-10-669-841-474
; Sequence 474, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26

```
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 474
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-474

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 96;
  Matches   11;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2081 GAAGGAATTTGGCAGAT 2097
              |||| ||:::|| |||:
Db          1 GAAGUAAUUUGGAAGAU 17


RESULT 114
US-10-669-841-1968/c
; Sequence 1968, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1968
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-1968

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1824 TAATAACATTGGGCTAA 1840
              || |||||||||| |||
Db         17 TAGTAACATTGGGATAA 1


RESULT 115
US-10-723-361-2781
; Sequence 2781, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2781
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-2781

  Query Match             1.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 96;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1666 CTCCTTCAAGCATCACC 1682
              | |||||||||| ||||
Db          1 CACCTTCAAGCACCACC 17


RESULT 116
US-10-712-633-4614
; Sequence 4614, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pamela
;  APPLICANT:  Sandberg, Jennifer
;  APPLICANT:  Gordon, Gilad
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Stinchcomb, Dan
```

; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-4614

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 96;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2453 GACTTCTAATATATAGA 2469
||||:: :|| |:|:|||
Db 1 GACUUUUAACAUAUAGA 17

RESULT 117
US-10-712-633-4648
; Sequence 4648, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4648
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-4648

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 96;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 1970 ATATATTTATAGATTGT 1986
|:|:|:::|:|| :|:
Db 1 AUAUAUUUAUAGUCUGU 17

RESULT 118
US-10-043-875-177/c
; Sequence 177, Application US/10043875
; Publication No. US20030054339A1
; GENERAL INFORMATION:
; APPLICANT: De Smet, Koenraad
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for Detection of Drug-Induced Mutations in the HIV Reverse
; TITLE OF INVENTION: Transcriptase Gene
; FILE REFERENCE: 11362-0033-NPUS01 (INNS:033)
; CURRENT APPLICATION NUMBER: US/10/043,875
; CURRENT FILING DATE: 2002-04-03
; PRIOR APPLICATION NUMBER: 60/286,102
; PRIOR FILING DATE: 2001-04-24
; PRIOR APPLICATION NUMBER: EP 01870085.6
; PRIOR FILING DATE: 2001-04-20
; PRIOR APPLICATION NUMBER: EP 01870005.4
; PRIOR FILING DATE: 2001-01-11
; NUMBER OF SEQ ID NOS: 884
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 177
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-043-875-177

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1969 CATATATTTATAGAT 1983
||||||| ||||||
Db 16 CATATATTGATAGAT 2

RESULT 119
US-10-131-827-3266/c
; Sequence 3266, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
; TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131,827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3266
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-3266

Query Match 1.4%; Score 13.2; DB 1; Length 50;
Best Local Similarity 61.8%; Pred. No. 38;

```
  Matches   21;  Conservative    0;  Mismatches   13;  Indels    0;  Gaps    0;

Qy       1883 GATGCAAAATATATACAAGCACTTTGTAAATTGT 1916
              || ||| |  | |||  ||| |  ||| | | ||
Db         37 GAAGCACAGCAGATATTAGCCCAATGTTATTAGT 4


RESULT 120
US-10-257-017B-12919
; Sequence 12919, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 12919
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0003014
US-10-257-017B-12919

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1582 AAATATAAAAATA 1594
              |||||||||||||
Db          1 AAATATAAAAATA 13


RESULT 121
US-10-257-017B-12920/c
; Sequence 12920, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 12920
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0003014
US-10-257-017B-12920

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1582 AAATATAAAAATA 1594
              |||||||||||||
Db         13 AAATATAAAAATA 1


RESULT 122
US-10-257-017B-23771/c
; Sequence 23771, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 23771
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0005308
US-10-257-017B-23771

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAAT 1593
              |||||||||||||
Db         13 AAAATATAAAAAT 1


RESULT 123
US-10-257-017B-23772
; Sequence 23772, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 23772
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0005308
US-10-257-017B-23772

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAAT 1593
              |||||||||||||
Db          1 AAAATATAAAAAT 13


RESULT 124
US-10-257-017B-50497/c
; Sequence 50497, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
```

```
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 50497
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0014187
US-10-257-017B-50497

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1888 AAAATATATACAA 1900
             |||||||||||||
Db         13 AAAATATATACAA 1


RESULT 125
US-10-257-017B-50498
; Sequence 50498, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 50498
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0014187
US-10-257-017B-50498

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1888 AAAATATATACAA 1900
             |||||||||||||
Db          1 AAAATATATACAA 13


RESULT 126
US-10-257-017B-52315/c
; Sequence 52315, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 52315
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0014536
US-10-257-017B-52315

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2008 ACAAATAAAATAT 2020
             |||||||||||||
Db         13 ACAAATAAAATAT 1


RESULT 127
US-10-257-017B-52316
; Sequence 52316, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 52316
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0014536
US-10-257-017B-52316

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2008 ACAAATAAAATAT 2020
             |||||||||||||
Db          1 ACAAATAAAATAT 13


RESULT 128
US-10-257-017B-100801
; Sequence 100801, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 100801
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0025074
US-10-257-017B-100801

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1972 ATATTTATAGATT 1984
||||||||||||
Db 1 ATATTTATAGATT 13

RESULT 129
US-10-257-017B-100802/c
; Sequence 100802, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 100802
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0025074
US-10-257-017B-100802

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1972 ATATTTATAGATT 1984
||||||||||||
Db 13 ATATTTATAGATT 1

RESULT 130
US-10-257-017B-132137/c
; Sequence 132137, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 132137
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032979
US-10-257-017B-132137

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1580 CAAAATATAAAAA 1592
||||||||||||
Db 13 CAAAATATAAAAA 1

RESULT 131
US-10-257-017B-132138
; Sequence 132138, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 132138
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032979
US-10-257-017B-132138

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1580 CAAAATATAAAAA 1592
||||||||||||
Db 1 CAAAATATAAAAA 13

RESULT 132
US-10-257-017B-162297/c
; Sequence 162297, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 162297
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0009377
US-10-257-017B-162297

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1770 CCACTACTAATTT 1782
||||||||||||
Db 13 CCACTACTAATTT 1

RESULT 133
US-10-257-017B-162298

; Sequence 162298, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 162298
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0009377
US-10-257-017B-162298

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1770 CCACTACTAATTT 1782
||||||||||||
Db 1 CCACTACTAATTT 13

RESULT 134
US-10-257-017B-179793
; Sequence 179793, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 179793
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0044520
US-10-257-017B-179793

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1585 TATAAAAATAGAG 1597
||||||||||||
Db 1 TATAAAAATAGAG 13

RESULT 135
US-10-257-017B-179794/c
; Sequence 179794, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 179794
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0044520
US-10-257-017B-179794

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1585 TATAAAAATAGAG 1597
||||||||||||
Db 13 TATAAAAATAGAG 1

RESULT 136
US-10-257-017B-193759/c
; Sequence 193759, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 193759
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0047657
US-10-257-017B-193759

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1951 TTACAAAATCCTA 1963
||||||||||||
Db 13 TTACAAAATCCTA 1

RESULT 137
US-10-257-017B-193760
; Sequence 193760, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046

; SEQ ID NO 193760
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0047657
US-10-257-017B-193760

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1951 TTACAAAATCCTA 1963
||||||||||||
Db 1 TTACAAAATCCTA 13

RESULT 138
US-10-257-017B-202391/c
; Sequence 202391, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 202391
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0008339
US-10-257-017B-202391

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1887 CAAAATATATACA 1899
||||||||||||
Db 13 CAAAATATATACA 1

RESULT 139
US-10-257-017B-202392
; Sequence 202392, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 202392
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0008339
US-10-257-017B-202392

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1887 CAAAATATATACA 1899
||||||||||||
Db 1 CAAAATATATACA 13

RESULT 140
US-10-257-017B-215295/c
; Sequence 215295, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 215295
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006400
US-10-257-017B-215295

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1821 CACTAATAACATT 1833
||||||||||||
Db 13 CACTAATAACATT 1

RESULT 141
US-10-257-017B-215296
; Sequence 215296, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 215296
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006400
US-10-257-017B-215296

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1821 CACTAATAACATT 1833
||||||||||||

```
Db          1 CACTAATAACATT 13


RESULT 142
US-10-257-017B-247011
; Sequence 247011, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 247011
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0060369
US-10-257-017B-247011

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 ATTTATAGATTGT 1986
              |||||||||||||
Db          1 ATTTATAGATTGT 13


RESULT 143
US-10-257-017B-247012/c
; Sequence 247012, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 247012
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0060369
US-10-257-017B-247012

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 ATTTATAGATTGT 1986
              |||||||||||||
Db         13 ATTTATAGATTGT 1

RESULT 144
US-10-257-017B-253051
; Sequence 253051, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 253051
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006570
US-10-257-017B-253051

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1908 GTAAATTGTAAAA 1920
              |||||||||||||
Db          1 GTAAATTGTAAAA 13


RESULT 145
US-10-257-017B-253052/c
; Sequence 253052, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 253052
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006570
US-10-257-017B-253052

  Query Match             1.4%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1908 GTAAATTGTAAAA 1920
              |||||||||||||
Db         13 GTAAATTGTAAAA 1

RESULT 146
US-10-140-293-6
; Sequence 6, Application US/10140293
; Publication No. US20030022833A1
; GENERAL INFORMATION:
;  APPLICANT: CHEN, WEN Y.
;  APPLICANT:  WAGNER, THOMAS E.
;  TITLE OF INVENTION: USE OF ANTI-PROLACTIN AGENTS TO TREAT PORLIFERATIVE
;  TITLE OF INVENTION:  CONDITIONS
;  FILE REFERENCE: 035879/0109
;  CURRENT APPLICATION NUMBER: US/10/140,293
```

```
;  CURRENT FILING DATE:  2002-05-08
;  PRIOR APPLICATION NUMBER: US/09/246,041
;  PRIOR FILING DATE: 1999-02-05
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-140-293-6

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 ATGAAAATCAAATGAT 1885
              ||||| |||||| |||
Db          1 ATGAACATCAAAGGAT 16


RESULT 147
US-10-138-674-6037/c
; Sequence 6037, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6037
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-6037

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1893 ATATACAAGCACTTTG 1908
              ||  ||||||||||||
Db         16 ATGAACAAGCACTTTG 1


RESULT 148
US-10-138-674-7113
; Sequence 7113, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7113
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7113

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 1.3e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 GAAATCTCCTTCAAGC 1676
              ||||:|:| : |||||
Db          1 GAAAUCUCUUGCAAGC 16


RESULT 149
US-10-287-949A-6037/c
; Sequence 6037, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6037
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6037

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 1.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1893 ATATACAAGCACTTTG 1908
              ||  ||||||||||||
Db         16 ATGAACAAGCACTTTG 1


RESULT 150
US-10-287-949A-7113
; Sequence 7113, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7113
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7113

  Query Match             1.4%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   68.8%;  Pred. No. 1.3e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 GAAATCTCCTTCAAGC 1676
```

```
                ||||:|:| : |||||
Db          1 GAAAUCUCUUGCAAGC 16


RESULT 151
US-10-257-017B-4851
; Sequence 4851, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 4851
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0001714
US-10-257-017B-4851

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 1.7e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2057 TAGATTATGTTAC 2069
                ||||||||||||:
Db          1 TAGATTATGTTAY 13


RESULT 152
US-10-257-017B-4852/c
; Sequence 4852, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 4852
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0001714
US-10-257-017B-4852

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 1.7e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2057 TAGATTATGTTAC 2069
                ||||||||||||:
Db         13 TAGATTATGTTAY 1


RESULT 153
US-10-257-017B-14279/c
; Sequence 14279, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 14279
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0003242
US-10-257-017B-14279

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 1.7e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1888 AAAATATATACAA 1900
                :||||||||||||
Db         13 RAAATATATACAA 1


RESULT 154
US-10-257-017B-14280
; Sequence 14280, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
;  FILE REFERENCE: E01/1193/WO
;  CURRENT APPLICATION NUMBER: US/10/257,017B
;  CURRENT FILING DATE:  2002-10-07
;  PRIOR APPLICATION NUMBER: DE 10019173.8
;  PRIOR FILING DATE: 2000-04-07
;  NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 14280
;   LENGTH: 13
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0003242
US-10-257-017B-14280

  Query Match             1.4%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 1.7e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1888 AAAATATATACAA 1900
                :||||||||||||
Db          1 RAAATATATACAA 13


RESULT 155
US-10-257-017B-31913/c
; Sequence 31913, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
;  APPLICANT: Alexander Olek
;  APPLICANT:  Christian Piepenbrock
;  APPLICANT:  Kurt Berlin
;  TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
;  TITLE OF INVENTION:  methylations
```

; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 31913
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0009939
US-10-257-017B-31913

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1997 ATCATTTAACCAC 2009
:||||||||||||
Db 13 RTCATTTAACCAC 1

RESULT 156
US-10-257-017B-31914
; Sequence 31914, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 31914
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0009939
US-10-257-017B-31914

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1997 ATCATTTAACCAC 2009
:||||||||||||
Db 1 RTCATTTAACCAC 13

RESULT 157
US-10-257-017B-38179/c
; Sequence 38179, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 38179
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0011829
US-10-257-017B-38179

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1581 AAAATATAAAAAT 1593
:||||||||||||
Db 13 RAAATATAAAAAT 1

RESULT 158
US-10-257-017B-38180
; Sequence 38180, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 38180
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0011829
US-10-257-017B-38180

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1581 AAAATATAAAAAT 1593
:||||||||||||
Db 1 RAAATATAAAAAT 13

RESULT 159
US-10-257-017B-59765/c
; Sequence 59765, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 59765
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0015985
US-10-257-017B-59765

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1582 AAATATAAAAATA 1594
              :||||||||||||
Db         13 RAATATAAAAATA 1
```

RESULT 160
US-10-257-017B-59766
; Sequence 59766, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 59766
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0015985
US-10-257-017B-59766

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1582 AAATATAAAAATA 1594
              :||||||||||||
Db          1 RAATATAAAAATA 13
```

RESULT 161
US-10-257-017B-111489
; Sequence 111489, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 111489
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0027841
US-10-257-017B-111489

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2282 GGAAAAAAAAATT 2294
              ||||||||||||:
Db          1 GGAAAAAAAAATY 13
```

RESULT 162
US-10-257-017B-111490/c
; Sequence 111490, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorhphisms [SNPs] and cytosine
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 111490
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0027841
US-10-257-017B-111490

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2282 GGAAAAAAAAATT 2294
              ||||||||||||:
Db         13 GGAAAAAAAAATY 1
```

Search completed: April 7, 2005, 05:59:34
Job time : 3 secs

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: April 7, 2005, 06:01:58 ; Search time 1 Seconds
(without alignments)
0.192 Million cell updates/sec

Title: US-10-630-399-3
Perfect score: 922
Sequence: 1 gacagtggttattaaagcat.....ctggacttctaatatataga 922

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 8 seqs, 104 residues

Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 9 summaries

Database : rst3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
c	1	13	1.4	16	1	AW250981	ACCESSION:AW250981
	2	12	1.3	12	1	CF331951	ACCESSION:CF331951
	3	10.4	1.1	12	1	CF302060	ACCESSION:CF302060
	4	10.4	1.1	12	1	CF330680	ACCESSION:CF330680
	5	10.4	1.1	13	1	CF291168	ACCESSION:CF291168
	6	10.4	1.1	13	1	CF299609	ACCESSION:CF299609
	7	10.4	1.1	13	1	CF300659	ACCESSION:CF300659
	8	10.4	1.1	13	1	AJ599990	ACCESSION:AJ599990
c	9	10.4	1.1	13	1	AJ599990	ACCESSION:AJ599990

ALIGNMENTS

RESULT 1
AW250981/c
LOCUS AW250981 16 bp mRNA linear EST 07-JAN-2000
DEFINITION 2822267.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2822267 3', mRNA sequence.
ACCESSION AW250981
VERSION AW250981.1 GI:6594070
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 16)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Other_ESTs: 2822267.5prime
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: DCTD/DTP cDNA Library Preparation: Ling Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Berkeley MGC sequencing project Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html Base Calling / Quality Scores: PHRED from University of Washingtion Genome Center. Vector Trimming: cross_match from University of Washingtion Genome Center PHRAP suite. Poly-T Identification: patMatch.pl from Berkeley Drosophila Genome Project. University of Washingtion Genome Center: http://www.genome.washington.edu Low Quality Sequence: 9 contiguous PHRED high quality bases following vector sequence. Very Low Quality Sequence: Trace file contained 16 contiguous distinct peaks following vector sequence. Polyadenylation: Based upon the presence of a XhoI site followed by a run of 14 or more T residues at the beginning of the sequence, this cDNA insert was polyadenylated.
Plate: LLCM8 row: P column: 12
High quality sequence stop: 9.
FEATURES Location/Qualifiers
source 1. .16
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2822267"
/tissue_type="small cell carcinoma"
/cell_line="MGC3"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH_MGC_7"
/note="Organ: lung; Vector: pOTB7; Site_1: XhoI; Site_2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

Query Match 1.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.63;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2280 CAGGAAAAAAAAA 2292
              |||||||||||||
Db         14 CAGGAAAAAAAAA 2
```

RESULT 2
CF331951
LOCUS CF331951 12 bp mRNA linear EST 18-AUG-2003
DEFINITION NACL--08-E07.g1 Rice callus plasmid cDNA library (NACL) Oryza sativa (japonica cultivar-group) cDNA clone NACL--08-E07, mRNA sequence.
ACCESSION CF331951
VERSION CF331951.1 GI:33812123
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 12)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers

```
     source          1. .12
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--08-E07"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             1.3%;  Score 12;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 1.6;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAA 1592
              ||||||||||||
Db          1 AAAATATAAAAA 12


RESULT 3
CF302060
LOCUS       CF302060                  12 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--07-E01.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--07-E01, mRNA
            sequence.
ACCESSION   CF302060
VERSION     CF302060.1  GI:33673821
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="7LEAF--07-E01"
                     /tissue_type="leaf"
                     /dev_stage="7 days after germination"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             1.1%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 4.4;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2268 GTTGTCAGCAAG 2279
              |||| |||||||
Db          1 GTTGACAGCAAG 12


RESULT 4
CF330680
LOCUS       CF330680                  12 bp    mRNA    linear   EST 18-AUG-2003
DEFINITION  NACL--06-H22.g1 Rice callus plasmid cDNA library (NACL) Oryza
            sativa (japonica cultivar-group) cDNA clone NACL--06-H22, mRNA
            sequence.
ACCESSION   CF330680
VERSION     CF330680.1  GI:33809584
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Oryza sativa (japonica cultivar-group)"
                     /mol_type="mRNA"
                     /cultivar="Nackdong"
                     /db_xref="taxon:39947"
                     /clone="NACL--06-H22"
                     /tissue_type="callus"
                     /dev_stage="proliferated callus on 2N6 media for 30 days"
                     /lab_host="E.coli DH10B"
                     /clone_lib="Rice callus plasmid cDNA library (NACL)"
                     /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                     with oligoribonucleotides and then used as templates for
                     RT-PCR."

  Query Match             1.1%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 4.4;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2268 GTTGTCAGCAAG 2279
              |||| |||||||
Db          1 GTTGACAGCAAG 12


RESULT 5
CF291168
LOCUS       CF291168                  13 bp    mRNA    linear   EST 14-AUG-2003
DEFINITION  14ROOT--01-H20.g1 Rice root plasmid cDNA library (14ROOT) Oryza
            sativa (japonica cultivar-group) cDNA clone 14ROOT--01-H20, mRNA
            sequence.
ACCESSION   CF291168
VERSION     CF291168.1  GI:33660201
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
```

```
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .13
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="14ROOT--01-H20"
                      /tissue_type="root"
                      /dev_stage="14 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice root plasmid cDNA library (14ROOT)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             1.1%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 4.1;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAA 1592
              |||||| |||||
Db          2 AAAATAAAAAAA 13


RESULT 6
CF299609
LOCUS       CF299609                 13 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--03-L04.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--03-L04, mRNA
            sequence.
ACCESSION   CF299609
VERSION     CF299609.1  GI:33671370
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .13
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="7LEAF--03-L04"
                      /tissue_type="leaf"
                      /dev_stage="7 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             1.1%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 4.1;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAA 1592
              |||||| |||||
Db          1 AAAATTTAAAAA 12


RESULT 7
CF300659
LOCUS       CF300659                 13 bp    mRNA    linear   EST 15-AUG-2003
DEFINITION  7LEAF--05-D14.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
            sativa (japonica cultivar-group) cDNA clone 7LEAF--05-D14, mRNA
            sequence.
ACCESSION   CF300659
VERSION     CF300659.1  GI:33672420
KEYWORDS    EST.
SOURCE      Oryza sativa (japonica cultivar-group)
  ORGANISM  Oryza sativa (japonica cultivar-group)
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzeae; Oryza.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
            Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
  TITLE     Large-scale Sequencing Analysis of Rice ESTs
  JOURNAL   Unpublished (2003)
COMMENT     Contact: Nahm B.H.
            Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
            of Bioscience and Bioinformatics, MyongJi University
            Yongin, Kyeonggi, Korea
            Tel: 82 31 330 6193
            Fax: 82 31 321 6355
            Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES              Location/Qualifiers
     source           1. .13
                      /organism="Oryza sativa (japonica cultivar-group)"
                      /mol_type="mRNA"
                      /cultivar="Nackdong"
                      /db_xref="taxon:39947"
                      /clone="7LEAF--05-D14"
                      /tissue_type="leaf"
                      /dev_stage="7 days after germination"
                      /lab_host="E.coli DH10B"
                      /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
                      /note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped
                      with oligoribonucleotides and then used as templates for
                      RT-PCR."

  Query Match             1.1%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 4.1;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1581 AAAATATAAAAA 1592
              |||||| |||||
Db          2 AAAATTTAAAAA 13


RESULT 8
AJ599990
LOCUS       AJ599990                 13 bp    DNA     linear   GSS 15-JAN-2004
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            497H02, genomic survey sequence.
ACCESSION   AJ599990
VERSION     AJ599990.1  GI:37949618
KEYWORDS    GSS; left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
```

```
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 13)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="497H02"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .13
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             1.1%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 4.1;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2051 CATTATTAGATT 2062
              |||| |||||||
Db          1 CATTTTTAGATT 12


RESULT 9
AJ599990/c
LOCUS       AJ599990                 13 bp    DNA     linear   GSS 15-JAN-2004
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            497H02, genomic survey sequence.
ACCESSION   AJ599990
VERSION     AJ599990.1  GI:37949618
KEYWORDS    GSS; left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 13)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="497H02"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .13
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             1.1%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 4.1;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1582 AAATATAAAAAT 1593
              |||| |||||||
Db         13 AAATCTAAAAAT 2


Search completed: April  7, 2005, 06:01:59
Job time : 1 secs
```